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ABSTRACT 
 
 Early breast cancer progression involves advancement through specific 
morphologic stages including atypical ductal hyperplasia (ADH), ductal carcinoma 
in situ (DCIS) and invasive mammary carcinoma (IMC), although not always in a 
linear fashion.  Histological studies have examined differences in breast tissues 
representing these stages of progression, but model systems which allow for 
experimental testing of factors influencing transition through these stages are 
scarce.  The purpose of these studies was to develop a 3D in vitro model of early 
breast cancer progression that reflected the in vivo sequence of events, and to 
use this system to identify and functionally test genes important in controlling the 
processes.  The 21T series cell lines, originally derived from the same patient 
with metastatic breast cancer, were shown to mimic specific stages of human 
breast cancer progression (21PT, ADH; 21NT, DCIS; 21MT-1, IMC) when grown 
in the mammary fat pad of nude mice.  When grown in 3D Matrigel, the cell lines 
showed characteristic morphologies in which aspects of the stage-specific in vivo 
behaviours were recapitulated. 
  Gene expression profiling of the 21T cells revealed characteristic patterns 
for each, with differential expression of certain key genes in common with clinical 
specimens.  Subsequent studies focused on functionally characterizing the roles 
of VANGL1, S100A2 and TBX3 in breast cancer progression.  Genes were up- or 
down-regulated to determine if alterations could affect transitioning between 
stages of progression.  VANGL1 was differentially expressed in the ADH (21PT) 
to DCIS (21NT) transition (higher in DCIS) and was found functionally to promote 
iv 
 
the transition from ADH to a malignant phenotype (DCIS and even IMC).  
S100A2 and TBX3 were both differentially expressed in the DCIS to IMC (21MT-
1) transition (S100A2 lower in IMC, TBX3 higher in IMC).  S100A2 was found to 
functionally inhibit the transition from DCIS to IMC, while TBX3 promoted 
progression to invasion.    
 These studies demonstrate that the 21T series cell lines provide a model 
of early breast cancer progression when grown in 3D.  In addition, the model 
provides a means of testing the functional effects of genes on transitions between 
stages of pre-malignant to malignant growth, which may elucidate potential 
therapeutic targets.     
 
 
KEYWORDS: Breast Cancer Progression, Atypical Ductal Hyperplasia, Ductal 
Carcinoma in situ, Invasive Mammary Carcinoma, Matrigel, VANGL1, S100A2, 
TBX3  
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 CHAPTER 1.  INTRODUCTION 
 
1.1.  EARLY BREAST CANCER PROGRESSION 
 
1.1.1. Breast Cancer 
Every hour of every day, 20 people in Canada are diagnosed with some 
form of cancer [1].  Cancer is characterized by uncontrolled growth of cells and 
can arise in many different organs within the body.  In fact, the Canadian Cancer 
Society recognizes over 30 different types of cancer, based on the organ in which 
the tumour originates.  Cancer may be characterized by uncontrolled growth, but 
this oversimplifies the complexity of the disease.  Research has determined that 
cancer is a highly complex, multistep process that involves numerous alterations 
at the molecular level and confers upon cells a growth advantage that facilitates 
the conversion of normal cells to malignant cells.  Even with this knowledge, our 
understanding of the molecular changes and how they drive progression of 
cancer is still greatly limited.       
Breast cancer is the most common cancer in women [2-4] and is the 
leading cause of death in women aged 40 to 59 and the second leading cause, 
after lung cancer, for women aged 60-79 [3].  Breast cancers generally arise in 
the terminal ductules of the lobular units of the breast [5].  When caught at an 
early stage, survivability is very high, as the disease has not spread and local 
excision may be curative.  However, once the cancer is able to spread to life-
supporting organs, chance of survival is greatly reduced [3].  If the factors 
responsible for promoting progression of breast cancer can be discovered, it will 
1
 be possible to develop new therapeutic interventions directed at inhibiting this 
process.  In order to find these factors, we need to study the mechanisms of early 
breast cancer progression and identify the genes that control the transitions 
between the stages of progression.  The gene targets may then be used to 
develop therapeutics for treatment.    
 
1.1.2. Morphology of Early Breast Cancer Progression 
Invasive ductal carcinoma (of “no specific type”), one of the most common 
types of breast cancer, accounts for 20-30% of all newly diagnosed breast 
cancers [6].  It has been documented that stem cells from the terminal duct 
lobular units (TDLUs) can give rise to atypical ductal hyperplasia (ADH) [5, 7-10].  
At the stage of ADH, the breast duct is partially filled with two epithelial cell 
populations (Figure 1.1).  One population includes atypical cells, which may be 
neoplastic, while the second population includes more normal-appearing cells [5, 
8, 9].  Ductal carcinoma in situ (DCIS) may arise from ADH and is characterized 
by a breast duct filled with neoplastic cells [5, 7, 11-13] (Figure 1.1).  If left 
untreated at the DCIS stage, the carcinoma may become invasive (invasive 
mammary carcinoma, IMC) and lead to metastases at distant sites [5, 7, 11, 12, 
14] (Figure 1.1).  These three stages of progression may not always occur in a 
linear fashion however, and the histologic patterns are most likely phenotypic 
indicators of the underlying molecular events which are driving the stages of 
progression [15].  Identification of these molecular events may elucidate both the 
timing and likelihood of a lesion’s progression to malignancy.  In addition, an 
2
duct
lobule
fat
muscle
chest wall / 
rib cage
Figure 1.1. Morphology of early breast cancer progression. Stem cells from
the lobular unit give rise to atypical ductal hyperplasia (ADH). During ADH,
two epithelial populations are present within the duct. One population
includes atypical cells, presumed to be neoplastic, while the other population
is more normal-appearing. ADH can progress to ductal carcinoma in situ
(DCIS), which is characterized by a breast duct filled with neoplastic cells.
Finally, DCIS can progress to invasive mammary carcinoma (IMC), in which
cells are able to invade through the basement membrane and move to distant
sites. This image was adapted from http://www.breastcancer.org/symptoms/
types/dcis/diagnosis.jsp.
ADH DCIS IMC
Normal breast cells 
Neoplastic cells 
3
 understanding of the molecular events may aid us in determining ways to halt 
progression at the early stages.   
 
1.1.3. Relative Risk of Progression to IMC 
Formation of metastases in vital organs, as a result of IMC is life 
threatening.  It has already been noted that breast cancer progression may not 
always follow a linear pathway from ADH through DCIS to IMC; however, 
histological examination of human specimens have demonstrated that ADH and 
DCIS are markers for higher risk of IMC occurrence [7, 9, 14, 16].  Atypical 
hyperplasias, including ADH and atypical lobular hyperplasia (ALH), are non-
obligate precursors of IMC and in fact a diagnosis of ADH or ALH correlates with 
an increased risk to develop IMC in either breast [9, 14, 16].  Compared to the 
general public, women who have had a biopsy positive for ADH or ALH have a 4-
5 times increased risk of developing IMC [9].  In contrast, DCIS is commonly 
regarded as an obligate precursor lesion for IMC and results in an 8-10 times 
increased risk for developing invasive disease [9].  DCIS is considered an 
obligate precursor due to the common discovery of invasion at the original site of 
DCIS diagnosis [16].  Even if progression does not always occur in a linear 
fashion, both non-obligate and obligate precursors commonly share histologic 
continuity with IMC [14, 15] and analyzing progression from a linear perspective 
serves as an appropriate framework for studies into the molecular mechanisms 
which drive tumour progression [9, 14, 16].   
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 1.1.4. Identification of Molecular Targets in Breast Cancer Progression 
The molecular events within a cell are driven by the cell’s genotypic 
signature.  Both microarray technology, which looks at the gene expression 
profile within a cell and proteomics, which looks at the proteins expressed within 
a cell, have identified candidate genes and their protein products potentially 
involved in breast cancer progression.  These candidates are thought to be 
involved in cancer characteristics, such as proliferation, apoptosis, migration, 
invasion and adhesion [17-22].  However, although changes have been 
associated in the literature with specific stages of progression, there is little 
information on what alterations are functionally involved in driving the transitions 
between the stages.  In essence, we are seeing a static picture of what is actually 
a very complex and dynamic process.  In order to address which alterations have 
significant functional effect, model systems to study progression are needed.   
 
1.1.5. Models of Breast Cancer Progression 
Using different approaches, several model systems of early breast cancer 
progression have been developed.  Some models have used human breast 
epithelial cell lines modified with activated oncogenes to drive production of 
premalignant lesions in immune deficient mouse hosts [23, 24, 24-27]).  Two of 
these models are the HMT-3522 series (reviewed in [23, 27]) and the MCF10AT 
series (reviewed in [24, 26, 28]).  The HMT-3522 series was derived from a 
woman with fibrocystic change and consists of three cell lines [23, 27].  The 
HMT-3522/S1 cell line, produced after in vitro culture of the explant, is 
nontumourigenic in nude mice [27].  The HMT-3522/S2 cell line was created by 
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 EGF-independent growth selection in vitro and is able to form tumours in nude 
mice.  However the tumours are slow growing and tumour take is low [27].  
Finally, the HMT-3522/T4-2 cell line was created from a HMT-3522/S2 tumour 
and these cells are highly tumourigenic [27].  The MCF10AT series was also 
derived from a woman with fibrocystic change and represents a wide range of 
breast cancer pathologies [24, 26, 28].  The MCF10A cells are normal 
immortalized breast epithelial cells [28].  These cells were transfected with T-24 
ras and renamed MCF10AneoT [24].  The MCF10AneoT cells are able to form 
tumours and in fact the MCF10AT cell line is a derivative of a MCF10AneoT 
lesion [24].  The MCF10AT cell line is able to form lesions with various 
premalignant histologies, including hyperplasia, ADH and DCIS with a quarter of 
the lesions able to progress to invasion [24, 28].  The most advanced cell line in 
the series are the MCF10CA cells, which are fully malignant and also form 
lesions with histological variation ranging from undifferentiated carcinomas to well 
differentiated adenocarcinomas [26, 28].  Both the HMT-3522 and MCF10AT 
series systems have proven useful; however, both series suffer from 
disadvantages.  Both HMT-3522 and MCF10AT series show mixed phenotypes 
and lack of stability of the phenotypes after culture.  Additionally, the HMT-3522 
series lack a pre-DCIS or early stage of progression, while the MCF10AT series 
is dependent on a ras transformation, which is an alteration that is uncommon in 
spontaneous human breast cancers.  Other breast cancer progression model 
systems have made use of murine models that have been genetically engineered 
to develop mammary epithelial preneoplasia or neoplasia (reviewed in [29]).  
Alternately, other murine models of progression have viral, chemical or hormonal 
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 agent induced premalignant lesions (reviewed in [30]).  It is worth noting however 
that in both types of murine models, the pre-malignant lesions being studied are 
mouse-derived and these lesions, while being similar to human lesions in some 
respects, are still different in other respects due to their mouse origins [29].  
Additionally, the morphological progression continuum that has been described in 
human breasts cancer has not been described in genetically engineered murine 
mammary glands [29].  In order to study the molecular events underlying early 
breast cancer progression most efficiently, a human model system that 
represents all stages of progression is needed.        
 
1.2. THE 21T SERIES HUMAN BREAST CANCER CELL LINES 
 
1.2.1. Establishment of the 21T Series Cell Lines 
The 21T human cell lines have been proposed to represent a progression 
series of early breast cancer.  The series consists of three cell lines, which were 
derived from a single patient and are representative of different stages of 
progression [31].  The 36 year old patient originally presented with estrogen- and 
progesterone-receptor negative DCIS plus infiltrating ductal carcinoma (no 
special type) [31].  The 21PT and 21NT cell lines were derived from the 
mastectomy specimen and have been found to be stably non-tumourigenic and 
tumourigenic but non-metastatic, respectively, in nude mice [31].  One year post-
mastectomy, the patient developed lung metastases with pleural effusion [31].  
The third cell line, 21MT-1 cells, was derived from this pleural effusion and has 
been found to be both tumourigenic and metastatic [31].   
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  In order to isolate the 21PT and 21NT cell lines from the mastectomy 
specimen, breast tissue was dissociated and cultured [31].  Fibroblasts from this 
mixed population were removed from the epithelial population by selective 
trypsinization [31].  The resulting pure epithelial population in 2D culture was 
composed of both normal-appearing epithelial cells and cells which looked to be 
more tumour-like [31].  The tumour-like cells were selectively expanded by both 
clonal isolation and serum selection and are what constitutes the 21PT and 21NT 
cells [31].  The 21MT-1 cells, which were isolated from the pleural effusion, were 
first pelleted down and then cultured in dishes [32].  After cells were attached, 
several washes were used to remove red blood cells and debris [32].  Loosely 
adhered mesothelial cells were also removed by repeated washing [32].  Percoll 
gradient fractionation was finally used to enhance the epithelial population [32].  
The few mesothelial cells that remained after fractionation senesced after 
prolonged culture [32].  These cells were named 21MT cells.  However, after 
approximately 100 population doublings two cell populations predominated [31].  
One population was easily released from the culture plastic and this population 
was dubbed the 21MT-1 cells [31].  All three cell lines (21PT, 21NT, 21MT-1) 
were in continuous culture for over 2 years before publication [31].  
 
1.2.2. Characteristics of the 21T Series Cells 
As mentioned above, the 21PT cells are non-tumourigenic, while the 21NT 
cells are tumourigenic, but not metastatic and the 21MT-1 cells are tumourigenic 
and metastatic [31].  Karyotype were originally explored by Band et al. [31] and 
further refined by our laboratory [33].  Additional characterization of the cell series 
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 has determined that the 21T cells all express cytokeratins 8, 18 and 19 [31, 34], 
as well as HMFG-2 [31], identifying them as epithelial cells of mammary origin.  
Although all three cell lines were initially thought to be ER and PR negative, as 
was the original tumour, subsequent work showed the 21PT cell line to express a 
variant ER-receptor, which is not well detected by conventional anti-ER 
antibodies [35, 36].  Mutations in the p53 gene were also investigated in the cell 
series since mutations in this gene are very common in breast cancer.  It was 
found that all the 21T series cells have a frame-shift mutation in the p53 gene, 
which results in the loss of p53 expression and p53-mediated effects [37].  
Finally, the 21T series cell lines all contain lower mRNA levels of epidermal 
growth factor receptor (EGFR) than normal breast epithelial cells, while mRNA 
levels of transforming growth factor alpha (TGFα), a ligand for EGFR, are 
reduced in 21MT-1 cells, but consistent with normal cells in 21PT and 21NT cells 
[31].  The HER-2 gene (neu, ERBB2; Human epidermal growth factor receptor 2), 
a marker for aggressive breast cancer, is overexpressed at both the mRNA and 
protein levels in all 21T series cells, with 21MT-1 cells producing higher levels 
than the other 21T series cells [31].   
 
1.3. IN VIVO VS 3D IN VITRO CULTURE  
 
1.3.1. Xenograft Mouse Model Limitations 
Xenograft mouse models are extremely useful when studying human 
disease due to the fact that they share organ systems and an immense degree of 
genetic similarity to humans [38].  In fact, in the modern era, nearly every 
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 successful cancer therapy has undergone xenograft testing [39].  Additionally, 
murine xenograft models have enabled the identification of early diagnostic 
markers and novel therapeutic targets, and an understanding of the in vivo 
biology and genetics of human tumour initiation, promotion, progression and 
metastasis [38].  However, xenograft mouse models are not perfect.  Growth of 
human cells in mice requires that the mouse host be immunodeficient.  The 
immunodeficiency of the mice means that the mouse host does not possess all 
the proper immune response that would be present in a human host [39].  
Additionally the fact that human cells are injected into a mouse background can 
often result in an inability of the human cells to adapt and can lead to low tumour 
take [39].  Other issues arise in the variability that can arise between mice.  In 
fact, mice purchased from different vendors may reproduce different experimental 
results due to genetic differences in the mouse strain between colonies [40].  
Finally, mouse models are often slow, making it difficult to produce high 
throughput studies and rendering the study of the effects of individual genes on 
tumour cells more cumbersome than an in vitro system.  The ease of 
manipulation of an in vitro system is also an advantage over an in vivo one.  Due 
to the shorter time frame and ease of manipulation, there is increasing interest in 
the use of 3D in vitro model systems.   
 
1.3.2. Matrigel and 3D In Vitro Culture  
In vitro systems are very useful for high throughput studies.  However, it 
has been shown that when grown in 2-dimensional (2D) in vitro culture, cell lines 
have distinctly different morphology and genetic profiles than when grown in vivo 
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 [41-47].   Moreover, important signals released by the extracellular matrix, which 
govern normal homeostasis and tissue phenotypes are lost when cells are 
cultured on 2D plastic [41].  Alternatively, if cells are grown in laminin-rich 
extracellular matrix 3D cultures, many of these signals remain present [41].  
Growing cells in 3D with extracellular matrix signals intact, allows for study of cell 
proliferation, apoptosis, cell morphogenesis and invasiveness in a closed system.  
In fact, there have been several studies using 3D systems to look at the 
molecular control of morphogenesis in breast epithelial cells [43, 48-57].  
However, use of a 3D system to directly model aspects of early breast cancer 
progression has been limited.  Growing the 21T series cell lines in a 3D in vitro 
model system, which will mimic the characteristics of their behaviour in vivo, 
should produce a more predictive model of the molecular/cellular events 
governing early tumour progression compared to a 2D in vitro system.   
 
1.4. THESIS BACKGROUND STUDIES AND HYPOTHESES 
 
1.4.1. 21T Series Cell Lines Mimic Stages of Breast Cancer Progression In 
Vivo 
Prior to my own work, experiments in our laboratory were performed in 
order to verify the in vivo growth characteristics of the 21T series cell lines.  The 
three 21T series cell lines were injected into the mammary fat pads of female 
nude mice, left for up to a year to develop lesions, and histology was performed 
on mammary fat pad and other organs on necropsy.  Through the course of this 
work, it was discovered that the lesions formed in each case were of 
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 characteristic morphology on hematoxylin and eosin (H&E) sectioning of the 
mammary fat pad (21PTci – ADH; 21NTci – DCIS; 21MT-1 – IMC).  The results 
of this work have been included in our recent publication [58] and contribute to 
the work discussed in Chapter 2 of this thesis.  The in vivo data included in 
Chapter 2 of this thesis was thus, completed before the beginning of the thesis 
work and was the basis for formation of the thesis hypothesis.   
   
1.4.2. Thesis Hypotheses  
I hypothesize first that the 21T series cells grown in a 3D culture system 
can be used to identify genes involved in the transitions between early stages of 
breast cancer.  Secondly, I also hypothesize that this 3D system can then be 
used to determine the functional role of the identified genes in early breast cancer 
progression. 
   
1.5. EXPERIMENTAL OBJECTIVES  
1. To determine the growth characteristics of the 21T series cell lines in 3D in 
vitro culture. 
2. To identify genes involved in the transition from ADH to DCIS and genes 
involved in the transition from DCIS to IMC.  
3. To functionally characterize validated genes in the 3D system to determine 
their role in induction of tumour progression inhibition.  
 
 These experimental objectives are described in detail in Chapters 2 and 3.  
Both objectives 1 and 2 are addressed in Chapter 2, which proposes that the 21T 
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 series cell lines are an appropriate model of early breast cancer progression 
when grown in 3D culture.  Furthermore, Chapter 2 identified genes that are 
specifically altered in the transitions from ADH to DCIS and DCIS to IMC.  Three 
of these genes, VANGL1, S100A2 and TBX3 were the focus of further study and 
are the subject of Chapter 3.  It was found that VANGL1 plays a role in the 
transition from ADH to DCIS, while both S100A2 and TBX3 are involved in 
controlling the transition from DCIS to an invasive phenotype (IMC).  
Together these two chapters demonstrate the ability of the 21T series cell 
lines to elucidate and test genes involved in controlling the transitions between 
stages of early breast cancer progression.  Furthermore, genes identified and 
validated with this system may prove to be potential therapeutic targets in the 
future.      
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 CHAPTER 2.  21T SERIES CELL LINES MIMIC SPECIFIC STAGES OF 
BREAST CANCER PROGRESSION IN 3D CULTURE AND SHOW STAGE-
SPECIFIC GENE EXPRESSION PATTERNS  
 
The contents of this chapter has been adapted from a paper entitled “Human 21T 
breast epithelial cell lines mimic breast cancer progression in vivo and in vitro and 
show stage specific gene expression patterns”, published in Laboratory 
Investigation, vol 90: pp. 1247-1258 (2010), by Lesley H. Souter, Joseph D. 
Andrews, Guihua Zhang, Amy C. Cook, Carl O. Postenka, Waleed Al-Katib, Hon 
S. Leong, David I. Rodenhiser, Ann F. Chambers and Alan B. Tuck.  The in vivo 
experiment was conducted prior to this thesis project.       
 
2.1. INTRODUCTION  
Pathologic and epidemiologic evidence has led to a histologic model of 
breast cancer evolution in which stem cells from the terminal duct lobular unit 
(TDLU) give rise to atypical ductal hyperplasia (ADH) or atypical lobular 
hyperplasia (ALH), which can then progress to ductal carcinoma in situ (DCIS) or 
lobular carcinoma in situ (LCIS) respectively, and eventually to invasive 
mammary carcinomas (IMC) [1-6].  These histologic patterns are, however, most 
likely only rough phenotypic indications of underlying cellular and molecular 
events determining progression [7], and may not necessarily occur in a linear 
fashion.  There is currently much interest in identifying the nature of the cellular 
and molecular events involved, not only for use in determining at which point a 
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 lesion is most likely to progress to malignancy, but also in hopes of finding a way 
to halt progression at these early stages.   
Microarray technology and proteomics have identified candidate genes 
with potential involvement in cell proliferation, cell death, cell adhesion, migration, 
invasion, etc., at different stages of breast cancer progression [8-13].  Although 
providing important information concerning gene expression between samples at 
any given stage of progression, this is only a static representation of what is 
presumed to be a dynamic process.  Model systems are thus needed, in addition 
to histological analysis of human breast specimens, to directly evaluate the 
effects of expression of specific genes, in order to determine the functional roles 
of these genes at different stages of tumour progression. 
There have been a number of different approaches to modeling early 
breast cancer progression.  Some have made use of murine models whereby 
premalignant lesions are induced by viral, chemical, or hormonal agents 
(reviewed in [14]), or whereby genetically engineered mice are generated which 
are susceptible to developing mammary epithelial neoplasia or preneoplasia 
(reviewed in [15]).  In these instances, it is mouse-derived pre-malignant lesions 
that are being generated and studied, which show both similarities and 
differences with their human counterparts.  Other models have used human 
breast epithelial cell lines that have been spontaneously transformed, transduced 
with oncogenic viruses, or transfected with activated oncogenes to derive altered 
cells that mimic premalignant lesions when tested in immune deficient rodent 
hosts (egs. HMT-3522 and MCF10AT series, reviews in [16, 17, 17-20]).  These 
systems are useful, but suffer the disadvantages of lack of representation of 
20
 earlier (pre-DCIS) stages of progression (HMT-3522 series), the presence of 
mixed phenotypes, lack of stability of the phenotypes after culture (both series), 
or the dependence on ras transformation (MCF10AT series). 
For ease of experimental manipulation, there has been much interest in 
comparing cells of premalignant and malignant status in 3D in vitro cultures [21-
27].  By allowing cells to grow in 3D conformation in extracellular matrix certain 
characteristics of cell morphogenesis, proliferation, apoptosis and invasiveness 
may be studied in a controlled system.  Using such 3D culture systems, much 
information has been generated on the molecular controls of morphogenesis in 
breast epithelial cells of different origins [21-23, 28-35].  To this point however, 
only limited use has been made of such 3D in vitro systems to directly model 
aspects of early breast cancer progression. 
The 21T series cell lines, which were derived from a single patient with 
metastatic breast cancer, have been proposed to represent a human breast 
cancer progression series [36].  The 21PT and 21NT cell lines were established 
from the mastectomy specimen and have been found to be stably non-
tumourigenic, and tumourigenic but non-metastatic, respectively, in nude mice 
[36].  The third cell line, 21MT-1, was derived from a malignant pleural effusion 
and has been found to be both tumourigenic and metastatic [36]. 21T series cells 
all express cytokeratins 8, 18 and 19, as well as HMFG-2 [36], identifying them 
as epithelial cells of mammary origin.  Although all three cell lines were initially 
thought to be ER and PR negative, subsequent work showed the 21PT cell line to 
express a variant ER-receptor, which is not well detected by conventional anti-ER 
antibodies [37, 38].   
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 To further explore the potential of the 21T series human breast cell lines 
as a functional model of early breast cancer progression, we have investigated 
their behaviour both histologically in vivo and in 3D in vitro cultures.  
Characterization of these cells at the molecular level, using gene expression 
profiling of cells grown in 3D culture, revealed stage-specific differences in genes 
involved in certain signalling pathways and functional categories reflective of 
progression to a more aggressive phenotype.  Comparison with published 
microarray data from clinical human specimens has generated a “genes of 
interest” short list, consisting of genes which have potential clinical relevance and 
are thus prime candidates for further functional testing and development as 
stage-specific targets to block breast cancer progression. 
 
2.2. MATERIALS AND METHODS  
 
2.2.1. Cell Lines and Culture 
The 21T series cell lines (21PT, 21NT, 21MT-1) were obtained as a kind 
gift of Dr Vimla Band (Dana Farber Cancer Institute) [36].  These cells were 
maintained in culture in α-MEM supplemented with 10% fetal bovine serum 
(FBS), 2 mM L-glutamine (both from Gibco Life Technologies, Grand Island, NY), 
insulin (1 µg/mL), epidermal growth factor (12.5 ng/mL), hydrocortisone (2.8 mM), 
10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1mM 
sodium pyruvate, 0.1 mM nonessential amino acids and 50 mg/mL gentamycin 
reagent (all from Sigma Chemical, St. Louis, MO), as previously described [39].  
After addition of all reagents, this growth medium was referred to as αHE.  The 
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 21PT and 21NT-derived cell lines used in this work, designated 21PTci and 
21NTci, are a pooled population of vector-only (pcDNA3) transfected cells and 
have been used as control cells for previous work in our laboratory [40].  Culture 
medium for these cell lines is the same as for the parental cell lines, with the 
addition of 0.2 mg/mL G418 as a selection marker (Gibco Life Technologies).   
 
2.2.2. In Vivo Studies 
Female athymic NCr nude mice (nu/nu) were housed and cared for in 
accordance with the recommendations of the Canadian Council on Animal Care, 
under a protocol approved by the University of Western Ontario Council on 
Animal Care.  Cell lines were grown in 150 mm tissue culture dishes to ~ 80% 
confluency (log phase of growth).  The cells were gently trypsinized, washed 
twice with sterile PBS, and resuspended in serum-free αHE media at a 
concentration of 1x107 cells per 100 µl.  Cells were injected into the second 
thoracic mammary fat pad of 8-9 week old female nude mice, as described 
elsewhere [41].  Animals were routinely monitored for health and primary 
tumours, when palpable, were measured every 7-14 days.  Animals were 
euthanized early if the tumour burden became too great, or at the end point of the 
experiment (1 year post-injection).  Animals were sacrificed and necropsies 
performed, examining the injected mammary fat pad, locoregional lymph nodes, 
and all major viscera, whether or not a palpable lesion was present.  Tissues 
were formalin-fixed, paraffin embedded, sectioned (4 µm thick) and examined 
histologically by hematoxylin and eosin (H&E) staining. 
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 2.2.3. 3D In Vitro Cultures 
For all 3D cultures, cells were grown in Matrigel Basement Membrane 
Matrix (BD Biosciences, Mississauga, ON) for 9 or 15 days.  Cultures were 
created in 48-well plates (Nunc Brand Products, Rochester, NY) with three 
distinct layers.  The bottom layer consisted of undiluted Matrigel for a solid base.  
The middle layer contained a 1:1 mix of Matrigel and 2 x 105 cells in media 
supplemented with 0.1% bovine serum albumin (BSA), instead of FBS.  These 
two layers were topped with growth media supplemented with 0.1% BSA (without 
FBS).  After growth in Matrigel, 10% neutral buffered formalin was added to the 
dishes for 48 hours and the cultures were removed as intact Matrigel plugs.  The 
formalin-fixed plugs were then processed, paraffin-embedded and sectioned for 
H&E staining and immunohistochemistry.         
 
2.2.4. Morphologic Characterization of 3D In Vitro Cultures 
Histomorphology was determined by examination of 4 μm, H&E stained 
sections of the Matrigel plugs.  Characterization of behaviour included 
assessment of extracellular lumen formation, number of groups with polarized 
cells, spherical (vs. non-spherical) colony formation and proportion of single cells.   
Each of these parameters was assessed in terms of a percentage of total 
“events” counted.  Appendix B Figure 1 illustrates each of the cell colony 
morphologies.  For each cell line, 10 high power (400X) fields of view from three 
replicate Matrigel plugs were examined.  This yielded between 200 and 275 
events per 10 high power fields.      
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 2.2.5. Proliferation and Apoptosis in 3D Culture 
The 21T series cell lines were grown in Matrigel for 9 or 15 days.  Matrigel 
plugs were immunostained for the proliferation marker, Ki67, and for the 
apoptotic marker, caspase 3.  For caspase 3 immunohistochemistry, 
deparaffinized sections were pretreated in a microwave oven for epitope retrieval.  
Caspase 3 antibody, which recognized cleaved caspase 3 (Cell Signaling 
Technologies, Danvers, MA) was applied (1/300 dilution) for 15 min at room 
temperature.  Ki67 staining was performed following a previously published 
protocol [42] with Ki67 antibody (Dako, Mississauga, ON) applied (1/150 dilution) 
overnight at 4oC.  For both caspase 3 and Ki67, detection was performed with the 
UltraVision LP Detection System HRP Polymer (Thermo Scientific, Waltham, MA) 
kit, following the manufacturer’s protocol.  Slides were counterstained with 
Harris’s Hematoxylin.  Positive and negative controls were included.  For each 
cell line, the Ki67 and caspase 3 indices, defined as the number of cells positive 
for Ki67 or caspase 3 staining divided by the total cells counted, were calculated 
from examination of 10 high power (400X) fields of view from three replicate 
Matrigel plugs per cell line, yielding between 200 and 350 cells.  In order to 
determine the balance of dividing cells vs. apoptosing cells, the ratio of 
proliferation over apoptosis was calculated for each cell line.   
 
2.2.6. Matrigel Invasion Assay  
21T series cell lines were grown in Matrigel for 9 days in 8-well chamber 
slides (Nunc Brand Products).  Matrigel cultures were formed as above, with 
adjustment made in volumes of the three layers for the smaller 8-well chamber 
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 slide.  1.5 x 104 cells were used in the middle layer.  Slides were then moved to 
an incubated stage platform of a Zeiss Axiovert 200M microscope for time lapse 
photography.  Z-stack microscopy images at 5 positions were taken for each cell 
line every 12 hours until day 15 of growth.  All cells found within the 5 positions 
per cell line (around 100 cells total) were then followed using AxioVision 4.5 
software (Carl Zeiss Imaging Solutions) to determine the percentage of cells that 
invaded through the Matrigel matrix and the distance the cells traveled.  A cell 
was defined as moving if any part of the cell was in a different location compared 
to the image taken 12 hours previously.  The minimum distance a cell could travel 
to be designated as moving was 5 µm.  The distance a moving cell travelled was 
measured using the AxioVision 4.5 software.      
 
2.2.7. Gene Expression Profiling in 3D Culture 
For expression profiling in 3D culture, cells were grown in Matrigel for 9 
days in 24-well plates (Nunc Brand Products).  Matrigel cultures were formed as 
above with an adjustment made in volumes of the three layers for the larger 24-
well plate volume.  Three wells per cell line, representing 3 biological replicates, 
were grown.  Total RNA from each biological replicate was isolated using Cell 
Recovery Solution (BD Biosciences) to non-enzymatically dissociate the Matrigel, 
followed by TRIzol (Invitrogen International, Mississauga, ON), as per the 
manufacturer's instructions.  RNA (10 μg) was then sent to the London Regional 
Genomics Centre (www.lrgc.ca, London, ON) and was used to produce Biotin 
labeled cRNA, which was hybridized to Affymetrix HGU133_Plus_2 arrays 
(Affymetrix, Inc., Santa Clara, CA).  Washing, scanning and probe quantification 
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 were carried out according to the manufacturer's instructions, using GeneChip 
Operating Software (GCOS, www.affymetrix.com), with target intensity set to 150.  
For each array, GCOS output was imported as .txt files into Genespring GX 7.3 
software (Agilent Technologies, Santa Clara, CA), and data were normalized as 
follows: Values <0.01 were set to 0.01 and the median intensity of each array 
was normalized to the 50th percentile of all arrays.  Finally, the intensity of each 
probe set in each of the three 21NTci or 21MT-1 arrays was divided by the 
normalized mean intensity of that probe set in the appropriate control arrays.  The 
geometric mean of these 3 ratios is reported.  In order to control the family-wise 
error rate, two separate analyses were performed: 21NTci vs. 21PTci, with 21PTi 
as control, and 21MT-1 vs. 21NTci, with 21NTci as control. After normalization, 
the data were first prefiltered.  Any probe set flagged ‘absent’ by GCOS software 
in all 9 arrays was removed from further consideration.  The full raw data for all 9 
arrays can be found at http://www.ncbi.nlm.nih.gov/geo/, data series GSE18370.  
Next, any probe set not changing at least 1.5-fold in 21NTci relative to 21PTci or 
21MT-1 relative to 21NTci was removed.  Probe sets passing these criteria were 
analyzed using the student’s t-test tool in Genespring, with the nominal p-value 
set at p<0.05. This resulted in two lists of genes, one with genes significantly 
changed in 21NTci vs. 21PTci (Supplemental Table 1) and the other with genes 
significantly changed in 21MT-1 vs. 21NTci (Supplemental Table 2).  In order to 
focus our search to genes relevant in a clinical setting, the “significantly altered” 
gene lists were then compared to gene expression profiling information on 
clinically relevant databases we established from the literature related to early 
progression, invasion/metastasis and prognosis of breast cancer [11-13, 43-51] 
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 (Supplemental Table 3).  New gene lists created from gene expression 
alterations in common with the clinical databases (Appendix B Table 1) were 
imported into Ingenuity Pathways Analysis® (IPA) (Ingenuity® Systems, 
www.ingenuity.com).  Each gene identifier in the data sets was mapped to its 
corresponding gene in the Ingenuity Pathways Knowledge Base, and if present, 
was considered for analysis.  Functional analysis identified biological functions 
and/or diseases that were most significant to the data set.  Canonical pathway 
analysis identified pathways from the IPA library that were most significant to the 
data set.     
 
2.2.8. Quantitative Real Time-PCR (qRT-PCR) Validation 
Total RNA was extracted from 4 biological replicates of each cell line 
following 9 days of growth in 3D Matrigel, using the same methodology employed 
for gene expression profiling.   cDNA was synthesized from 1μg total RNA using 
Superscript II (Invitrogen International), with random primers (Invitrogen 
International), as per the manufacturer's instructions.  qRT-PCR was performed 
using a Rotor-Gene RG-3000 (Corbett Life Science, San Francisco, CA), in 
combination with SYBR-Green.  RT2 qPCR primers for the selected targets 
(BAX, CCL20, CCR1, CDH1, CXCR4, DCN, MAX, MCM4, MGA, S100A2, 
S100A3, SERPINB5, SNAI2, TBX3, TFF2, TNFAIP3, VANGL1, WISP1, WNT5A) 
and RT2 SYBR-Green qPCR Master Mix were purchased from SuperArray 
Bioscience Corporation. 18S rRNA was used as an endogeneous control 
(SuperArray Biosciences Corporation).  Genes were considered to be validated if 
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 the qRT-PCR results showed statistically significant expression alterations in 
agreement with the microarray.   
 
2.2.9. Statistical Analysis  
The differences between experimental groups were analyzed using one-
way analysis of variance (ANOVA), followed by Tukey’s test for post hoc 
analysis.  For the Matrigel invasion assay, a Kruskal-Wallis nonparametric 
ANOVA was used when calculating the percent of cells that moved, as the values 
were not normally distributed.  This was also followed by a Tukey’s post hoc test.  
For all statistics, a p-value of less than 0.05 was considered statistically 
significant.   
 
2.3. RESULTS 
 
2.3.1. In Vivo Cultures of 21T Series Cell Lines Model Stages of Early 
Progression 
Mice injected in the mammary fat pad with each of the three 21T series 
cell lines were monitored for tumour growth for up to a year.  This study 
confirmed the previously published findings of Band and colleagues [36] that 
21PT-derived cells are non-tumourigenic and non-metastatic, 21NT-derived cells 
are tumourigenic but non-metastatic, and 21MT-1 cells are tumourigenic and 
metastatic in some mice (Table 2.1).  In addition, in our study, systematic 
histologic examination of the mammary fat pads of all animals, whether or not 
tumours were palpable, was performed at end-point and provided some very 
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Table 2.1.  Histopathology of 21T series cell lines in vivo one year after 
orthotopic mammary fat pad injection into 6-8 week old female nude mice. 
 
 
No. of mice 
showing ADH1 
only 
No. of mice 
showing 
DCIS2 only 
No. of mice 
showing 
invasive 
carcinoma 
No. of mice 
showing 
metastases 
21PTci 2/32 0/32 0/32 0/32 
21NTci 0/29 6/29 1/29 0/29 
21MT-1 0/15 0/15 10/15 5/15 
 
______________________________ 
1 ADH, atypical ductal hyperplasia 
2 DCIS, ductal carcinoma in situ  
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 novel information.  Where microscopically discernible lesions formed, each of the 
injected cell lines gave rise to a characteristic histomorphology.  Mammary fat 
pads of 21PTci-injected mice showed scattered ducts with features of ADH 
(Table 2.1 and Figure 2.1A).   In keeping with ADH [6], involved ducts of these 
animals showed a mixture of two epithelial cell populations, one 
atypical/neoplastic appearing (non-high grade), and the other normal/benign 
appearing (Figure 2.1A inset).   None of the ducts in 21PTci-injected mice 
displayed a morphology that met criteria for DCIS (incomplete duct filling by 
atypical cell population, < 2.0 mm in greatest extent).  In contrast, mammary fat 
pads of 21NTci-injected mice showed a pattern of DCIS (intermediate and high 
nuclear grade, solid and cribriform, with zonal necrosis), which in 6/7 of those 
mice forming lesions had no associated invasive component (Table 2.1 and 
Figure 2.1B). In the one 21NTci-injected animal where associated invasive 
carcinoma was present, the degree of invasion was minimal, and no metastases 
were seen (Table 2.1).  In sharp contrast to both, mammary fat pads of 21MT-1 
injected mice showed a pattern of IMC in all instances where a histologically 
discernable lesion formed, and half of these were also associated with pulmonary 
metastases (Table 2.1 and Figure 2.1C).  The in vivo growth characteristics of 
these three 21T series cell lines thus reproducibly model distinct histologic stages 
of early breast progression, from ADH (21PTci) to DCIS (21NTci) to IMC (21MT-
1), up to one year after mammary fat pad injection in mice.        
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21PTci 21NTci 21MT-1
A) B) C)
Figure 2.1. Histopathology of 21T series cells in vivo, 1 year after injection of
1 x 107 cells into the mammary fat pad of 6-8 week old female nude mice.
Histology was analyzed for mammary fat pads of all mice injected. A) 21PTci
cells mimicked aspects of ADH, with both atypical (non-high grade) and
normal-appearing populations visible in a given involved duct/ductule and
with the atypical cell population represented over an area of < 2.0 mm (i.e.
not meeting pathologic criteria for DCIS). B) 21NTci cell morphology
mimicked DCIS, with the neoplastic cells filling an entire mammary fat pad
duct, often with accompanying central zonal necrosis. This pattern was seen
in multiple duct cross-sections (over an area > 2.0mm). C) 21MT-1 cells
displayed a histology of IMC (no special type, SBR Grade III/III), associated
with a background DCIS. All sections are H&E stained. Scale bars represent
200μm, except for the inset of a) and b), which represents 100μm. All
images are 24-bit resolution TIFFs (1.8 MP) captured with an Aperio
Scanscope, scanning with the 400x objective.
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 2.3.2. 3D In Vitro Cultures of 21T Series Cells Display Features of Specific 
Stages of Early Progression  
In order to develop a more rapid, readily manipulatable in vitro system for 
assessing the biologic differences between these cells, we made use of a 3D 
Matrigel model.  Cells were grown in 3D Matrigel plugs for 9 or 15 days, and 
characterized using a number of morphologic and functional parameters, 
including colony profile (spherical vs. irregular), lumen formation, cell polarization, 
proportion of single cells, Ki67 proliferation index, caspase 3 apoptosis index and 
cell invasion (by time lapse microscopy).  By day 15, 21PTci cells were found to 
form many spherical colonies, which had a high proportion of polarized cells and 
extracellular lumen formation (Figure 2.2A, D, G).  Interestingly, many of the 
21PTci cell colonies had an admixture of cells with nuclei that appeared either 
normal or atypical in morphology.  In contrast, 21NTci cells showed fewer 
spherical colony profiles, and a lesser degree of cell polarization and lumen 
formation than the 21PTci cells (Figure 2.2B, E, G).  Most of the 21NTci cell 
groups showed significant nuclear atypia.  Finally, 21MT-1 cells showed a much 
lower proportion of spherical colonies (more were of irregular profile) and a high 
proportion of single cells than either of the other lines.  Additionally, 21MT-1 cell 
groups show even less polarization and extracellular lumen formation than 
21NTci cells (Figure 2.2C, F, G).   
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21PTci 21NTci 21MT-1
A) B) C)
D) E) F
)
G)
Figure 2.2. In vitro characteristics of 21PTci, 21NTci and 21MT-1 cells after 15
days growth in 3D Matrigel. 21PTci cells (A,D,G) formed more polarized cell groups
than 21NTci (p<0.05) or 21MT-1 (p<0.05) cells, with higher frequency of extra-
cellular lumen formation (~10%, p<0.01 and ~17%, p<0.001 respectively) and more
crisply-defined spherical colonies than 21NTci (p<0.05) or 21MT-1 (p<0.001) cells.
21NTci cells (B,E,G) formed large numbers of cohesive spherical colonies (~38%
compared to 21MT-1 cells, p<0.001), but have less tendency towards cell
polarization. 21MT-1 cells (C,F,G) were present more as single cells (~26% more
than 21PTci cells, p<0.001 and ~13% more than 21NTci cells, p<0.001) and small
groups, which were non-spherical and less polarized (than 21PTci), in an invasive
pattern of distribution. All sections are H&E stained. Images were chosen to
demonstrate structures of 3D cell colonies and not typical cell density within a
Matrigel plug. In (G) for ‘single cells’, an “event” is either a single cell or a cell
group/colony, while for the ‘spherical colonies’, ‘lumen formation’ and ‘polarized
cells’ comparisons, an “event” was defined as a cell group/colony. Also for (G) all
bars within each group are significantly different from each other at a p-value of at
least < 0.05, except when indicated by NS (non significant). Scale bars for (A,B,C)
represent 100μm, while scale bars for (D,E,F) represent 50μm.
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 2.3.3. Differential Proliferation, Apoptosis and Invasiveness of 21T Series 
Cells 
Assessment of proliferative rates by Ki67 immunohistochemistry showed 
that at day 9, 21NTci cells showed significantly more proliferative events than 
21PTci or 21MT-1 cells (p<0.01) (Figure 2.3A).  However, the proliferative rate of 
both 21NTci and 21PTci had dropped off by 15 days of growth in Matrigel, 
whereas that of 21MT-1 cells was highest at day 15 (3x that of 21PTci, p<0.01) 
(Figure 2.3A).  Apoptotic rates by caspase 3 immunohistochemistry showed that 
there were no significant differences between cell lines at day 9, however by day 
15, apoptotic rates drop slightly and not significantly for 21PTci cells and slightly 
and significantly (p<0.01) for 21MT-1 cells (Figure 2.3B).  The ratios of 
proliferation/apoptosis were calculated for the 21T series cell lines grown in 
Matrigel, using Ki67 (proliferation) vs. caspase 3 (apoptosis) index.  Results 
indicate that at day 9, 21NTci cells had the highest ratio of proliferation/apoptosis, 
compared to 21PTci cells (p<0.05) or 21MT-1 cells (p<0.05) (Figure 2.3C).  
However, by day 15, 21MT-1 cells showed an increased proliferation/apoptosis 
ratio, which was higher than either of the other 2 cell lines (p<0.01 compared to 
21PTci and 21NTci) (Figure 2.3C).  The 21NTci cells, which showed a high rate 
of growth at day 9, had a significantly decreased (p<0.05) ratio on day 15 (Figure 
2.3C).  The 21PTci cells showed a trend towards a decrease in 
proliferation/apoptosis at day 15 compared to day 9, but this was not significant.  
Interestingly, by day 15 (vs. day 9), a higher proportion of 21PTci and 21NTci 
cells were present as polarized groups showing extracellular lumen formation, 
suggesting that the decrease in ratio of cell proliferation/apoptosis may be related 
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Figure 2.3. Proliferative and apoptotic activity of 21PTci, 21NTci and 21MT-1 cells
after 9 and 15 days growth in 3D Matrigel. A) Proliferation was quantified by Ki67
immunohistochemical staining of Matrigel plugs. 21PTci cells showed a modest
proliferative activity at day 9, which trailed off by day 15. 21NTci cells showed an
initial burst of proliferative activity at day 9, which decreased significantly (p<0.01) by
day 15. 21MT-1 cells showed a modest proliferative activity that was higher by day
15. B) Apoptosis was quantified by caspase 3 immunohistochemical staining of
Matrigel plugs. At day 9, there were no significant differences in apoptotic rates
among cell lines. At day 15, apoptotic rates of both 21PTci and 21MT-1 cells
decreased slightly (non significantly and significantly (p<0.05), respectively). C)
When the ratio of proliferation/apoptosis was calculated, 21PTci cells showed a
modest cell division over cell death ratio at day 9, which trended towards a
decreased ratio at day 15, at which time there was evidence of differentiation in
terms of extracellular lumen formation and polarized groups (c.f. Figure 2.2).
21NTci cells showed an initial burst of proliferative activity over apoptosis at day 9,
which decreased significantly (p<0.05) by day 15. 21MT-1 cells showed a modest
proliferation/apoptosis ratio at day 9, which significantly increased (p<0.05) at day
15. * indicates significance at a level of p<0.05.
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 to increased differentiation (data not shown), while the 21MT-1 showed very little 
polarization/extracellular lumen formation and instead exhibited increased growth 
between day 9 and day 15 (cf. Figure 2.2, Figure 2.3).   
Finally, to assess invasive ability, cells were grown in Matrigel for 9 days 
and then followed with time lapse microscopy until day 15.  It was found that 
100% of 21MT-1 cells were able to travel through the Matrigel in both horizontal 
and vertical directions, compared to only 25% of 21PTci and 30% of 21NTci cells 
(Figure 2.4A).  In addition 21MT-1 cells traveled 219μm on average over the 
seven days, which was significantly (p<0.01) farther than that for 21PTci (22μm) 
and 21NTci (18μm) cells (Figure 2.4B).  Whereas the majority of 21MT-1 cells 
that moved showed individual translational cell movement, 21PTci and 21NTci 
cell movement predominantly involved localized arrangement into cell groups 
within a confined area.            
 
2.3.4. Profiling Elucidates Differential Gene Expression between the Three 
21T Series Cell Lines Grown in 3D 
In order to determine differential gene profiles between the 21T series cell 
lines, 3D in vitro microarray expression arrays were performed, which identified 
stage-specific gene alterations.  For the 21PTci to 21NTci comparison, 366 probe 
sets were at least 1.5-fold altered (p<0.05) (Supplemental Table 1), whereas for 
the 21NTci to 21MT-1 comparison, 3067 probe sets were at least 1.5-fold up- or 
down-regulated (p<0.05) (Supplemental Table 2).  In order to assess whether 
these alterations would potentially apply to breast cancer progression in a clinical 
situation (i.e. to establish potential clinical relevance), we compared our list of 
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Figure 2.4. 21T series cell invasion through Matrigel matrix. Cells were
grown in Matrigel for 9 days and then transferred to the incubator stage
platform of a time lapse microscope until day 15. Z-stack images were taken
every 12 hours. All individual cells imaged were followed for the full 6 day
interval. A) Percentage of total cells that moved (invaded) through the
Matrigel matrix. A cell was defined as moving if any part of the cell was in a
different location compared to the image taken 12 hours previously. 100% of
21MT-1 cells showed translational movement, compared to only 27% of
21PTci and 33% 21NTci cells. B) Distance (µm) moving cells traveled
through Matrigel matrix. 21MT-1 cells moved significantly further than 21PTci
(p<0.01) or 21NTci (p<0.01) cells, which each showed minimal translational
movement/invasive ability, consistent with the invasive (21MT-1) vs. non-
invasive (21PTci, 21NTci) morphologies of these cells when grown in vivo.
*indicates significance at a level of p<0.05.
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 differentially expressed genes with a database we generated from established 
literature on gene expression profiling of clinical cancer specimens, including 
papers related to progression [11-13, 49-51], metastasis [45, 46, 48, 49] and 
prognosis [43, 44, 47, 50, 51] of breast cancer (Supplemental Table 3).  Overlaps 
between our initial gene lists (Supplemental Table 1 and 2) and the clinically-
relevant databases (Supplemental Table 3) were used to make two more focused 
gene lists of statistically altered and potentially clinically-relevant genes (21PTci 
to 21NTci: 23 probe IDs; 21NTci to 21MT-1: 208 probe IDs) (Appendix B, Table 
1).  These gene lists were then uploaded into Ingenuity Pathways Analysis (IPA) 
for further analysis, which identified representation of several major functional 
and canonical categories.  Gene lists were then pared down to all genes found 
within the top 10 functional categories and canonical pathways (21PTci to 
21NTci: 20 genes; 21NTci to 21MT-1: 66 genes) and the gene function as 
described by GeneCards (www.gencards.org) was recorded (Table 2.2).  Based 
on gene function as described by GeneCards, 19 representative genes between 
the two transitions were chosen for 3D qRT-PCR validation, with 2 genes (DCN, 
WNT5A) represented in both transitions (Table 2.3).  If a gene was significantly 
different (p<0.05) between the 2 cell lines of interest and in the same direction as 
the microarray, the gene was considered validated.  Of the 19 genes, all genes 
except BAX and MCM4 were validated by qRT-PCR (Table 2.3).  For the 21PTci 
to 21NTci comparison, differential expression of BAX, DCN, MAX, MCM4, MGA, 
VANGL1, WISP1 and WNT5A were analyzed by real-time PCR.  CCL20, CCR1, 
CDH1, CXCR4, DCN, S100A2, S100A3, SERPINB5, SNAI2, TBX3, TFF2, 
TNFAIP3 and WNT5A were validated in the 21NTci to 21MT-1 comparison.  It is 
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Table 2.2.  Genes that are concurrently: (1) significantly different among the 21T 
series cell lines1, (2) present on clinically relevant databases from the literature2 
and (3) found within the top 10 functional and canonical pathways represented 
according to Ingenuity Pathways Analysis. 
 
Common 
Name Gene Name GeneCard Function 
Microarray 
Fold 
Change 
21PTci to 21NTci 
ATRX 
Alpha thalassemia/mental 
retardation syndrome X-
linked 
Transcription regulator  1.97 
BAX BCL-2 associated X protein Accelerates programmed cell death  -1.75 
DCN Decorin Affects rate of fibrils formation 7.52 
ECGF1 Endothelial cell growth factor 1 
Role in maintaining integrity of blood 
vessels 1.6 
JMJD2C Jumonji domain containing 2C Histone demethylase  1.66 
HIST1H4H Histone cluster 1, H4h Core component of nucleosome 1.56 
MAX MYC associated factor X Transcription regulator -1.54 
MCM4 Minichromosome maintenance complex 4 Involved in control of DNA replication -1.56 
MGA MAX gene associated Transcription regulator 3.23 
MMP1 Matrix metallopeptidase 1 Cleaves collagen -4.17 
NEFL Neurofilament, light polypeptide 
involved in maintenance of neuronal 
caliber -3.23 
PCM1 Pericentriolar material 1 Required for centrosome assembly and function -1.54 
PIK3R1 Phosphoinositide-3-kinase, regulatory subunit Binds to activated protein-Tyr kinase  1.75 
PIP Prolactin-induced protein Binding factor that plays a role in host defense against infections 3.95 
SFRP4 Secreted frizzled-related protein 4 Modulator of Wnt signalling -1.53 
SLIT2 Slit homolog 2 Acts as a molecular guidance cue in cellular migration -1.92 
UPLC1 
Development and 
differentiation enhancing 
factor-like 1 
Promotes cell proliferation 9.31 
VANGL1 Vang-like 1 Planar cell polarity signalling molecule 2.19 
WISP1 WNT1 inducible signal pathway protein 1 
Downstream regulator in the 
Wnt/Frizzled signalling pathway 2.18 
WNT5A 
Wingless-type MMTV 
integration site family, 
member 5A 
Ligand for members of frizzled family -1.89 
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21NTci to 21MT-1 
AIM2 Absent in melanoma 2 Tumour suppressor 7.16 
ALDH3A1 Aldehyde dehydrogenase 3 family, member A1 
Involved in detoxification of alcohol-
derived acetaldehyde -93.46 
ANGPTL4 Angiopoietin-like 4 Regulator of angiogenesis -3.58 
BCL3 B-cell CLL/lymphoma 3 Transcriptional activating factor 1.84 
BLNK B-cell linker 
Central linker protein that bridges 
kinases associated with B-cell receptor 
with multiple signalling pathways 
26.67 
CASP1 Caspase 1, apoptosis-related cysteine peptidase Thiol protease that cleaves IL-1 beta  3.62 
CCL20 Chemokine (C-C motif) ligand 20 Chemotactic factor  19.98 
CCR1 Chemokine receptor 1 Receptor for C-C type chemokine 7.85 
CDH1 Cadherin 1, type 1, E-cadherin 
Promotes non-amyloidogenic 
degradation  -59.88 
CDH11 Cadherin 11, type 2, OB-cadherin 
Calcium dependent cell adhesion 
protein -4.13 
CDK2 Cyclin-dependent kinase 2 Involved in the control of cell cycle -3.77 
CHI3L1 Chitinase 3-like 1 Carbohydrate-binding lectin with a preference for chitin -7.47 
CLDN4 Claudin 4 
Plays a major role in tight junction-
specific obliteration of intercellular 
space 
-45.87 
CLU Clusterin May play a role in resistance to chemotherapy 3.43 
COL4A3 Collagen, type IV, alpha 3 Tumstatin, a cleavage fragment 1.64 
CST7 Cystatin F Inhibits papain and cathepsin L 18.14 
CX3CL1 Chemokine (C-X3-C motif) Soluble form is chemotactic for T-cells and monocytes,  2.04 
CXCL2 Chemokine (C-X-C motif) ligand 2 
Produced by activated monocytes and 
neutrophils and expressed at sites of 
inflammation 
-23.81 
CXCR4 Chemokine (C-X-C motif) receptor 4 
Receptor for the C-X-C chemokine 
CXCL12/SDF-1 -3.81 
CYP1B1 
Cytochrome P450, family 
1, subfamily B, 
polypeptide 1 
Participates in metabolism of an 
unknown biologically active molecule 1.48 
DCN Decorin Affects rate of fibrils formation 33.94 
DGKA Diacylglycerol kinase, alpha 
Upon cell stimulation converts the 
second messenger diacylglycerol into 
phosphatidate  
-4.37 
EFEMP1 
EGF-containing fibulin-like 
extracellular matrix protein 
1 
An antagonist of angiogenesis {{146 
Sadr-Nabavi,A. 2009; }} -13.69 
EMP1 Epithelial membrane protein 1 
Involved in the drug-resistance 
mechanism of tumours -1.81 
ETV1 ETS variant 1 Transcriptional activator  2.05 
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IL13RA2 Interleukin 13 receptor, alpha 2 
Binds as a monomer with high affinity 
to interleukin 13 13.55 
IL15 Interleukin 15 Cytokine that stimulates the proliferation of T-lymphocytes 6.56 
IL18 Interleukin 18 Augments natural killer cell activity  -16.5 
ITGB4 Integrin, beta 4 Integrin alpha-6/beta-4 is a receptor for laminin -23.69 
KRT7 Keratin 7 Blocks interferon-dependent interphase and stimulates DNA synthesis -9.44 
LAMB1 Laminin, beta 1 
Mediates attachment, migration and 
organization of cells into tissues during 
embryonic development 
1.84 
LTBP1 
Latent transforming growth 
factor beta binding protein 
1 
May be involved in the assembly, 
secretion and targeting of TGFB1 15.51 
LY75 Lymphocyte antigen 75 
Acts as an endocytic receptor to direct 
captures antigens from the 
extracellular space to a specialized 
antigen-processing compartment 
-6.34 
MAPRE2 
Microtubule-associated 
protein, RP/EB family, 
member 2 
May be involved in microtubule 
polymerization and spindle function -10.73 
MCAM Melanoma cell adhesion molecule 
Plays a role in cell adhesion and in 
cohesion of the endothelial monolayer 
at intercellular junctions in vascular 
tissue 
3.28 
MME Membrane metallo-endopeptidase 
Biologically important in the destruction 
of opioid peptides  2.16 
MMP2 Matrix metallopeptidase 2 Cleaves gelatin, collagens and KiSS1 -2.09 
MMP3 Matrix metallopeptidase 3 
Can degrade fibronectin, laminin, 
gelatins, collagens and cartilage 
proteoglycans 
7.41 
MMP7 Matrix metallopeptidase 7 Degrades casein, gelatins and fibronectin -4.2 
NDP Norrie disease 
Activates the canonical Wnt signalling 
pathway through FZD4 and LRP 
coreceptor 
-1.61 
NNMT Nicotinamide N-methyltransferase 
Catalyzed the N-methylation of 
nicotinamide and other pyridines to 
form pyridinium ions 
5.23 
NOX4 NADPH oxidase 4 Constitutive NADPH oxidase 1.91 
ORM1 Orosomucoid 1 Modulates activity of the immune system during acute-phase reaction 46.41 
PCOLCE Procollagen C-endopeptidase enhancer 
May have metalloproteinase inhibitory 
activity 3.31 
PDGFC Platelet derived growth factor C 
Potent mitogen and chemoattractant 
for cells of mesenchymal origin -14.29 
PDGFRL Platelet derived growth factor receptor-like May function as a tumour suppressor 7.3 
PLAU Plasminogen activator, urokinase 
Cleaves the zymogen plasminogen to 
form active enzyme plasmin -1.82 
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PSCDBP Cytohesin 1 interacting protein Modifies activation of ARFs  18.29 
PTPN12 
Protein tyrosine 
phosphatase, non-
receptor type 12 
May have a regulatory role in 
controlling cell shape and mobility 1.67 
S100A2 S100 calcium binding protein 2 
Plays a role in suppressing tumour cell 
growth -1.59 
S100A3 S100 calcium binding protein 3 
Involved in calcium-dependent cuticle 
cell differentiation 3.67 
SDC1 Syndecan 1 Cell surface proteoglycan  -4.34 
SERPINB5 Maspin 
Tumour suppressor, blocks growth, 
invasion and metastatic properties of 
mammary tumours 
-31.33 
SLC2A3 Solute carrir family 2 Facilitative glucose transporter 4.06 
SNAI2 Snail homolog 2, Slug Transcriptional repressor 2.93 
SOCS3 Suppressor of cytokine signalling 3 
Involved in negative regulation of 
cytokines 7.01 
TBX3 T-box 3 Transcription repressor involved in developmental processes 2.84 
TFF2 Trefoil factor 2 Inhibits gastrointestinal motility 9.71 
TNFAIP3 Tumour necrosis factor, alpha-induced protein 3 Inhibitor of programmed cell death 3.94 
TNFSF10 
Tumour necrosis factor 
(ligand) superfamily, 
member 10 
Induces apoptosis  -14.93 
TP53 Tumour protein p53 Acts as a tumour suppressor; induces growth arrest or apoptosis 1.62 
TSLP Thymic stromal lymphopoietin 
Cytokine that induces release of T cell-
attracting chemokines  3.88 
TUSC3 Tumour suppressor candidate 3 May be involved in N-glycosylation -1.99 
TXNIP Thioredoxin interacting protein 
May act as an oxidative stress 
mediator  -3.21 
WNT5A 
Wingless-type MMTV 
integration site family, 
member 5A 
Ligand for members of frizzled family 9.3 
ZNF185 Zinc finger protein 185 
May be involved in the regulation of 
cellular proliferation and/or 
differentiation 
-2.7 
 
____________________________ 
1 Supplemental Table 1 and 2 
2 Supplemental Table 3 
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Table 2.3.   qRT-PCR validated genes of interest showing significant difference 
between 21T series cell lines that are of potential clinical relevance1 and are of 
the top 10 functional and canonical pathways represented (IPA).   
 
Common 
Name Gene Name GeneCard Function 
Microarray 
Fold 
Change 
qRT-PCR 
Fold 
Change2 
21PTci to 21Ntci 
BAX BCL2-associated X protein 
Accelerates programmed cell 
death  -1.75 1.03 
DCN Decorin Affects rate of fibrils formation 7.52 6.38 
MAX MYC associated factor X Transcription regulator -1.54 -1.38 
MCM4 Minichromosome maintenance complex 4 
Involved in control of DNA 
replication -1.56 1.14 
MGA MAX gene associated Transcription regulator 3.23 2.75 
VANGL1 Vang-like 1 Planar cell polarity signalling molecule 2.19 1.60 
WISP1 WNT1 inducible signal pathway protein 1 
Downstream regulator in the 
Wnt/Frizzled signalling 
pathway 
2.18 2.15 
WNT5A 
Wingless-type MMTV 
integration site family, 
member 5A 
Ligand for members of 
frizzled family -1.89 -1.61 
21NTci to 21MT-1 
CCL20 Chemokine (C-C motif) ligand 20 Chemotactic factor  19.98 10.90 
CCR1 Chemokine receptor 1 Receptor for C-C type chemokine 7.85 4.10 
CDH1 Cadherin 1, type 1, E-cadherin 
Promotes non-amyloidogenic 
degradation  -59.88 -2.31 
CXCR4 Chemokine (C-X-C motif) receptor 4 
Receptor for the C-X-C 
chemokine CXCL12/SDF-1 -3.81 -33.33 
DCN Decorin Affects rate of fibrils formation 33.94 72.51 
S100A2 S100 calcium binding protein 2 
Plays a role in suppressing 
tumour cell growth -1.59 -3.02 
S100A3 S100 calcium binding protein 3 
Involved in calcium-
dependent cuticle cell 
differentiation 
3.67 6.44 
SERPIN
B5 Maspin 
Tumour suppressor, blocks 
growth, invasion and 
metastatic properties of 
mammary tumours 
-31.33 -47.20 
SNAI2 Snail homolog 2, Slug Transcriptional repressor 2.93 33.58 
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TBX3 T-box 3 
Transcription repressor 
involved in developmental 
processes 
2.84 2.70 
TFF2 Trefoil factor 2 Inhibits gastrointestinal motility 9.71 6.80 
TNFAIP3 Tumour necrosis factor, alpha-induced protein 3 
Inhibitor of programmed cell 
death 3.94 2.31 
WNT5A 
Wingless-type MMTV 
integration site family, 
member 5A 
Ligand for members of 
frizzled family 9.30 9.34 
 
___________________________ 
1 Genes found on clinical databases created from the literature [11-13, 43-51] 
(Supplemental Table 3)  
 
2 Seventeen genes (not BAX and MCM4) validating the microarray data      
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 apparent from this analysis that genes associated with the Wnt pathway (e.g. 
WNT5A, VANGL1, WISP1), and control of cell proliferation vs cell death (eg. 
MAX, MGA), were particularly associated with the 21PTci to 21NTci (ADH vs 
DCIS) comparison, whereas in the 21NTci to 21MT-1 (DCIS vs IMC) comparison, 
loss of tumour suppressors (e.g. SERPINB5, S100A2), alterations in 
transcriptional regulators (eg. TBX3, TNFAIP3, SNAI2), chemokines and their 
receptors (e.g. CCL20, CCR1), and genes associated with motility/invasiveness 
(e.g. TFF2, SERPINB5, S100A2) were identified. 
 
2.4. DISCUSSION 
With the institution of mammographic screening programs and advances 
in breast imaging in recent years, breast cancer is being detected at earlier 
stages [52].  The liberal use of core biopsies to assess abnormalities detected on 
imaging has reduced the number of patients inappropriately going to open biopsy 
when these lesions are benign [53], but has also increased the number of 
patients for which potential precursor lesions (such as ADH or DCIS) are 
detected [54].  When ADH or DCIS are identified on core biopsy, the mainstay of 
management is surgical excision (with radiotherapy in most cases of DCIS).  
However, there is little information on the natural biology and progression of 
these lesions [55].  When there is a chance of residual disease following 
treatment, options are limited as to further management when the lesions are 
difficult to detect (eg. lack associated calcifications) or are widespread.  Further, 
in patients who are genetically predisposed to developing these lesions (such as 
BRCA1/BRCA2 carriers), management options (short of prophylactic 
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 mastectomies) are limited [56, 57].  Although there are a few molecularly based 
systemic options for the management of DCIS either existing or under 
investigation, (e.g. tamoxifen for ER positive DCIS, trastuzumab for HER2-
positive DCIS), a better understanding of the molecular basis of progression is 
needed to develop further targeted therapy for these early lesions [58].   
Information from clinical studies examining pre-invasive lesions vs. 
invasive mammary carcinoma has yielded abundant gene expression profile 
differences between stages of progression (ADH vs. DCIS vs. IMC) (eg. [11-13, 
49, 50]).  What is lacking is the understanding of  which of these differentially 
expressed genes may be key players regulating transition through the stages of 
breast progression, not only to predict which of the lesions are more likely to 
progress, but to provide potential novel targets for preventative therapies.  
Unfortunately, few in vivo and in vitro model systems exist that would allow 
individual candidate genes to be tested for their influence on human breast 
cancer progression, or to allow for efficient screening of the many candidate 
genes of interest.  One such system, the HMT-3522 human breast epithelial cell 
series, has been described and utilized to identify specific matrix 
metalloproteinases required for the invasive phenotype [59].  A major advantage 
of such a system, wherein all of the representative cell lines are derived from the 
same patient, is that variability related to the individual’s genetic background is 
eliminated (a common problem in comparing across cell lines of differing patient 
origin).  The system we describe here has all the same advantages, and has the 
further advantage of representation of an even earlier stage, pre-DCIS (ADH-like) 
phenotype (as we described for the 21PTci cells).   
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 We found the 21PT-derived cell line 21PTci to be consistently non-
tumourigenic and non-metastatic after injection into the mammary fat pads of 
nude mice, confirming previous work [36].  However, upon histologic examination 
of the mammary fat pad of these mice, we found occasional lesions mimicking 
that of atypical ductal hyperplasia (ADH).  Features consistent with ADH were the 
mixture of two epithelial cell populations within a given duct, one normal-
appearing, the other atypical (and non-high grade), with the atypical cell 
population represented over an area of < 2.0 mm [2-4, 6].  Interestingly, when 
these cells were grown in 3D Matrigel, they were capable of forming large 
numbers of well-defined tubular/acinar structures, with maintenance of cell 
polarity in the vast majority of the groups.  Furthermore, many of these groups 
showed a mixture of cells with normal-appearing and more atypical nuclei.  
Proliferative and apoptosis rates were low and cell movement was largely 
restricted to collective organization within these groups.  
In contrast, we found the 21NT-derived cells to be tumourigenic and non-
metastatic in those mice that did form lesions (tumour take in about 20%), as 
described by Band et al. [36].  Although these cells were tumourigenic, we found 
that the majority of mice in which lesions formed showed a histology 
representative of DCIS, with no associated invasion.  The involved ducts showed 
a uniform neoplastic cell population, with intermediate and high grade nuclei, 
solid and cribriform architectural patterns, with zonal necrosis.  Only 1/7 of the 
injected animals that formed lesions showed an associated invasive component, 
which was localized to the fat pad, with no evidence of locoregional lymph node 
involvement or distant metastases.  This cell line thus represents a good model of 
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 DCIS, in that although in most injected animals it maintains morphology of DCIS 
only, it does show the potential for a low rate of spontaneous progression to 
invasive ability.  The phenotype is similar to that described for MCF10DCIS cells 
[60], although in contrast to MCF10DCIS, 21NT cells are not ras-transformed (a 
rare event in spontaneous human breast cancer), and show a more stable (less 
“leaky”) DCIS phenotype than MCF10DCIS cells, which have a higher propensity 
for invasion with time in vivo [17].  When 21NTci cells are grown in 3D Matrigel, 
features consistent with DCIS-like behaviour, including the tendency of cells to 
arrange into groups, but with poor polarization of the constituent cells, nuclear 
atypia in all the constituent cells, the spherical, non-infiltrative nature of colonies 
that formed, and a lack of translational invasive behaviour when followed by time 
lapse microscopy, were observed.      
The 21MT-1 cells, as described by Band et al. [36], were found to be 
tumourigenic (in the majority of orthopically-injected mice), and metastatic in half 
the mice that formed primary tumours.  Upon histologic examination, we found 
that all of the mice that formed tumours showed invasive mammary carcinoma 
(no special type, SBR grade III/III), most with admixed DCIS of intermediate and 
high nuclear grade in the background. Consistent with this in vivo phenotype, 
when the cells were grown in 3D Matrigel, they formed more disorganized, non-
spherical colonies, less polarization or lumen formation of cell groups, more 
single cells, and a much greater ability to show translational movement through 
Matrigel upon time-lapse microscopy, when compared to the other two cell lines.    
We have identified unique differential gene expression profiles for each of 
the 21T series cell lines, grown in Matrigel.  Interestingly, of those genes with 
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 evidence for clinical relevance, Wnt pathway alterations (eg. WNT5A, VANGL1, 
WISP1) are particularly predominant in the comparison between 21PTci and 
21NTci (representing the ADH to DCIS transition).  This is consistent with recent 
studies implicating both the canonical and noncanonical Wnt signalling pathways 
in initiation and maintenance of breast tumourigenesis (reviewed in [61]), as well 
as in cancer stem cell self renewal and the initiation of the epithelial to 
mesenchymal transition [62].  In particular, the planar cell polarity (PCP) pathway 
(a non-canonical Wnt pathway), involving ligand WNT5A, has been said to have 
either inhibitory or promoting roles in various cancers, depending on the context 
(reviewed in [63]).  It has been suggested that early in progression, the PCP 
pathway functions mainly in an inhibitory role, by down-regulating canonical Wnt 
signalling (through β-catenin), and promoting differentiation, whereas later in 
progression, the PCP pathway may promote progression, by stimulating cell 
migration and invasion [64].   In the 21T series cell lines, WNT5A is down-
regulated between 21PTci and 21NTci (ADH to DCIS), and is upregulated 
between 21NTci and 21MT-1 (DCIS to IMC), in keeping with an early suppressive 
role and a later promoting role on progression.   
Also prominent amongst genes differentially expressed between 21PTci 
and 21NTci were genes associated with signalling processes potentially involved 
with control of cell growth vs. apoptosis (eg. MAX, MGA).  Such changes, 
resulting in a net increase in cell growth (vs. apoptosis), would be consistent with 
the morphologic transition from ADH to DCIS, where the neoplastic cell 
population is seen to expand from partially, to completely filling duct cross-
sections.   In the comparison between 21NTci (DCIS-like) and 21MT-1 (IMC-like), 
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 which focuses on progression to an invasive and metastatic phenotype, 
differentially expressed genes of potential clinical relevance included the loss of 
tumour suppressors (eg. SERPINB5, S100A2), alterations in transcriptional 
regulators believed to be involved in regulating cell senescence/apoptosis (eg. 
TBX3, TNFAIP3) and promoting invasiveness and epithelial to mesenchymal 
transition (EMT) (eg. SNAI2), certain chemokines and their receptors (eg. CCL20, 
CCR1), and genes more directly associated with motility/invasiveness (eg. TFF2, 
SERPINB5, S100A2).  Collectively, these alterations would be expected to 
increase the malignancy of breast cancer cells, allowing for invasive and 
metastatic phenotypes to emerge in the DCIS to IMC transition.   
The advantages of the approach we have taken in these 21T cell 
comparisons are two-fold.  Firstly, by using a filter for genes showing altered 
expression in published clinical literature on early breast cancer progression, 
invasion/metastasis and prognosis, we have narrowed our initial search to genes 
with potential relevance in a clinical setting.  This is not to say that genes showing 
altered expression that did not “make” this list are irrelevant, but simply allows us 
to focus our search to those with some existing support for clinical import.  
Second, the use of the 21T model provides us with a manipulatable in vitro and in 
vivo system for future studies to test the relative functional impact of specific 
genes on transitions between these early stages of breast cancer progression 
(ADH to DCIS to IMC).  We expect that use of this system will provide an 
important tool to unlocking some of the intricacies of the molecular influences on 
early breast progression.  The information gathered will be critical to our ability to 
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 target and prevent this process and effectively stop breast cancer not just “in its 
tracks”, but “before it makes tracks”. 
 
2.5. REFERENCES 
 
1. Lakhani SR, Collins N, Stratton MR, Sloane JP: Atypical ductal 
hyperplasiaof the breast: clonal proliferation with loss of heterozygosity 
on chromosomes 16q and 17p. J Clin Pathol 1995, 48(7):611-615.  
 
2. Page DL, Dupont WD, Rogers LW, Rados MS: Atypical hyperplastic 
lesions of the female breast. A long-term follow-up study. Cancer 1985, 
55(11):2698-2708.  
 
3. Page DL, Dupont WD: Anatomic indicators (histologic and cytologic) of 
increased breast cancer risk. Breast Cancer Res Treat 1993, 28(2):157-
166.  
 
4. Allred DC, Mohsin SK, Fuqua SA: Histological and biological evolution of 
human premalignant breast disease. Endocr Relat Cancer 2001, 8(1):47-
61.  
 
5. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, 
O'Connell P, Tsimelzon A, Medina D: Ductal carcinoma in situ and the 
emergence of diversity during breast cancer evolution. Clin Cancer Res 
2008, 14(2):370-378.  
6. Arpino G, Laucirica R, Elledge RM: Premalignant and in situ breast 
disease: biology and clinical implications. Ann Intern Med 2005, 
143(6):446-457.  
 
7. Polyak K: Is breast tumor progression really linear? Clin Cancer Res 2008, 
14(2):339-341.  
 
8. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR,Jr, Elkahloun AG: In 
vivo gene expression profile analysis of human breast cancer 
progression. Cancer Res 1999, 59(22):5656-5661.  
 
9. Worsham MJ, Pals G, Raju U, Wolman SR: Establishing a molecular 
continuum in breast cancer DNA microarrays and benign breast 
disease. Cytometry 2002, 47(1):56-59.  
 
10. Li Z, Tsimelzon A, Immaneni A, Mohsin SK, Hilsenbeck SG, Clark GC, Fuqua 
SAW, Osborne CK, O’Connell P, Allred DC: A cDNA microarray study 
52
 comparing noninvasive and invasive human breast cancer. Proc Am 
Assoc Cancer Res 2002, 43:901-902.  
 
11. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, 
Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, 
Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC: Gene expression 
profiles of human breast cancer progression. Proc Natl Acad Sci U S A 
2003, 100(10):5974-5979.  
 
12. Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, Gaddis S, 
Sahin A, Baggerly K, Aldaz CM: Transcriptomic changes in human breast 
cancer progression as determined by serial analysis of gene expression. 
Breast Cancer Res 2004, 6(5):R499-513.  
 
13. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, 
Solomayer E, Riess O, Wallwiener D, Kurek R, Neubauer HJ: Progression-
specific genes identified by expression profiling of matched ductal 
carcinomas in situ and invasive breast tumors, combining laser capture 
microdissection and oligonucleotide microarray analysis. Cancer Res 
2006, 66(10):5278-5286.  
 
14. Medina D: The preneoplastic phenotype in murine mammary 
tumorigenesis. J Mammary Gland Biol Neoplasia 2000, 5(4):393-407.  
 
15. Cardiff RD, Moghanaki D, Jensen RA: Genetically engineered mouse 
models of mammary intraepithelial neoplasia. J Mammary Gland Biol 
Neoplasia 2000, 5(4):421-437.  
 
16. Weaver VM, Howlett AR, Langton-Webster B, Petersen OW, Bissell MJ: The 
development of a functionally relevant cell culture model of progressive 
human breast cancer. Semin Cancer Biol 1995, 6(3):175-184.  
 
17. Miller FR: Xenograft models of premalignant breast disease. J Mammary 
Gland Biol Neoplasia 2000, 5(4):379-391.  
 
18. Stampfer MR, Yaswen P: Culture models of human mammary epithelial 
cell transformation. J Mammary Gland Biol Neoplasia 2000, 5(4):365-378.  
 
19. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman 
SR, Heppner GH, Miller FR: Malignant MCF10CA1 cell lines derived from 
premalignant human breast epithelial MCF10AT cells. Breast Cancer Res 
Treat 2001, 65(2):101-110.  
 
20. Briand P, Lykkesfeldt AE: An in vitro model of human breast 
carcinogenesis: epigenetic aspects. Breast Cancer Res Treat 2001, 
65(2):179-187.  
 
53
 21. Fauquette W, Dong-Le Bourhis X, Delannoy-Courdent A, Boilly B, Desbiens 
X: Characterization of morphogenetic and invasive abilities of human 
mammary epithelial cells: correlation with variations of urokinase-type 
plasminogen activator activity and type-1 plasminogen activator 
inhibitor level. Biol Cell 1997, 89(7):453-465.  
 
22. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, 
Bissell MJ: Reversion of the malignant phenotype of human breast cells 
in three-dimensional culture and in vivo by integrin blocking antibodies. 
J Cell Biol 1997, 137(1):231-245.  
 
23. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu 
R, Bissell MJ: Reciprocal interactions between beta1-integrin and 
epidermal growth factor receptor in three-dimensional basement 
membrane breast cultures: a different perspective in epithelial biology. 
Proc Natl Acad Sci U S A 1998, 95(25):14821-14826.  
 
24. Meiners S, Brinkmann V, Naundorf H, Birchmeier W: Role of morphogenetic 
factors in metastasis of mammary carcinoma cells. Oncogene 1998, 
16(1):9-20.  
 
25. Benton G, Crooke E, George J: Laminin-1 induces E-cadherin expression 
in 3-dimensional cultured breast cancer cells by inhibiting DNA 
methyltransferase 1 and reversing promoter methylation status. FASEB 
J 2009.  
 
26. Wang X, Zhang X, Sun L, Subramanian B, Maffini MV, Soto AM, 
Sonnenschein C, Kaplan DL: Preadipocytes stimulate ductal 
morphogenesis and functional differentiation of human mammary 
epithelial cells in 3D silk scaffolds. Tissue Eng Part A 2009.  
 
27. Shaw KR, Wrobel CN, Brugge JS: Use of three-dimensional basement 
membrane cultures to model oncogene-induced changes in mammary 
epithelial morphogenesis. J Mammary Gland Biol Neoplasia 2004, 9(4):297-
310.  
 
28. Hirai Y, Lochter A, Galosy S, Koshida S, Niwa S, Bissell MJ: Epimorphin 
functions as a key morphoregulator for mammary epithelial cells. J Cell 
Biol 1998, 140(1):159-169.  
 
29. Soriano JV, Pepper MS, Orci L, Montesano R: Roles of hepatocyte growth 
factor/scatter factor and transforming growth factor-beta1 in mammary 
gland ductal morphogenesis. J Mammary Gland Biol Neoplasia 1998, 
3(2):133-150.  
 
30. Simian M, Hirai Y, Navre M, Werb Z, Lochter A, Bissell MJ: The interplay of 
matrix metalloproteinases, morphogens and growth factors is necessary 
54
 for branching of mammary epithelial cells. Development 2001, 
128(16):3117-3131.  
 
31. Niemann C, Brinkmann V, Birchmeier W: Hepatocyte growth factor and 
neuregulin in mammary gland cell morphogenesis. Adv Exp Med Biol 
2000, 480:9-18.  
 
32. Ball EM, Risbridger GP: Activins as regulators of branching 
morphogenesis. Dev Biol 2001, 238(1):1-12.  
 
33. Debnath J, Brugge JS: Modelling glandular epithelial cancers in three-
dimensional cultures. Nat Rev Cancer 2005, 5(9):675-688.  
 
34. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS: 
The role of apoptosis in creating and maintaining luminal space within 
normal and oncogene-expressing mammary acini. Cell 2002, 111(1):29-
40.  
 
35. Hebner C, Weaver VM, Debnath J: Modeling morphogenesis and 
oncogenesis in three-dimensional breast epithelial cultures. Annu Rev 
Pathol 2008, 3:313-339.  
 
36. Band V, Zajchowski D, Swisshelm K, Trask D, Kulesa V, Cohen C, Connolly 
J, Sager R: Tumor progression in four mammary epithelial cell lines 
derived from the same patient. Cancer Res 1990, 50(22):7351-7357.  
 
37. Biswas DK, Cruz A, Pettit N, Mutter GL, Pardee AB: A therapeutic target for 
hormone-independent estrogen receptor-positive breast cancers. Mol 
Med 2001, 7(1):59-67.  
 
38. Biswas DK, Averboukh L, Sheng S, Martin K, Ewaniuk DS, Jawde TF, Wang 
F, Pardee AB: Classification of breast cancer cells on the basis of a 
functional assay for estrogen receptor. Mol Med 1998, 4(7):454-467.  
 
39. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, 
Chambers AF: Osteopontin induces multiple changes in gene expression 
that reflect the six "hallmarks of cancer" in a model of breast cancer 
progression. Mol Carcinog 2005, 43(4):225-236.  
 
40. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, 
Chambers AF: Osteopontin induces increased invasiveness and 
plasminogen activator expression of human mammary epithelial cells. 
Oncogene 1999, 18(29):4237-4246.  
 
41. Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO, Al-
Katib W, Chambers AF, Tuck AB: Beta(3) integrin expression increases 
55
 breast carcinoma cell responsiveness to the malignancy-enhancing 
effects of osteopontin. Mol Cancer Res 2003, 1(11):810-819.  
 
42. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, 
Groom AC: Multistep nature of metastatic inefficiency: dormancy of 
solitary cells after successful extravasation and limited survival of early 
micrometastases. Am J Pathol 1998, 153(3):865-873.  
 
43. Asaka S, Fujimoto T, Akaishi J, Ogawa K, Onda M: Genetic prognostic 
index influences patient outcome for node-positive breast cancer. Surg 
Today 2006, 36(9):793-801.  
 
44. O'Brien N, O'Donovan N, Foley D, Hill AD, McDermott E, O'Higgins N, Duffy 
MJ: Use of a Panel of Novel Genes for Differentiating Breast Cancer from 
Non-Breast Tissues. Tumour Biol 2008, 28(6):312-317.  
 
45. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev 
V, Gerald WL, Blasberg R, Massague J: Distinct organ-specific metastatic 
potential of individual breast cancer cells and primary tumors. J Clin 
Invest 2005, 115(1):44-55.  
 
46. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, 
Guise TA, Massague J: A multigenic program mediating breast cancer 
metastasis to bone. Cancer Cell 2003, 3(6):537-549.  
 
47. Shen R, Ghosh D, Chinnaiyan AM: Prognostic meta-signature of breast 
cancer developed by two-stage mixture modeling of microarray data. 
BMC Genomics 2004, 5(1):94.  
 
48. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, 
Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, 
Foekens JA: Gene-expression profiles to predict distant metastasis of 
lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-
679.  
 
49. Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, Yoshimoto M, 
Tsunoda T, Hirata K, Nakamura Y: Genome-wide gene-expression profiles 
of breast-cancer cells purified with laser microbeam microdissection: 
identification of genes associated with progression and metastasis. Int J 
Oncol 2004, 25(4):797-819.  
 
50. Milovanovic T, Planutis K, Nguyen A, Marsh JL, Lin F, Hope C, Holcombe RF: 
Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast 
epithelium and infiltrating breast carcinoma. Int J Oncol 2004, 25(5):1337-
1342.  
 
56
 51. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, 
van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, 
Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling 
predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-
536.  
 
52. Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, Myles JP, 
Warwick J: Overdiagnosis and overtreatment of breast cancer: estimates 
of overdiagnosis from two trials of mammographic screening for breast 
cancer. Breast Cancer Res 2005, 7(6):258-265.  
 
53. El-Sayed ME, Rakha EA, Reed J, Lee AH, Evans AJ, Ellis IO: Predictive 
value of needle core biopsy diagnoses of lesions of uncertain malignant 
potential (B3) in abnormalities detected by mammographic screening. 
Histopathology 2008, 53(6):650-657.  
 
54. Provenzano E, Pinder SE: Pre-operative diagnosis of breast cancer in 
screening: problems and pitfalls. Pathology 2009, 41(1):3-17.  
 
55. Simpson JF: Update on atypical epithelial hyperplasia and ductal 
carcinoma in situ. Pathology 2009, 41(1):36-39.  
 
56. Kauff ND, Brogi E, Scheuer L, Pathak DR, Borgen PI, Hudis CA, Offit K, 
Robson ME: Epithelial lesions in prophylactic mastectomy specimens 
from women with BRCA mutations. Cancer 2003, 97(7):1601-1608.  
 
57. Isern AE, Loman N, Malina J, Olsson H, Ringberg A: Histopathological 
findings and follow-up after prophylactic mastectomy and immediate 
breast reconstruction in 100 women from families with hereditary breast 
cancer. Eur J Surg Oncol 2008, 34(10):1148-1154.  
 
58. Boughey JC, Gonzalez RJ, Bonner E, Kuerer HM: Current treatment and 
clinical trial developments for ductal carcinoma in situ of the breast. 
Oncologist 2007, 12(11):1276-1287.  
 
59. Rizki A, Weaver VM, Lee SY, Rozenberg GI, Chin K, Myers CA, Bascom JL, 
Mott JD, Semeiks JR, Grate LR, Mian IS, Borowsky AD, Jensen RA, Idowu 
MO, Chen F, Chen DJ, Petersen OW, Gray JW, Bissell MJ: A human breast 
cell model of preinvasive to invasive transition. Cancer Res 2008, 
68(5):1378-1387.  
 
60. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR: MCF10AT: a model 
for the evolution of cancer from proliferative breast disease. Am J Pathol 
1996, 148(1):313-319.  
 
61. Mohinta S, Wu H, Chaurasia P, Watabe K: Wnt pathway and breast cancer. 
Front Biosci 2007, 12:4020-4033.  
57
  
62. DiMeo TA, Anderson K, Phadke P, Feng C, Perou CM, Naber S, 
Kuperwasser C: A novel lung metastasis signature links Wnt signaling 
with cancer cell self-renewal and epithelial-mesenchymal transition in 
basal-like breast cancer. Cancer Res 2009, 69(13):5364-5373.  
 
63. Kikuchi A, Yamamoto H: Tumor formation due to abnormalities in the 
beta-catenin-independent pathway of Wnt signaling. Cancer Sci 2008, 
99(2):202-208.  
 
64. Wang Y: Wnt/Planar cell polarity signaling: a new paradigm for cancer 
therapy. Mol Cancer Ther 2009, 8(8):2103-2109.  
 
58
CHAPTER 3.  THE ROLES OF VANGL1, S100A2 AND TBX3 IN THE 
TRANSITIONS BETWEEN STAGES OF EARLY BREAST CANCER 
PROGRESSION  
 
3.1. INTRODUCTION 
 
 Ductal carcinoma is one of the most prevalent forms of breast cancer [1].  
The transition from a premalignant to a malignant, in situ lesion and the transition 
from a malignant, in situ lesion to one that can invade and metastasize are both 
important transitions in early progression.  With reference to ductal neoplasia, 
premalignant atypical ductal hyperplasia (ADH) may give rise to ductal carcinoma 
in situ (DCIS) [2-6].  This DCIS may then acquire the molecular factors necessary 
to penetrate the basement membrane, escape the breast duct and become 
invasive (invasive mammary carcinoma, IMC), potentially leading to metastasis at 
distant sites [2-4, 6, 7].  The histopathology of these distinct stages is well 
described; however, the underlying molecular events controlling progression 
remain unclear.  To study the molecular and cellular processes involved in 
controlling mammary tumour progression through these stages, predictive model 
systems are needed. 
          Chapter 2 of this thesis described the 21T human breast epithelial cell line 
3D model system of early breast cancer progression [8].  The 21T series cell 
lines were originally derived from a single patient with metastatic breast cancer 
[9] and show characteristics of different stages of breast cancer progression.  
Specifically, histologic examination of the lesions arising in nude mice injected 
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with these cells, into mammary fat pads, revealed morphologic characteristics of 
atypical ductal hyperplasia (ADH) [21PT], ductal carcinoma in situ (DCIS) without 
invasion [21NT], and invasive mammary carcinoma (IMC) [21MT-1].  When the 
21T series cell lines were grown in a 3D culture system, which mimics the tissue 
environment, these growth characteristics were retained.  Additionally, gene 
expression profiling of the 21T series cells in 3D culture has revealed stage-
specific patterns and has identified many key targets which may be involved in 
controlling the transitions between stages of early breast cancer progression [8].   
 The key targets identified by gene profiling were common to literature 
based on clinical specimens of ADH, DCIS and invasive breast cancer (IMC).  
The present study sought to functionally characterize the role of three of the 
identified targets in controlling the transitions between stages of early breast 
cancer progression.  For the transition from ADH to DCIS, VANGL1, which was 
expressed at higher levels in 21NT (DCIS-like) cells compared to 21PT (ADH-
like) cells, was functionally characterized to determine its role in promoting 
conversion to malignancy (Figure 3.1).  Two genes in the DCIS to IMC transition 
were chosen for further analysis.  S100A2, which was expressed at a lower level 
in 21MT-1 (IMC-like) cells compared to 21NT (DCIS-like) cells, was assessed for 
its role in inhibiting progression to invasion (Figure 3.1).  TBX3, which was 
expressed at higher levels in 21MT-1 (IMC-like) cells compared to 21NT (DCIS-
like) cells, was characterized to determine its role in the transition to an invasive 
phenotype (Figure 3.1).        
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↑ VANGL1 ↓ S100A2
↑ TBX3
Figure 3.1. Genes identified as altered between 21T series cell lines and
breast cancer progression stages. VANGL1 is increased in 21NT (DCIS-like)
cells compared to 21PT (ADH-like) cells. S100A2 is decreased in 21MT-1
(IMC-like) cells compared to 21NT (DCIS-like) cells. Finally, TBX3 is
increased in 21MT-1 (IMC-like) cells compared to 21NT (DCIS-like) cells.
ADH
(21PT)
DCIS
(21NT)
IMC
(21MT-1)
Normal breast cells 
Neoplastic cells 
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3.1.1.  Van Gogh-like 1 (VANGL1) 
 Van Gogh-like 1 (VANGL1) is a member of the transmembrane 4 
superfamily and is the human homolog of the Drosophila polarity gene, van 
gogh/strabismus.  VANGL1 has been found to promote malignancy and invasion 
in several types of cancer, including gastric, squamous cell and laryngeal [10-12].  
Additionally, loss of VANGL1 suppresses colon cancer metastasis [13].  
Recently, VANGL1 was identified as a binding partner of the metastasis 
suppressor KAI1 (CD82) and renamed to KAI1 COOH-terminal interacting 
tetraspanin (KITENIN) [10].  It was theorized that VANGL1 promoted metastasis 
by interfering with the metastasis-suppressing ability of KAI1 either through its 
interaction with KAI1 or by regulating downstream signalling effectors involved in 
cell invasion [10] (Figure 3.2).  Specifically, KAI1 interacts with integrin α3β1 and 
the binding of KAI1 with VANGL1 may interfere with the KAI1-integrin interaction, 
leading to a release of α3β1 and an inhibition of integrin-mediated invasion [10].  
Additionally, KAI1 is associated with protein kinase C (PKC), which mediates 
phosphorylation of MARCKS (myristoylated alanine-rich C kinase substrate) and 
ERMs (ezrin, radixin and moesin) resulting in a reorganization of existing actin 
structures and allowing for reassembly of new actin structures that promote 
migration [14].  It has been theorized that KAI1 suppresses cell motility through a 
negative influence on PKC, c-Met and epidermal growth factor receptor (EGFR) 
[14].  It is possible that the binding of VANGL1 to KAI1 eliminates the KAI1 
suppression effects.   
The noncanonical Wnt/planar cell polarity (PCP) pathway plays a role in 
cancer progression.  The PCP pathway is activated by the binding of 
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Figure 3.2. VANGL1 cell signalling. VANGL1 interacts with the metastasis-
suppressor KAI1. KAI1 interacts with α3β1 integrin to inhibit invasion. KAI1
also negatively influences protein kinase C (PKC), which mediates
phosphorylation of ERM and MARCKs, leading to actin cytoskeleton
organization and migration. VANGL1 is a core plan cell polarity component
of the Wnt/planar cell polarity (PCP) pathway and acts as a scaffolding
protein for Dishevelled (Dvl) and PKC. This functional complex promotes
motility through signalling with MAPK/ERK to elevate levels of the AP-1
transcription factor. Finally, in mammalian cells, interaction of VANGL1 with
the atypical cadherins Celsr1-3 may be involved in establishment of cell
polarity in a fashion similar to complexes with Flamingo (Fmi) in Drosophila.
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noncanonical Wnt molecules, such as Wnt5a, to the Frizzled (Fzd) receptor.  
VANGL1 is a core planar cell polarity component and acts as a scaffolding 
protein for Dishevelled (Dvl) and PKC [15] (Figure 3.2).  A recent study found that 
the functional complex formed by VANGL1, Dvl and PKCδ promotes colorectal 
cancer cell migration and invasion [16].  The increased cell motility is dependent 
on MAPK/ERK (Mitogen-activated protein kinase/extracellular signal-regulated 
kinase) signalling, which leads to elevated levels of the AP-1 transcription factor.  
The AP-1 transcription factor is composed of c-Jun, c-Fos and Fra-1 and 
regulates expression of matrix metalloproteinases (MMPs), adhesion and 
cytoskeleton regulators, which control cell motility and invasion.  A separate study 
found that AP-1 activation by VANGL1 causes tumour progression in human 
gastric cancer [17].  Finally, in Drosophila, Vangl1 has been found to assist in the 
establishment of cell polarity through interaction with the atypical cadherin 
Flamingo (Fmi) in one cell and a Fmi-Fzd complex in an adjoining cell [14].  In 
mammalian cells, atypical cadherin Celsr molecules (1,2,3) have been found to 
complex with VANGL1 and may be involved in cell-cell contacts and polarization 
similar to Fmi in flies [18-20].  The involvement of VANGL1 in the PCP pathway 
further points to the role of VANGL1 in malignancy, as well as invasion.                  
 Although a role for VANGL1 has been established in many types of cancer 
(eg. colonic, gastric, head and neck), the role of VANGL1 in breast cancer has 
yet to be elucidated.  In relation to the 21T human breast epithelial cell line 3D 
model system of early breast cancer progression, VANGL1 was elevated in 21NT 
(DCIS-like) cells compared to 21PT (ADH-like) cells.  The present study made 
use of the 21T series cells grown in 3D culture to test the hypothesis that 
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overexpressing VANGL1 in 21PT cells would results in the cells acquiring 
characteristics of malignancy, making them more like 21NT (or 21MT-1) cells.         
 
3.1.2.  S100A2 
 S100A2 is a member of the S100 EF-hand calcium binding protein family, 
several of which have been implicated in cancer progression [21].  S100A2 is an 
unusual member in that unlike the majority of the S100 family members, S100A2 
expression is downregulated in many cancers and it has been shown to be a 
potential tumour suppressor [21].  The exact mechanisms of the tumour 
suppressor activity of S100A2 are at present uncertain, although there are 
several potential regulatory functions suggested based on its involvement in 
different protein-protein interactions, particularly at the nuclear level.  It was 
recently discovered that S100A2 binds the p53 tumour suppressor and this may 
be involved in the stimulation of p53 activity by S100A2 [22], resulting in cell cycle 
arrest and apoptosis (Figure 3.3).  A study in lung adenocarcinomas found further 
functions of S100A2, including induction of RUNX3 (runt-related transcription 
factor 3), and repression of EGFR and NFkB2 (nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 2) [23] (Figure 3.3).  Runt domain 
transcription factor RUNX3 (runt-related transcription factor 3) is a gastric and 
colon tumour suppressor that functions downstream of TGFβ (transforming 
growth factor beta) [24].  EGFR signalling is potentially involved in multiple 
aspects of malignancy, including tumour growth, inhibition of apoptosis, cell 
migration and invasion [25], while NFkB2 has been linked to control over tumour 
cell growth, migration and invasion [26].  The tumour suppressing action of 
65
TGFβ
S100A2
Nuclear effects
Cox 2 expression
EGFR expression
NFkB2 expression
p53 expression & activity
RUNX3 expression
Cox-2 EP1,3,4
PGE2
Cell migration
Cell invasion
Cell proliferation
Cell cycle arrest
Apoptosis
? Differentiation
EGF
EGFR
Cell growth
Cell migration
Cell invasion
Figure 3.3. Nuclear effects of S100A2. S100A2 has been shown to reduce
expression of cyclooxygenase-2 (Cox-2), which normally results in the
synthesis and release of prostaglandin E2 (PGE2). PGE2 subsequently
promotes cell migration, proliferation and invasion. S100A2 also inhibits
epidermal growth factor receptor (EGFR) expression, repressing the cell
growth, migration and invasion effects of EGF. Similarly, S100A2 inhibits
NFkB2 (nuclear factor of kappa light polypeptide gene enhancer in B-cells 2)
expression and its associated downstream signalling. S100A2 also
promotes p53 expression and activity, leading to cell cycle arrest and
apoptosis. Finally, S100A2 has been found to induce RUNX3 (Runt-related
transcription factor 3), which functions downstream of transforming growth
factor β (TGFβ).
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S100A2 has also been theorized to be in part a result of its ability to reduce 
cyclooxygenase-2 (Cox-2), the upregulation of which is associated with 
tumourigenesis in many cancers [27] (Figure 3.3).  In fact, it was found that in 
breast cancer cells, Cox-2 overexpression enhanced cell motility and 
invasiveness [28].  Cox-2 expression results in the release of the pro-
inflammatory mediator prostaglandin E2 (PGE2), which acts on its cell surface 
receptors EP1, EP2, EP3 and EP4 [29].  In head and neck squamous cell 
carcinoma (HNSCC), exogenous PGE2 induced cell proliferation and it was 
concluded that PGE2 produced in the tumour microenvironment, as a result of 
Cox-2 overexpression, promoted the growth of HNSCC cells in both an autocrine 
and paracrine fashion by acting on EP receptors, which are widely expressed in 
most HNSCC cells [29].  Thus, blocking of Cox-2 by S100A2 should result in 
reduced cell motility, proliferation and invasiveness.  Consequently, loss of 
S100A2 results in tumour progression.                
 Although various studies have shown S100A2 to be downregulated in 
malignancy of breast cancer [30, 31], very little is known about the exact 
functional roles of S100A2 in breast cancer.  In relation to the 21T human breast 
epithelial cell line 3D model system of early breast cancer progression, S100A2 
expression was decreased in 21MT-1 (IMC-like) cells compared to 21NT (DCIS-
like) cells.  The present study used the 21T series cells grown in 3D culture to 
test the hypothesis that knocking down S100A2 in 21NT cells would result in the 
cells becoming more invasive, with characteristics similar to the 21MT-1 cells.       
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3.1.3.  T-box 3 (TBX3) 
 TBX3 is a member of the T-box family of transcription factors that play an 
important role in development of many animal species.  Specifically, TBX3 
mutant mice have demonstrated that TBX3 is required for expression of Lef-1 
and Wnt10b, which induce mammary placodes [32].  In mouse embryo 
development, a model has emerged in which TBX3 expression is both induced 
and maintained in early mammary gland initiation by Wnt and FGF (fibroblast 
growth factor) [33].  Also in mouse development, TBX3 and Sonic hedgehog 
(Shh) regulate one another and loss of TBX3 results in loss of Shh [32] (Figure 
3.4).  In humans, ulnar-mammary syndrome (UMS), a congenital autosomal-
dominant disorder, is caused by mutations that result in haplo-insufficiency of the 
TBX3 protein.  UMS is characterized by upper-limb anomalies and mammary 
gland hypoplasia, as well as hair, genital and dental defects [34].  Additionally, 
TBX3 has been linked to tumourigenesis and is involved in cell cycle control and 
inhibition of cell senescence, through both p53-dependent and independent 
pathways [35-37].  The p53-dependent pathway signals through p14 (ARF), a 
tumour suppressor and cell cycle control protein, which is in turn repressed by 
TBX3 [35] (Figure 3.4).  More recently, it was discovered that the mechanism of 
TBX3 repression of p14 (ARF) involves recruitment of histone deacetylases 
(HDACs) [38].  Downregulation or inhibition of p14 (ARF) leads to increased 
proliferation and immortalization, as well as failure of apoptosis [32].  Apart from 
the p14 (ARF) dependent function of TBX3, in melanoma it was found that TBX3 
repressed E-cadherin expression, which leads to enhanced invasiveness [39] 
(Figure 3.4).  In a similar fashion to that occurring during development, it was 
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Figure 3.4. Effects and signalling of TBX3. In development, TBX3 is
induced and maintained by Wnt and fibroblast growth factor (FGF) signalling.
It is also both regulated by Sonic hedgehog (Shh) and regulates Shh. In
cancer, TBX3 has been shown to inhibit senescence and promote
proliferation through repression of P14 (ARF) and consequently p53. TBX3
has also been shown to be inversely related to E-cadherin, resulting in
increased invasiveness and reduced cell-cell adhesion. Finally, in stem cells,
TBX3 promotes pluripotency and reprogramming and dampens
responsiveness to differentiation signals, a function that has not yet been
proven in cancer.
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found in liver cancer that TBX3 transcription is activated by Wnt/β-catenin 
signalling [40].  This same study found that TBX3 is a mediator of β-catenin 
activity, influencing cell proliferation and survival.  TBX2, and TBX3 by relation, 
have also been implicated in regulating cell cycle control.  TBX2 has been shown 
to upregulate Cdc2, which promotes entry into mitosis, and MAD2, which is 
involved in spindle checkpoint activation [32].  A recent study of induced 
pluripotent stem (iPS) cells found a role for TBX3 in promoting pluripotency [41].  
The stem cells are generally generated from mouse embryonic fibroblasts after 
treatment with a combination of Oc4, Sox2 and Klf4.  However, the addition of 
TBX3 improved the pluripotency and reprogramming potential of the cells, 
dampening the response to differentiation signals.                         
 Two different isoforms of TBX3 have been identified, TBX3 and TBX3+2a.  
The TBX3+2a variant has an extra 22 amino acids, encoded by exon 2a, inserted 
into the T-box domain [34].  It was theorized that since the 2a insertion was inside 
the highly conserved T-box domain, which is required for deoxyribonucleic acid 
(DNA)-binding and protein-protein interactions, this variant would have altered 
DNA-binding properties [42].  In fact, Fan and colleagues [42] did find that the 
TBX3+2a isoform was unable to bind the consensus T-box DNA-binding site and 
this resulted in the isoform not inhibiting senescence, as has been shown for 
TBX3, but instead accelerating senescence.  A more recent study, however, has 
found that TBX3+2a can bind the DNA-binding site and is an anti-senescence 
factor in melanoma [43].  The original paper that described TBX3 as an anti-
senescence factor was published by Brummelkamp and colleagues [35].  
Interestingly, the study by Hoogaras et. al. [43] sequenced the cDNA from the 
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original Brummelkamp paper and found that it was in fact the TBX3+2a splice 
variant that was used in the study, indicating that Brummelkamp et al. [35] 
provides further evidence that the TBX3+2a variant does in fact exhibit a 
functional effect.  The present study also seeks to examine both TBX3 isoforms.  
Since most literature refers to TBX3 in general and not in reference to any 
isoform, for simplicity in this thesis, when we are referring to both isoforms of 
TBX3 (or when an isoform is not identified), we will state TBX3.  The two splice 
variants will be referred to as TBX3 isoform 1 (TBX3 variant) and TBX3 isoform 2 
(TBX3+2a variant). 
  Very little is known about TBX3 function in breast cancer, although it has 
potential as a master regulator and clinical studies have shown it to be elevated 
during progression.  In relation to the 21T human breast epithelial cell line 3D 
model system of early breast cancer progression, TBX3 expression was 
increased in 21MT-1 (IMC-like) cells compared to 21NT (DCIS-like) cells.  The 
present study used the 21T series cells grown in 3D culture to test the hypothesis 
that overexpressing both isoforms of TBX3 in 21NT cells would result in the cells 
acquiring the characteristics of an invasive phenotype, similar to the 21MT-1 
cells.       
 
3.2. MATERIALS AND METHODS   
 
3.2.1.  Cell Lines and Culture 
The 21T series cell lines (21PT, 21NT, 21MT-1) were maintained in culture 
in αHE media, which consists of α-MEM (minimal essential medium) 
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supplemented with 2mM L-glutamine (Gibco Life Technologies, Grand Island, 
NY), insulin (1 µg/mL), epidermal growth factor (12.5 ng/mL), hydrocortisone (2.8 
mM), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM 
sodium pyruvate, 0.1 mM nonessential amino acids and 50mg/mL gentamycin 
reagent (all from Sigma Chemical, St. Louis, MO).  For regular culture conditions, 
the αHE media was further supplemented with 10% fetal bovine serum (FBS; 
Gibco Life Technologies) and named αHE10F.  Transfected cell lines, created 
from the parental 21T series cells were also maintained in αHE10F media.  Both 
the VANGL1 transfected cells (21PT+EV, 21PT+VANGL1) and the TBX3 
transfected cells (21NT+EV, 21NT+ TBX3 Iso1, 21NT+TBX3 Iso2) had 0.2 
mg/mL G418 (Gibco Life Technologies) added to the culture medium as a 
selection marker, while 0.2 µg/mL Puromycin (Invitrogen Life Technologies, 
Mississauga, ON) was added to the medium of S100A2 transfected cells 
(21NT+EV, 21NT+shS100A2) as a selection marker.    
 
3.2.2.  VANGL1 Expression Vector 
 An expression vector for VANGL1 was constructed in order to overexpress 
VANGL1 protein in 21PT cells and assess its functional role in early breast 
cancer progression.  To construct the expression vector, VANGL1 cDNA was 
PCR-amplified using a pCMV-SPORT expression vector containing VANGL1 
(Genbank accession number: BC065272), provided by the Centre for Applied 
Genomics at The Hospital for Sick Children (University of Toronto) as the cDNA 
template.  PCR amplification was performed using Phusion High-Fidelity DNA 
Taq Polymerase (New England BioLabs, Pickering, ON) and the following 
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conditions: 98oC for 30 sec, followed by 40 cycles of 98oC for 7 sec, 62oC for 15 
sec and 72oC for 45 sec and finally a 72oC hold for 8 min.  The primers for PCR 
amplification can be found in Table 3.1.  Five separate PCR reactions were 
completed and run on a 1% agarose gel.  Bands at the appropriate size (~1500 
kb) were gel extracted, using a QIAquick gel extraction kit (Qiagen, Mississauga, 
ON) and pooled.  Next, the VANGL1 PCR product was incubated with T4 
polynucleotide kinase (T4 PNK; New England BioLabs) to phosphorylate the 
insert.  Finally, the VANGL1 PCR product was purified using a QIAquick PCR 
purification kit (Qiagen), following the manufacturer’s protocol and the 
concentration was determined by spectrophotometry, using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific, Mississauga, ON).   
 VANGL1 was inserted into a pcDNATM3.1/myc-His B plasmid (Invitrogen 
Life Technologies), such that the myc tag would be fused to the C-terminus of 
VANGL1.  To prepare the plasmid for ligation with the VANGL1 insert, the 
plasmid was digested with EcoRV (New England BioLabs) to insert the VANGL1 
downstream of the pCMV promoter, into the multiple cloning site (Figure 3.5).  
EcoRV digestion results in a blunt end cut.  The plasmid was subsequently 
incubated with calf intestinal phosphatases (CIP; New England BioLabs) to de-
phosphorylate the plasmid.  The plasmid was then electrophoresed on a 1% 
agarose gel and extracted using the QIAquick gel extraction kit (Qiagen).  The 
concentration of the processed plasmid was determined using the NanoDrop 
1000 Spectrophotometer (Thermo Scientific).   
 The plasmid and VANGL1 PCR product were incubated overnight with 
ATP (adenosine triphosphate) and T4 DNA ligase (both from New England 
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Table 3.1.  Primer sequences for VANGL1 cloning, TBX3 cloning and TBX3 qRT-
PCR.  
  
Primer Name Sequence 
 
VANGL1 Cloning Primers  
Forward  5’-GCC ACC ATG GAT ACC GAA TCC ACT-3’ 
Reverse  5’-AAC GGA TGT CTC AGA CTG TAA GCG-3’ 
 
TBX3 Cloning Primers  
Iso2 / Iso1 Frag 1 Forward  5’-GCC ACC ATG AGC CTC TCC ATG AGA-3’ 
Iso1 Frag1 Reverse  5’-CAT GGA GTT CAA TAT AGT AAA TCC ATG TTT GAC-3’ 
Iso1 Frag2 Forward  5’-TGG ATT TAC TAT ATT GAA CTC CAT GCA CAA AT-3’ 
Iso2 / Iso1 Frag2 Reverse  5’-TTC GGG ACC GCC TGC GGG ACC TGT CCG GC-3’ 
 
TBX3 qRT-PCR Primers 
Endogenous Forward 5’-GCG GAC TTG TCC CCG GCT GG-3’ 
Endogenous Iso1 Reverse 5’-CAT GGA GTT CAA TAT AGT AAA TCC ATG TTT GTC TG-3’ 
Endogenous Iso2 Reverse 5’-CAC TTG GGA AGG CCA AAG TAA ATC CAT G-3’ 
TBX3-ZsGreen Forward 5’-CAC CGC CAC CCC TTC CTC AAT CTG AAC AC-3’ 
TBX3-ZsGreen Reverse 5’-GTG GCG ACC GGT AGC AAC TAC GGG GAC GCG-3’ 
 
Cloning primers for VANGL1 were used to PCR amplify VANGL1, using a pCMV-
SPORT expression vector containing VANGL1 as template.  Cloning primers for 
TBX3 were used to PCR amplify isoforms of TBX3 using a pOTB7 expression 
vector containing TBX3 as template.  A Kozak consensus sequence was added 
to the forward primer of the cloning primers, immediately upstream of the 
translation start site of the specific gene (VANGL1 or TBX3), to ensure a high 
level of translation initiation.  Extra amino acids were also added to the reverse 
primer of the cloning primers to ensure the specific gene (VANGL1 or TBX3) was 
in frame in relation to the plasmid (VANGL1, pcDNATM3.1/myc-His B; TBX3, 
pZsGreen-C1).  Lastly, the stop codon was removed from the reverse primers so 
that myc (VANGL1) or ZsGreen (TBX3), fused to the C-terminus, would be 
transcribed.  The two isoforms of TBX3 were PCR-amplified separately.  
Amplification of TBX3 Iso1 required production of two TBX3 fragments, which 
were annealed to produce TBX3 Iso1, while the forward primer of fragment 1 
(Frag1) and the reverse primer of fragment 2 (Frag2) were used to PCR amplify 
TBX3 Iso2 (see Figure 3.6).  TBX3 qRT-PCR primers were used to amplify 
endogenous TBX3 Iso1 and Iso2, as well as the TBX3-ZsGreen fusion product.  
For endogenous TBX3, the forward primer was common for both isoforms and   
was located within the 5’UTR.  The reverse primers for endogenous TBX3 Iso1 
spanned the splice junction, while TBX3 Iso2 reverse primer was within the 22 aa 
insert, thus ensuring specificity of each isoform during PCR amplification.  The 
forward primers for TBX3-ZsGreen were downstream of the splice junction, in 
order to amplify both isoforms.  The reverse primer for TBX3-ZsGreen spanned 
the junction between TBX3 and ZsGreen.      
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Figure 3.5. Plasmid map for VANGL1 expression vector. Protein expression
was driven by a human cytomegalovirus (CMV) promoter. VANGL1 was
inserted into the multiple cloning site of a pcDNATM3.1/myc-His B plasmid by
restricting enzyme digest with EcoRV, which creates a blunt cut. Insertion
into the multiple cloning site allowed insertion in frame with the myc epitope,
the polyhistide C-terminal tag and the stop codon. The plasmid also
contained a Neomycin resistance gene to enable selection of stable
transfectants.
PCMV T7 myc
6X 
His
TGA NeomycinVANGL1
EcoRV
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BioLabs) at 16 degrees to complete the ligation (Figure 3.5).  Competent bacteria 
(DH5alpha, made in-house) were then transformed with the ligated plasmid and 
streaked on Luria Bertani (LB) agar (Invitrogen Life Technologies) plates with 50 
µg/mL ampicillin (Gibco Life Technologies).  Thirty bacteria colonies were picked 
and expanded in LB+ ampicillin media, and DNA was isolated using a GenElute 
mammalian genomic DNA miniprep kit (Sigma Chemical).  The DNA was 
digested with KpnI (New England BioLabs) and run on a 1% agarose gel as a 
preliminary check to see if the insertion was the correct size and in the correct 
orientation.  Seven of the 30 clones were sent to the DNA Sequencing Facility at 
Robarts Research Institution (London, ON) for sequencing.  Clones with the 
proper sequence were used for stable transfections.                            
 
3.2.3.  TBX3 Expression Vector 
Two expression vectors for TBX3 were constructed in order to 
overexpress TBX3 protein in 21NT cells and to subsequently assess its functional 
role in early breast cancer progression.  Since TBX3 has two variants/isoforms, 
an expression vector was constructed for both, referred to here as TBX3 Isoform 
1 (TBX3 Iso1) and TBX3 Isoform 2 (TBX3 Iso2) (also referred to as TBX3+2a).  
To construct the expression vectors, TBX3 Iso1 and TBX3 Iso2 cDNA was PCR-
amplified using a pOTB7 expression vector containing TBX3 Iso2 (Genbank 
accession number: BC025258; Open Biosystems, Thermo Scientific) as the 
cDNA template.  TBX3 Iso2 has an additional 22 amino acid (66 base pair (bp)) 
sequence, encoded by exon 2a, inserted into the T-box domain [34].  To obtain 
TBX3 Iso2, PCR amplification of the whole transcript was performed using 
76
Phusion High-Fidelity DNA Taq polymerase (New England BioLabs) and the 
following conditions: 98oC for 30 sec, followed by 40 cycles of 98oC for 5 sec, 
62oC for 15 sec and 72oC for 1 min and finally a 72oC hold for 8 min.  To produce 
TBX3 Iso1, two PCR product fragments, representing the transcript before 
(fragment 1) and after (fragment 2) the 66 bp TBX3 Iso2 addition, were PCR 
amplified (Figure 3.6A), using the same conditions as for TBX3 Iso2.  PCR primer 
sequences for TBX3 Iso2 and both fragments of TBX3 Iso1 can be found in Table 
3.1.  Three separate PCR reactions were completed for TBX3 Iso2 and each 
fragment of TBX3 Iso1 and then run on a 1% agarose gel.  Bands representing 
TBX3 Iso2 at approximately 2000 kb were extracted and pooled.  For TBX3 Iso1, 
a band at ~660 kb for fragment 1 and a band at ~1380 kb for fragment 2 were gel 
extracted and pooled.  When designing the PCR primers for the two fragments of 
TBX3 Iso1, the reverse primer of the upstream amplicon (fragment 1) and the 
forward primer for the downstream amplicon (fragment 2) had a 20 bp overlap to 
ensure that the ends of these amplicons would anneal in a subsequent PCR 
reaction to melt the fragments together.  To anneal these two fragments and 
generate TBX3 Iso1, 100 ng of each fragment was used as template in a PCR 
reaction without primers, using Phusion High-Fidelity DNA Taq polymerase (New 
England BioLabs).  The cycling conditions were 98oC for 5 min and then 72oC for 
15 min.  The annealed TBX3 Iso1 PCR product was purified using a QIAquick 
PCR purification kit (Qiagen) and then complete TBX3 Iso1 was PCR amplified 
using the annealed product as template.  The primers for this PCR amplification 
were the forward primer for the translational start site for TBX3 (TBX3 Iso2/TBX3 
Iso1 fragment 1 forward primer) and the end of the coding sequence immediately 
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Figure 3.6. Cloning primer design and plasmid map for TBX3 expression
vector. A) TBX3 isoform 2 contains a 22 amino acid insert encoded by exon
2a. Since isoform 1 was missing the exon 2a insert, primers were designed
to amplify 2 fragments of isoform 1 separately. Fragment 1 encompassed
TBX3 before the 2a insert, while Fragment 2 encompassed TBX3 after the 2a
insert. In addition, an amino acid linker from the Fragment 2 forward primer
was added to the reverse primer for Fragment 1, while an amino acid linker
from the Fragment 1 reverse primer (positive strand) was added to the
forward primer of Fragment 2. Also, the Fragment 1 forward primer
contained a Kozak sequence, while in the Fragment 2 reverse primer, the
stop codon was removed and 2 amino acids were added so that the insert
would be in frame with ZsGreen. The forward primer for Fragment 1 and
reverse primer for Fragment 2 were used to PCR-amplify both isoform 2 and
the complete isoform 1 product once the two fragments were annealed
together. B) Protein expression was driven by a human (CMV) immediate
early (IE) promoter. TBX3 isoforms were inserted into the pZsGreen-C1
plasmid before the ZsGreen coding sequence by restricting enzyme digest
with AfeI, which creates a blunt cut. TBX3 was inserted before ZsGreen,
instead of in the multiple cloning site (MCS) so that ZsGreen would be fused
to the C-terminal of the TBX3 isoforms. The plasmid also contained a
Neomycin resistance gene to enable selection of stable transfectants .
A)
B)
TBX3 Isoform 1 (TBX3 variant)
TBX3 Isoform 2 (TBX3+2a variant)
1 2100
Exon 2a
AfeI
PCMV IE ZsGreen NeomycinMCS
TBX3 Isoform 1 DNA insert OR
TBX3 Isoform 2 DNA insert
TBX3
Fragment 1 Fragment 2 
1 658 718 2100
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upstream of the stop codon (TBX3 Iso2/TBX3 Iso1 fragment 2 reverse primer).  
The complete TBX3 Iso1 PCR product was then run on a 1% agarose gel and 
extracted using a QIAquick gel extraction kit (Qiagen).  The extracted TBX3 Iso1 
and TBX3 Iso2 PCR products were then incubated with T4 PNK (New England 
BioLabs), PCR purified and the concentration of each was determined by 
spectrophotometry (NanoDrop 1000 Spectrophotometer, Thermo Scientific).              
TBX3 Iso1 and TBX3 Iso2 were inserted separately into pZsGreen-C1 
plasmids (Clonetech Laboratories, Mountain View, CA), such that the ZsGreen 
was fused to the C-terminus of TBX3 Iso1 or TBX3 Iso2.  To prepare the plasmid 
for ligation with the TBX3 inserts, the plasmid was digested with AfeI (New 
England BioLabs) so TBX3 was inserted upstream of the ZsGreen1 coding 
sequence and not in the multiple cloning site (Figure 3.6B).  AfeI digestion results 
in a blunt end cut.  After digestion, the plasmid was incubated with CIP (New 
England BioLabs) to de-phosphorylate the plasmid.  The plasmid was then 
electrophoresed on a 1% agarose gel and extracted using a QIAquick gel 
extraction kit (Qiagen).  The concentration of the processed pZsGreen-C1 
plasmid was determined using a NanoDrop 1000 Spectrophotometer (Thermo 
Scientific).   
 The plasmid and TBX3 isoform PCR products were incubated overnight 
with ATP and T4 DNA ligase (New England BioLabs) at 16oC to complete the 
ligation (Figure 3.6B).  Competent bacteria (DH5alpha) were then transformed 
with the ligated plasmids and streaked on LB agar (Invitrogen Life Technologies) 
plates with 50 µg/mL kanamycin (Gibco Life Sciences).  Fifteen bacteria colonies 
per TBX3 isoform were picked and expanded in LB+kanamycin media, and the 
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DNA was isolated using a GenElute mammalian genomic DNA miniprep kit 
(Sigma Chemicals).  The DNA was digested with the following restriction enzyme 
pairs: AgeI and KpnI, MfeI and XhoI, Nhe1 and HndIII (New England BioLabs).  
The resulting fragments were run on a 1% agarose gel as a preliminary check to 
see if the insertions were the correct size and in the correct orientation.  Five 
clones for each isoform were sent to the DNA Sequencing Facility at Robarts 
Research Institution (London, ON) for sequencing.  Clones with the proper 
sequence were used for stable transfections.                            
 
3.2.4.  shRNA against S100A2 
 Short hairpin ribonucleic acid (shRNA) against S100A2 was constructed in 
order to determine the role of S100A2 in early breast cancer progression.  The 
shRNA was a kind gift from Dr Michael Golding (Texas A&M University).  Three 
separate S100A2 shRNAs in addition to an empty vector shRNA were 
constructed (Figure 3.7) [44].  Competent bacteria were transformed with the 
plasmids expressing the shRNA’s and streaked on LB agar (Invitrogen Life 
Technologies) plates with 50 µg/mL ampicillin (Gibco Life Sciences).  Ten 
colonies were chosen for each shRNA plasmid.  In order to determine which of 
the shRNA’s against S100A2 knocked down S100A2 gene expression most 
efficiently, 21NT cells were transiently transfected with all three shRNA’s 
separately.  qRT-PCR was used to determine the change in S100A2 mRNA 
expression, following the same methodology as above.  One shRNA construct 
was able to reduce S100A2 mRNA expression by 45% and was subsequently 
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Figure 3.7. Plasmid map for S100A2 shRNA vector. The plasmid was
obtained as a kind gift from Dr Michael Golding and the map has been
adapted from the one provided by him. This is a miR-based shRNA
expression cassette and is driven by an RNA polymerase II (Pol II) promoter.
The DNA sequence for S100A2 shRNAmir amplification is cloned in between
XhoI and EcoR1 sites. The plasmid contains a Puromycin resistance gene to
enable selection of stable transfectants. The plasmid also contains an
internal ribosome entry site (IRES) for translational initiation in the middle of
the mRNA sequence and a green florescent protein (GFP) tag.
5’LTR Puromycin IRES GFP 3’LTR
Packaging 
Signal
Long terminal  repeat
Strong Pol II promoter
miR5’ miR3’
XhoI EcoR1
DNA sequence for S100A2 shRNAmir amplification
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used for stable transfections.  The sequence of the shRNA chosen for S100A2 
knockdown can be found in Appendix C Table 1. 
   
3.2.5.  Transient and Stable Transfections 
 Stably transfected cell lines were created to overexpress VANGL1 in 21PT 
cells and both isoforms of TBX3 in 21NT cells.  In addition, 21NT cells were 
stably transfected with shRNA against S100A2, after preliminary transient 
transfections with the three S100A2 shRNA constructs mentioned above.  For all 
stable transfections, empty vector controls were also transfected into the 
appropriate cell line.  Lipofectin® Reagent (Invitrogen Life Technologies) 
methodology was used for both stable and transient transfections.  The day 
before transfection, 21PT or 21NT cells were seeded in 6-well plates at a density 
that would result in 80% confluency the next day (350,000 cells per well).  The 
following day, cells were transfected with 1µg of the appropriate expression 
vector or shRNA DNA, following the manufacturer’s protocol.  One day after 
transfection, the transfection media was replaced with αHE10F.  Three days 
following transfection, total RNA was collected from 21NT cells transiently 
transfected with shRNA against S100A2 using TRIzol (Invitrogen Life 
Technologies) methodology.  Stable transfections were subcultured into T25 
culture flasks (Nunc Brand Products, Rochester, NY) three days following 
transfection.  Puromycin (S100A2 shRNA vector) or G418 (VANGL1 and TBX3 
expression vectors) selection was added to αHE10F growth medium the day 
following subculture.  Stably transfected cells were expanded and frozen vials 
were placed at -80oC.   
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3.2.6.  3D In Vitro Cultures 
For all 3D cultures, cells were grown in Matrigel Basement Membrane 
Matrix (BD Biosciences, Mississauga, ON) for 9 or 15 days.  Cultures were 
created in 24-well plates (Nunc Brand Products) for mRNA and protein extraction 
and 48-well plates (Nunc Brand Products) for H&E staining and 
immunohistochemistry.  The cultures contained three distinct layers.  The bottom 
layer consisted of undiluted Matrigel for a solid base.  The middle layer contained 
a 1:1 mix of Matrigel and cells (4.0 x 105 for 24-well, 2.0 x 105 for 48-well) in αHE 
media supplemented with 0.1% bovine serum albumin (BSA; Gibco Life 
Sciences).  These two layers were topped with growth media supplemented with 
0.1% BSA.     
 
3.2.7.  Collection and Quantification of RNA and Protein from 3D Cultures  
After 9 days in 3D culture, cells were removed from Matrigel using Cell 
Recovery Solution (BD Biosciences), which non-enzymatically dissociates the 
Matrigel.  For each experiment, 3 biological replicates were grown per cell line.  
Total RNA and protein were either extracted at the same time or separately.   
When total RNA was extracted separately, cell pellets were treated with 
TRIzol (Invitrogen Life Technologies) and RNA was extracted as per the 
manufacturer’s instructions.  RNA concentrations were determined by 
spectrophotometry using a NanoDrop 1000 Spectrophotometer (Thermo 
Scientific).  Aliquots of total RNA were stored at -20oC until conversion to 
complementary DNA (cDNA).        
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When only protein was required, cells were washed with RIPA buffer (10 
mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5 mM EGTA, 150 mM NaCl, 1% Tx-100, 
0.5% DOC, and 0.1% SDS) containing protease inhibitors (1 Complete Mini 
Protease Inhibitor cocktail tablet /10 mL, Roche; Mannheim, Germany) and 
passed through a 22-gauge needle several times to lyse the cells.  Sterile 
microcentrifuge tubes, containing the cell lysates were incubated on ice for 10 
minutes and then spun down at 4°C.  Supernatants were transferred to new 
microcentrifuge tubes and stored at -20°C.  Protein concentrations were 
determined using the BioRad Bradford Assay (Mississauga, ON) and 
concentrations were standardized to known BSA concentrations.     
When mRNA expression validation was immediately followed by protein 
expression validation, RNA and protein were extracted from the same cells.  For 
these experiments, RNA and protein were extracted using the GE Healthcare 
IllustraTM triple prep kit (Baie d’Urfe, QC), following the manufacturer’s protocol.  
RNA and protein concentrations were determined in the same method as above.   
  
3.2.8.  Quantitative Real Time-PCR (qRT-PCR) Validation  
Complementary DNA was synthesized from 1μg total RNA using 
Superscript II, with random primers (both from Invitrogen Life Technologies).  
qRT-PCR was conducted using a Rotor-Gene RG-3000 temperature cycler 
(Corbett Life Science, San Francisco, CA) and RT2 SYBR-Green qPCR Master 
Mix (SuperArray Biosciences Corporation, Frederick, MD), following the 
manufacturer’s protocol.  Since SYBR-Green binds to the minor groove of all 
double stranded DNA, RT2 qPCR primers for VANGL1, TBX3, S100A2 and 18S 
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rRNA were purchased from SuperArray, which were guaranteed to produce 
minimal primer dimers and non-specific product.  Primer sets for the different 
isoforms of endogenous TBX3 and the TBX3-ZsGreen fusion protein were 
designed in house and the sequences can be found in Table 3.1.  Expression 
levels of all genes were calculated based on a standard curve for that gene.  
Standard curves were created with six dilutions from the reverse transcription 
product (1, 1:5, 1:25, 1:125, 1:625, 1:3125) and in triplicate.  Expression levels of 
the housekeeping gene 18S rRNA was also determined for each sample and 
quantities were used to normalize values obtained for each gene of interest.  All 
samples were assayed using three biological replicates and in duplicate.  All 
experiments were performed in triplicate with similar results.   
 
3.2.9.  Western Blotting  
Western blots were conducted using the BioRad Mini Protean II Cell 
system.  Either 10% (VANGL1 and TBX3) or 12% (S100A2) polyacrylamide gels 
containing sodium dodecyl sulphate (SDS) were loaded with denatured whole cell 
lysates (25-50 µg) and 5X reducing loading buffer.  Gels were run at 60V for 
approximately 20 minutes, so the dye front was through the stacking gel and then 
the voltage was increased to 120 V for approximately 90 minutes.  Polyvinylidene 
fluoride (PVDF) membranes (Amersham, GE Healthcare), which had been 
activated in methanol, were incubated with gels in cold transfer buffer for at least 
10 minutes.  Gels and membranes were then transferred at 100 V for 1.5 hours.  
Membranes were blocked in 5% milk in TBS-T (tris-buffered saline with 0.1% 
Tween) for one hour.  To detect VANGL1, a mouse monoclonal antibody (R&D 
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Systems, Burlington, ON, catalogue no. MAB5476) was used at 1:1000 in TBS-T.  
To detect TBX3 a mouse monoclonal antibody (Sigma Chemicals, catalogue no. 
WH0006926M10) was used at 1:1000.  Finally to detect S100A2 a mouse 
monoclonal antibody (Abgent, San Diego, CA, catalogue no. AT3754a) was used 
at 1:1000 in TBS-T.  Membranes were incubated with primary antibodies 
overnight at 4°C, while rocking according to the manufacturers’ instructions.  An 
antibody against β-tubulin (Invitrogen Life Technologies; catalogue no. 32-2600) 
was used as a loading control at 1:2000 in TBS-T and was incubated with 
membranes for 1 hour, while rocking.  After the primary antibody, the membranes 
were washed 3 times for 5 minutes each with TBS-T and then incubated with the 
secondary anti-mouse antibody, conjugated to HRP (Amersham, catalogue no. 
NXA931; 1:10 000 in TBS-T), for 1 hour at room temperature, while rocking.  
After 3 more washes at 5 minutes each with TBS-T, membranes were incubated 
with ECL Plus Western Blotting Detection System (Amersham) and then exposed 
to film in a dark room.   
Alterations to the above Western blot methodology were made in order to 
resolve protein bands with the ZsGreen antibody for the TBX3 overexpressing 
cells.  An 8% SDS polyacrylamide gel was overloaded (329 µg TBX3 Iso1, 203 
µg TBX3 Iso2) and run without denaturing/boiling the lysates and without adding 
a reducing agent.  The gel was run at 65 V for approximately 30 minutes and 
then the voltage was increased to 125 V for approximately 90 minutes.  A PVDF 
membrane, which had been activated in methanol, was incubated with the gel in 
cold transfer buffer for at least 10 minutes.  The gel and membrane were then 
transferred at 35 V for 1.5 hours.  The membrane was blocked in 0.1% gelatin 
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(Sigma Chemical) in TBS-T for 1.5 hours.  To detect ZsGreen, a rabbit polyclonal 
antibody (Clonetech Laboratories, catalogue no. 632474) was used at 1:1000 in 
0.1% gelatin in TBS-T and incubated with the membrane overnight at 4°C, while 
rocking.  After incubation, the membrane was washed 5 times for 5 minutes each 
with TBS-T and then incubated with the secondary anti-rabbit antibody 
conjugated with HRP (Millipore, Billerica, MA, catalogue no. AP132P; 1:10 000 in 
0.1% gelatin in TBS-T) for 1.5 hours at room temperature, while rocking.  After 3 
more washes at 5 minutes each with TBS-T, the membrane was incubated with 
ECL Plus Western Blotting Detection System and then exposed to film in a dark 
room as above.   
   
3.2.10.  Morphologic Characterization of 3D In Vitro Cultures 
After 9 and 15 days growth in Matrigel, 10% neutral buffered formalin was 
added to the 48-well dishes for 48 hours.  Once cultures were stiffened, the 
cultures were removed as intact Matrigel plugs.  The formalin-fixed plugs were 
then processed, paraffin-embedded and sectioned into 4µm slices for H&E 
staining and immunohistochemistry.   
Histomorphology of the cell lines in 3D culture was determined by 
examination of H&E stained sections of the Matrigel plugs.  Morphologic 
characterization was based on assessment of extracellular lumen formation, 
number of groups with polarized cells, spherical (vs. non-spherical) colony 
formation and proportion of single cells (Appendix B Figure 1).  Each of these 
parameters was assessed in terms of a percentage of total “events” counted.  In 
relation to extracellular lumen formation, number of groups with polarized cells 
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and spherical colonies, an event was defined as a cell group.  In relation to the 
proportion of single cells seen in the plug, an event was defined as either a single 
cell or a cell group.  For each cell line being studied, 10 high power (400X) fields 
of view from three replicate Matrigel plugs were examined.  This yielded between 
200 and 275 events per 10 high power fields.      
   
3.2.11.  Proliferation and Apoptosis in 3D Cultures 
Matrigel plugs from 9 and 15 days cultures were immunostained for the 
proliferation marker Ki67, and for the apoptotic marker caspase 3.  Ki67 
immunohistochemistry was performed as described previously [45] with the Ki67 
antibody (Dako, Mississauga, ON, catalogue no. M7240) applied (1/150 dilution) 
overnight at 4oC.  For caspase 3 immunostaining, a microwave oven was used to 
pretreat deparaffinized sections for epitope retrieval.  Caspase 3 antibody, which 
recognized cleaved caspase 3 (Cell Signaling Technologies, Danvers, MA, 
catalogue no. 9662) was applied (1/300 dilution) for 15min at room temperature.  
For both Ki67 and caspase 3, positive staining was detected with an UltraVision 
LP Detection System HRP Polymer (Thermo Scientific, Waltham, MA) kit, 
following the manufacturer’s protocol.  Positive and negative controls were 
included for both assays.  All slides were counterstained with Harris’s 
Hematoxylin.     
Both Ki67 and caspase 3 indices were calculated for each cell line.  The 
indices were defined as the number of cells positive for Ki67 or caspase 3 
staining divided by the total cells counted.  For each cell line being studied, 10 
high power (400X) fields of view from three replicate Matrigel plugs were 
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examined, yielding between 200 and 350 cells.  A ratio of proliferation over 
apoptosis was also calculated for each cell line, in order to determine the balance 
of dividing cells vs. apoptosing cells. 
 
3.2.12.  Transwell Invasion Assay 
A transwell system was used to look at the invasion potential of VANGL1 
overexpressing cells.  The systems consisted of 2 chambers separated by a 
porous membrane coated with Matrigel.  Cells were seeded in the upper chamber 
of the transwell system and allowed to invade towards a chemoattractant (FBS) 
in the lower chamber.  The day before the assay, transwell inserts with 8 µm 
pores (Corning Life Sciences, Lowell, MA) were coated with 20 µg Matrigel, 
diluted in sterile water.  Plates were left to dry overnight in the tissue culture 
hood.  The following day, Matrigel coated transwells were reconstituted by adding 
100µL αHE media supplemented with 0.1% BSA.  The plates were incubated on 
a shaker at room temperature for 90 minutes.  During this incubation, cells were 
collected and diluted to 4 x 105 cells/mL in αHE plus 0.1% BSA.  In order to 
determine the invasive ability of the cells, 800µL of αHE plus 10% FBS was 
added to the lower chamber of the transwell system.  To the upper chamber, 100 
µL of the cell suspension was added (final cell concentration of 4 x 104 cells/well).  
Plates were then incubated for 72 hours at 37oC and 5% CO2.  After the assay 
was complete, the upper chambers of the transwells were removed, inverted and 
fixed for 20 minutes with 1% gluteraldehyde in 1X PBS.  The membranes of the 
upper transwells were then rinsed with sterile water.  Cells were stained with 
Harris’ haematoxylin for 15 minutes and then the membranes were rinsed again.  
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Addition of 1% NH4OH (in sterile water) for 1 minute was used to intensify the cell 
staining.  The transwell membranes were rinsed one final time with sterile water.  
Non-invasive cells which were attached to the upper surface of the transwell 
membranes were removed using a cotton Q-tip.  The transwells were then 
allowed to dry overnight.  Once dry, five high powered fields (200X) were 
photographed per transwell membrane.  Cells that invaded to the underside of 
the membrane were counted from these pictures using the cell counter plug-in on 
ImageJ (Open source software, National Institute of Health, USA).  Three 
biological replicates were used for this assay and the experiment was completed 
twice with similar results.                      
 
3.2.13.  Matrigel Invasion Assay  
Time lapse microscopy was used to quantify the invasive ability of S1002 
knockdown and TBX3 overexpressing 21NT cells through 6 days of culture in 
Matrigel.  An invasion assay using time lapse microscopy was chosen for genes 
involved in the 21NT (DCIS) to 21MT-1 (IMC) transition because 21MT-1 cells 
are unable to pass through the 8 µm pores of a transwell system.  On average, 
21MT-1 cells are 30 µm in diameter, are often polygonally-shaped and when 
grown in a transwell system, many cell aggregates form on the upper surface of 
the transwell membrane.  In contrast, 21NT cells are 19 µm in diameter, more 
spindle-shaped in a transwell system and pass freely through 8 µm pores.  Thus, 
a transwell system would not provide a fair assessment of the invasive ability of 
the S100A2 knockdown and TBX3 overexpressing 21NT cells compared to the 
21MT-1 cells.  For the time lapse Matrigel invasion assay, cells were grown 3D 
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Matrigel in 8-well chamber slides (Nunc Brand Products) for 9 days.  Matrigel 
cultures were made as described previously, with scaled down volumes of the 
three layers for the 8-well chamber slide.  In addition, the number of cells in the 
middle layer was reduced to 1.5 x 104.  After 9 days, the slides were then moved 
to an incubated stage platform of a Zeiss Axiovert 200M microscope for time 
lapse photography.  Z-stack microscopy images at 5 positions were taken for 
each cell line every 12 hours until day 15 of growth.  All cells found within the 5 
positions per cell line (about 100 cells total) were then followed using AxioVision 
4.5 software (Carl Zeiss Imaging Solutions), to determine the percentage of cells 
that invaded through the Matrigel matrix and the distance the moving cells were 
able to travel.  A cell was defined as moving if any part of the cell was in a 
different location compared to the image taken 12 hours previously.  The 
minimum distance a cell could travel to be termed as moving was 5 µm.  The 
distance a moving cell travelled was measured using the AxioVision 4.5 software. 
  
3.2.14.  Confocal Microscopy 
 Confocal microscopy was used to detect protein levels of the TBX3-
ZsGreen fusion product transfected cells.  21NT, 21NT+TBX3 Iso1, 21NT+TBX3 
Iso2 and 21NT+EV cells were grown on 22 mm round tissue culture grade 
coverslips (VWR, Mississauga, ON) inside 6-well plates (Nunc Brand Products) 
for 24 hours.  Cell medium was removed and cells were fixed with 2% formalin for 
10 minutes.  Wells were rinsed with 1X PBS and then permeabilization buffer 
(0.05% saponin, 0.10% BSA, 0.075% glycine) was added for 10 minutes.  After 
rinsing with PBS, the cells were blocked with 10% normal goat serum (Invitrogen 
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Life Technologies) for 30 minutes.  Without removing the goat serum, primary 
antibodies were added in more goat serum.  To detect TBX3, the same mouse 
monoclonal antibody (Sigma Chemicals) used for Western blotting was used at a 
concentration of 1:400.  To detect vimentin, a mouse monoclonal antibody (Dako, 
Burlington, ON; clone 3B4, catalogue no. 632474) was used at a concentration of 
1:250.  To detect E-cadherin, a mouse monoclonal antibody (BD Biosciences, 
catalogue no. 610181) was used at 1:650.  Finally, an IgG1 k isotype control 
mouse monoclonal antibody (BD Pharmigen, catalogue no. BD554121) was used 
at 1:300.  Primary antibodies were incubated with cells overnight at 4oC.  After 
primary antibody was removed and wells were rinsed with 1X PBS, AlexaFluor 
594 goat anti-mouse IgG (Invitrogen Life Technologies, catalogue no A-11005; 
1:1000 in goat serum) was incubated with cells for 1.5 hours.  Wells were rinsed 
again and Hoecsht 33342 (Invitrogen Life Technologies, catalogue no. H1399; 
1:5000 in PBS) was added for 45 minutes in the dark.  After rinsing the wells one 
final time with PBS, coverslips were mounted onto glass slides for confocal 
microscopy.           
   Confocal laser scanning microscopy was performed using an Olympus 
FluoViewTM FV1000 coupled to the IX81 Motorized Inverted System Microscope 
at The Victoria Research Laboratory Confocal Microscope Core Facility.  
Sequential channel scans of each stained section were optimized for maximum 
signal to noise ratio and minimal laser power output.  Image analysis and 
processing were performed with ImageJ software (NIH).     
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3.2.15.  Statistical Analysis  
The differences between experimental groups were analyzed using one-
way analysis of variance (ANOVA), followed by Tukey’s test for post hoc 
analysis.  Statistical analysis was performed using GraphPad Instat 3 (La Jolla, 
CA).  For all statistics, a p-value of less than 0.05 was considered statistically 
significant.  In all bar graphs, bars labeled with letters that are not the same 
indicate this significant difference.  Alternately, bars labeled with the same letters 
are not significantly different from each other.     
 
3.3. RESULTS  
 
3.3.1.  VANGL1  
 In work described in Chapter 2, VANGL1 was found to be elevated in 
21NT (DCIS-like) cells compared to 21PT (ADH-like) cells [8].  To determine the 
functional role of VANGL1 in this transition (ADH to DCIS), VANGL1 was 
transfected into 21PT cells and the cells were analyzed using several functional 
assays, including colony profile (spherical vs. irregular), lumen formation, cell 
polarization, proportion of single cells, proliferation index, apoptosis index and 
cell invasion. 
  
3.3.1.1.  VANGL1 mRNA Expression Levels are Altered in 21NT Compared 
to 21PT Cells 
 Since the 21T series model of early breast progression was created in a 
3D system, before generating transfectants, we first wanted to determine whether 
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the differential expression of VANGL1 mRNA (between 21PT and 21NT) could 
also be seen in 2D culture.  Using qRT-PCR, we determined that when grown in 
2D culture, VANGL1 is in fact elevated 1.8-fold in 21NTci compared to 21PTci 
cells (Figure 3.8).  However, this was less of an increase than that seen for 3D 
culture (2.2-fold; Figure 3.8).  Thus, the progression stage-specific expression of 
VANGL1 is more pronounced when cells are grown in 3D than in 2D.      
Additionally, the 21PT and 21NT cells used for the microarray analysis 
contained an empty neo-selection vector (21PTci, 21NTci).  Since we planned to 
transfect VANGL1 into the 21PT cells, we decided to use the parental 21PT and 
21NT cells, to eliminate any issues that may arise with two transfected vectors.  
To ensure that VANGL1 mRNA was similarly altered in the parental cell lines, 
qRT-PCR was used to determine the difference in VANGL1 mRNA expression 
between the parental lines.  It was found that VANGL1 mRNA is increased 2.6-
fold in 21NT parental cells compared to 21PT parental cells (Figure 3.9).  From 
these data, it was determined that VANGL1 mRNA is elevated in parental 21NT 
(DCIS-like) cells compared to parental 21PT (ADH-like) cells.       
 
3.3.1.2.  VANGL1-Transfected 21PT Cells Show mRNA and Protein Levels 
Similar to 21NT Cells 
 A myc-tagged VANGL1 expression vector was constructed and 
transfected into 21PT cells (21PT+VANGL1).  In addition, a control empty vector 
was also transfected into 21PT cells (21PT+EV).  Both qRT-PCR and Western 
blotting were used to determine if levels of VANGL1 were increased in 
21PT+VANGL1 cells and how these levels compared to 21PT and 21NT 
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Figure 3.8. mRNA expression levels of VANGL1 in 21PTci and 21NTci cells
grown in 2D and 3D culture. For ease of comparison, the mRNA expression
level for 21PTci was set to 1 for both 2D and 3D. In 2D culture, VANGL1
mRNA is 1.8-fold higher in 21NTci compared to 21PTci cells, while in 3D
culture, the difference in mRNA expression is 2.1-fold. For 2D culture, cells
were grown in 6-well plates for 72 hours, while for 3D culture, cells were
grown in Matrigel for 9 days. mRNA expression levels were calculated as a
ratio with 18S rRNA, a housekeeping gene. In this figure and all subsequent
figures, bars labeled with letters that are not the same indicate significant
difference between the bars at a p-value of at least <0.05 (i.e. ‘a’ vs ‘b’, ‘a’ vs
‘c’ and ‘b’ vs ‘c’). Statistics were performed before levels were modified to set
21PTci levels as 1.
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Figure 3.9. mRNA expression levels of VANGL1 in 21PTci, 21NTci, 21PT
and 21NT cells grown in 3D culture. For ease of comparison, the mRNA
expression level for 21PTci was set to 1. VANGL1 mRNA was expressed at
the same level in both 21PTci and the parental 21PT cell lines. The mRNA
expression is 2.2-fold higher in 21NTci cells compared to 21PTci cells. For
the parental cell lines, VANGL1 mRNA is 2.6-fold higher in 21NT cells vs.
21PT cells. Cells were all grown in 3D Matrigel for 9 days before RNA was
extracted. mRNA expression levels were calculated as a ratio with 18S
rRNA, a housekeeping gene. Bars labeled with letters that are not the same
indicate significant difference between the bars at a p-value of at least <0.05.
Statistics were performed before levels were modified to set 21PTci levels as
1.
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(parental) cells.  It was found that VANGL1 mRNA and protein levels were indeed 
increased in transfected cells to the same levels as 21NT cells (Figure 3.10).        
 
3.3.1.3.  3D In Vitro Cultures of 21PT+VANGL1 Cells Display Features of 
More Advanced Progression than 21PT+EV Cells 
 In order to assess the ability of VANGL1 to alter morphologic 
characteristics of 21PT cells in 3D, VANGL1 transfected cells, as well as control, 
21PT, 21NT and 21MT-1 cells, were grown in Matrigel matrix for 9 and 15 days.  
By day 15, it was apparent that 21PT+VANGL1 cells had a reduced ability to form 
extracellular lumena and polarized cells compared to 21PT+EV (and 21PT 
parental) cells (Figure 3.11).  In fact, 21PT+VANGL1 cells did not form any 
lumena.  Additionally, the reduced ability to form polarized cells was even more 
pronounced than for the 21MT-1 (IMC-like) cells (29% compared to 43%).  These 
findings suggest that the 21PT+VANGL1 cells were less organized than the 
21PT+EV cells, or even 21NT and 21MT-1 cells.  In addition, 21PT+VANGL1 
cells had a reduced ability to form spherical colonies over that of the 21PT+EV 
control and parental 21PT cells, as well as both the 21NT and 21MT-1 cells 
(Figure 3.11).  A higher proportion of single cells compared to 21PT+EV cells 
were also noted in the 21PT+VANGL1 Matrigel plugs (Figure 3.11).  Reduced 
ability to form spherical colonies and a greater proportion of single cells are 
characteristics consistent with more invasive phenotype, a feature that was 
directly tested as described in section 3.3.14.  Similar 3D morphologic trends 
were seen in day 9 cultures (Appendix C, Figure 1).  
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Figure 3.10. mRNA and protein levels of VANGL1 after transfection into
21PT cells. VANGL1 was fused to a myc-tag and stably transfected into
21PT cells using Lipofectin Reagent. mRNA and protein were extracted from
cells grown in Matrigel for 9 days. A) VANGL1 mRNA levels are highest in
21PT+VANGL1 cells and 21NT cells. Control 21PT+empty vector (EV) cells
had the same mRNA level of VANGL1 as 21PT cells. mRNA levels were
obtained using real-time quantitative PCR. Bars labeled with letters that are
not the same indicate significant difference between the bars at a p-value of
at least <0.05. Western blotting (B) shows a similar increase in VANGL1
(70kDa) protein expression in 21NT+VANGL1 cells. Proteins were detected
with a monoclonal anti-VANGL1 antibody.
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Figure 3.11. Characteristics of 21T and VANGL1 overexpressing cells after
15 days growth in 3D Matrigel. 21PT+VANGL1 cells show no lumen
formation and fewer polarized cells than 21PT+EV cells, indicating that the
VANGL1 cells are more disorganized. In addition, VANGL1 transfected cells
also formed far fewer spherical colonies, with the percentage being lower than
even 21MT-1 cells. The percentage of single cells seen in Matrigel plugs for
21PT+VANGL1 cells was at the same level as 21NT cells. 21PT+EV cells
show no differences from 21PT cells. For (A), all sections were H&E stained
and the scale bar represents 50 µm. In (B) for ‘single cells’, an event is either
a single cell or a cell group, whereas for the ‘lumen formation’ , ‘polarized
cells’ and ‘spherical colonies’ comparisons, an ‘event’ was defined as a cell
group only. Bars labeled with letters that are not the same indicate significant
difference between the bars at a p-value of at least <0.05. Statistics for each
comparison were calculated separately from the other comparisons.
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3.3.1.4.  Altered Proliferation, Apoptosis and Invasive Ability of 
21PT+VANGL1 Cells Indicate Conversion to a Later Stage of Progression  
 Proliferation and apoptosis indices were calculated for the VANGL1 
overexpressing cells.  Ki67 immunohistochemistry for proliferation was conducted 
for cells grown in Matrigel for 9 and 15 days.  By day 15, proliferation rates for 
21PT+VANGL1 were 17.5%, compared to only 2% for 21PT+EV cells and 3.5% 
for 21NT cells (Figure 3.12A).  Assessment of apoptosis by caspase 3 was done 
on cells grown in Matrigel for 9 and 15 days, and showed that by day 15, 
21PT+VANGL1 cells had an increased apoptosis index compared to 21PT+EV 
cells (Figure 3.12B).  However, this increase in apoptosis mirrored that of 21NT 
cells.  The ratios of proliferation/apoptosis were calculated for 21PT, 21PT+EV, 
21PT+VANGL1 and 21NT cell lines grown in Matrigel, using the Ki67 
(proliferation) divided by the caspase 3 (apoptosis) index.  Results indicate that at 
day 15, 21PT+VANGL1 cells have a much higher ratio of proliferation/apoptosis, 
compared to 21PT, 21PT+EV or 21NT cells (p<0.001) (Figure 3.12C).  Similar 
results were seen at day 9 (Appendix C, Figure 2). 
 To assess the invasive ability of the VANGL1 overexpression cells, 
invasion assays were conducted using a transwell system.  21PT, 21PT+EV, 
21PT+VANGL1 and 21NT cells were all seeded in the upper chamber of the 
transwell system and allowed to invade through Matrigel to reach the FBS 
chemoattractant in the lower chamber of the transwell system.  It was found that 
significantly more 21PT+VANGL1 cells were able to invade through the Matrigel 
than either the 21PT (or 21PT+EV) or 21NT cells (Figure 3.13).  These results 
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Figure 3.12. Proliferative and apoptotic activity of 21T and VANGL1
overexpressing cell lines after 15 days growth in 3D Matrigel. Proliferation
(A) was quantified by Ki67 immunohistochemical staining of Matrigel plugs,
while apoptosis (B) was quantified by caspase 3 immunohistochemistry.
21PT+VANGL1 cells showed a large increase in proliferation (A) over
21PT+EV cells, while apoptosis levels (B) increased to 21NT cell levels.
When the ratio of proliferation/apoptosis was calculated (C), VANGL1
overexpressing cells showed a much higher ratio than the 21PT+EV and
even the 21NT cells. 21PT+EV cells showed no differences from the 21PT
cells. Bars labeled with letters that are not the same indicate significant
difference between the bars at a p-value of at least <0.05.
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Figure 3.13. Invasion of VANGL1 overexpressing cells using a transwell
system. VANGL1 overexpressing cells, as well as 21PT, 21PT+EV and 21NT
cells were seeded in the upper chamber of the transwell system and allowed
to invade through 20 µg of Matrigel, towards FBS. After 72 hours, more
21PT+VANGL1 cells were able to invade than any of the other 21T cell lines.
For each cell line, 5 high power fields (HPF) were counted per three
replicated. Bars labeled with letters that are not the same indicate significant
difference between the bars at a p-value of at least <0.05.
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indicate that the VANGL1 overexpressing cells are more invasive than 21PT or 
21NT cells.            
 
3.3.2.  S100A2  
As described in Chapter 2, S100A2 was found to be reduced in 21MT-1 
(IMC-like) cells compared to 21NT (DCIS-like) cells [8].  To determine the 
functional role of S100A2 in the transition to an invasive phenotype, shRNA 
against S100A2 was transfected into 21NT cells and the cells were analyzed 
using several functional parameters, including colony profile (spherical vs. 
irregular), lumen formation, cell polarization, proportion of single cells, 
proliferation index, apoptosis index and cell invasion by time lapse microscopy. 
 
3.3.2.1.  S100A2 mRNA Expression Levels are Altered in 21MT-1 Compared 
to 21NT Cells 
 Since the 21T series breast cell line model of early breast cancer 
progression was created in a 3D system, prior to generating transfectants we 
wanted to determine whether this differential expression of S100A2 mRNA 
between 21NTci and 21MT-1 would also be seen when the 21T series cells were 
grown in 2D culture.  Using qRT-PCR, we determined that when cells are grown 
in 2D, S100A2 is in fact decreased 3.4-fold in 21MT-1 compared to 21NTci cells 
(Figure 3.14).  This reduction in S100A2 mRNA is comparable to the 3.2-fold 
reduction seen in 21MT-1 cells grown in 3D (Figure 3.14).  From these data, it 
was determined that the stage-specific gene expression pattern of S100A2 can 
be found in cells grown in both 2D and 3D culture.     
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Figure 3.14. mRNA expression levels of S100A2 in 21NTci and 21MT-1 cells
grown in 2D and 3D culture. For ease of comparison, the mRNA expression
level for 21NTci was set to 1 for both 2D and 3D. In 2D culture, S100A2
mRNA is 3.4-fold lower in 21MT-1 compared to 21NTci cells, which is not
significantly different from the 3.2-fold difference seen in 3D culture. For 2D
culture, cells were grown in 6-well plates for 72 hours, while for 3D culture,
cells were grown in Matrigel for 9 days. mRNA expression levels were
calculated as a ratio of 18S rRNA, a housekeeping gene. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05. Statistics were performed before levels were
modified to set 21NTci levels as 1.
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The previous microarray analysis used 21NT cells containing an empty 
neo-selection vector (21NTci).  Since we planned to knockdown S100A2 in the 
21NT cells, we decided to use the parental 21NT cells, to eliminate any issues 
that may arise with two transfection vectors in the same cell line.  qRT-PCR was 
used to determine the differential expression of S100A2 in 21MT-1 cells vs. the 
parental 21NT cell line.  It was found that S100A2 mRNA is decreased 3.5-fold in 
21MT-1 cells compared to 21NT parental cells (Figure 3.15).  Thus, S100A2 
mRNA is indeed reduced in 21MT-1 (IMC-like) cells compared to parental 21NT 
(DCIS-like) cells.    
 
3.3.2.2.  21NT+shS100A2 Cells Show mRNA and Protein Levels Similar to 
21MT-1 Cells 
 Short hairpin (sh) RNA against S100A2 was obtained and transfected into 
21NT cells (21NT+shS100A2).  In addition, a control empty shRNA vector was 
also transfected into 21NT cells (21NT+EV).  Both qRT-PCR and Western 
blotting were used to determine if levels of S100A2 were decreased in 
21NT+shRNA cells and how these levels compared to 21NT and 21MT-1 cells.  It 
was found that S100A2 mRNA and protein levels were indeed decreased in 
transfected cells to the same levels as 21MT-1 cells (Figure 3.16).        
 
3.3.2.3.  3D In Vitro Cultures of 21NT+shS100A2 Cells Display Features of a 
Later Stage of Progression  
 3D in vitro cultures were used to assess the ability of S100A2 to alter 
morphologic characteristics of 21NT cells.  S100A2 knockdown cells, as well as 
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Figure 3.15. mRNA expression levels of S100A2 in 21NTci and 21NT cells
compared to 21MT-1 cells. For ease of comparison, the mRNA expression
level for 21NTci was set to 1. S100A2 mRNA was expressed at the same
level in both 21NTci and the parental 21NT cell lines. The mRNA expression
is decreased 3.2-fold in 21MT-1 cells compared to 21NTci cells and 3.5-fold
compared to 21NT parental cells. Cells were all grown in 3D Matrigel for 9
days before RNA was extracted. mRNA expression levels were calculated as
a ratio with 18S rRNA, a housekeeping gene. Bars labeled with letters that
are not the same indicate significant difference between the bars at a p-value
of at least <0.05. Statistics were performed before levels were modified to
set 21NTci levels as 1.
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Figure 3.16. mRNA and protein levels of S100A2 after shRNA transfection
into 21NT cells. An shRNA vector against S100A2 was stably transfected
into 21NT cells using Lipofectin Reagent. mRNA and protein were extracted
from cells grown in Matrigel for 9 days. A) S100A2 mRNA is knocked down
in 21NT+shS100A2 cells to 21MT-1 levels. Control 21NT+empty vector (EV)
cells had the same mRNA level of S100A2 as 21NT cells. mRNA levels were
obtained using real-time quantitative PCR. Bars labeled with letters that are
not the same indicate significant difference between the bars at a p-value of
at least <0.05. B) Western blotting shows a similar decreased in S100A2
(12kDa) expression in 21NT+shS100A2 cells. Proteins were detected with a
monoclonal anti-S100A2 antibody.
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control vector transfected 21NT, 21NT parental and 21MT-1 cells, were grown in 
Matrigel matrix for 9 and 15 days.  By day 15, it was obvious that 
21NT+shS100A2 cells had completely lost the ability to form extracellular lumena 
(Figure 3.17).  In addition, S100A2 knockdown cells had a reduced ability to form 
polarized cells compared to 21NT+EV, 21NT and 21MT-1 cells (Figure 3.17).  
These findings suggest that the 21NT+shS100A2 cells were less organized than 
21NT cells, or even 21MT-1 cells.  The ability to form spherical colonies was also 
reduced in 21NT+shS100A2 cells, to the same level as the invasive 21MT-1 cell 
line (Figure 3.17).  Additionally, the proportion of single cells seen in 
21NT+shS100A2 Matrigel plugs was the same as those seen for 21MT-1 cells 
(Figure 3.17).  Thus, the S100A2 knockdown cells possessed several 
characteristics consistent with increased invasiveness, similar to 21MT-1 cells.  
Similar trends were seen in day 9 cultures (Appendix C, Figure 3).  Alteration in 
invasiveness of 21NT+shS100A2 cells was then directly assessed as described 
in 3.3.2.4.   
 
3.3.2.4.  21NT+shS100A2 Cells Exhibit Characteristics of a More Aggressive 
Phenotype Including Alterations in Proliferation, Apoptosis and Invasion  
 Assessment of proliferative rates by Ki67 immunohistochemistry and 
apoptosis rates by caspase 3 were performed for the S100A2 knockdown cells.  
Immunohistochemistry for proliferation and apoptosis was conducted on Matrigel 
plugs from cells grown in Matrigel for 9 and 15 days.  By day 15, proliferation 
rates for 21NT+shS100A2 were 11.5%, compared to 3.5% for 21NT+EV cells 
and 6% for 21MT-1 cells (Figure 3.18A).  The apoptosis index showed that at day 
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Figure 3.17. Characteristics of 21T and S100A2 knockdown cells after 15
days growth in 3D Matrigel. 21NT+shS100A2 cells show complete loss of
lumen forming ability and fewer polarized cells than 21NT+EV or 21MT-1
cells, indicating that the S100A2 knockdown cells are less organized. In
addition, S100A2 shRNA cells also formed fewer spherical colonies than
21NT+EV cells and in line with 21MT-1 cells. The percentage of single cells
seen in Matrigel plugs for 21NT+shS100A2 cells was at the same level as
21MT-1 cells. 21NT+EV cells show no differences from 21NT cells. For (A),
all sections were H&E stained and the scale bar represents 50 µm. In (B) for
‘single cells’, an event is either a single cell or a cell group, whereas for the
‘lumen formation’ , ‘polarized cells’ and ‘spherical colonies’ comparisons, an
‘event’ was defined as a cell group only. Bars labeled with letters that are not
the same indicate significant difference between the bars at a p-value of at
least <0.05. Statistics for each comparison were calculated separately from
the other comparisons.
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Figure 3.18. Proliferative and apoptotic activity of 21T and S100A2 knockdown
cell lines after 15 days growth in 3D Matrigel. Proliferation (A) was quantified by
Ki67 immunohistochemical staining of Matrigel plugs, while apoptosis (B) was
quantified by caspase 3 immunohistochemistry. 21NT+shS100A2 cells showed
an increase in proliferation (A) over 21NT+EV and 21MT-1 cells, while apoptosis
levels (B) of S100A2 shRNA cells were not different from 21NT+EV cells. When
the ratio of proliferation/apoptosis was calculated (C), S100A2 knockdown 21NT
cells showed a ratio in line with 21MT-1 cells. 21NT+EV cells showed no
differences from the 21NT cells. Bars labeled with letters that are not the same
indicate significant difference between the bars at a p-value of at least <0.05.
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15, there was no difference in apoptosis rates between 21NT+EV and 
21NT+shS100A2 cells (Figure 3.18B).  However, 21MT-1 cells have a lower 
apoptosis rate at day 15 compared to 21NT, 21NT+EV and S100A2 21NT 
knockdowns.  Ratios of proliferation/ apoptosis were calculated for 21NT, 
21NT+EV, 21NT+shS100A2 and 21MT-1 cell lines grown in Matrigel, using the 
Ki67 (proliferation) vs. the caspase 3 (apoptosis) index.  The ratios indicate that 
at day 15, 21NT+shS100A2 cells have a proliferation/apoptosis ratio that is the 
same as 21MT-1 cells and higher than 21NT+EV and 21NT cells (Figure 3.18C).  
Similar results were seen at day 9 (Appendix C, Figure 4).  These results indicate 
that S100A2 knockdown cells have a similar growth profile to the invasive 21MT-
1 (IMC-like) cells.   
To assess the invasive ability of the S100A2 knockdown cells, 21NT, 
21NT+EV, 21NT+shS100A2 and 21MT-1 cells were grown in Matrigel for 9 days 
and then followed with time lapse microscopy until day 15.  It was found that 
similarly to 21MT-1 cells, 100% of 21NT+shS100A2 cells were able to travel 
through the Matrigel in both horizontal and vertical directions, compared to only 
~30%% of 21NT+EV cells (Figure 3.19).  In addition, S100A2 knockdown cells 
traveled 212 μm on average over the six days, which was significantly (p<0.01) 
farther than 21NT+EV cells (15 μm) cells, but similar to 21MT-1 cells (205 μm).  
These results indicate that the S100A2 knockdown cells invade in a manner 
similar to 21MT-1 cells.         
 
 
 
111
Figure 3.19. Cell invasion through Matrigel matrix for 21T and S100A2
knockdown cells. Cells were grown in Matrigel for 9 days and then
transferred to the incubator stage platform of a time lapse microscope until
day 15. Z-stack images were taken every 12 h and all cells were followed for
the entire 6-day incubation. (A) Percentage of total cells that invaded
(moved) through the Matrigel matrix. A higher percentage of 21NT+
shS100A2 cells were able to move than 21NT or 21NT+EV cells. The
percentage of S100A2 knockdown cells that were able to invade through
Matrigel was 100%, similar to 21MT-1 cells. Similarly, when looking at the
distance (µm) moving cells are able to travel through the matrix (B), S100A2
knockdown cells were able to travel as far as 21MT-1 cells. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05.
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3.3.3.  TBX3  
In work described in Chapter 2, TBX3 was found to be increased in 21MT-
1 (IMC-like) cells compared to 21NT (DCIS-like) cells [8].  There are two isoforms 
of TBX3, created by alternative splicing.  TBX3 isoform 2 (TBX3 Iso2), also 
known as TBX3+2a is the full transcript, while TBX3 Isoform 1 (TBX3 Iso1), also 
known as TBX3 (common form), has 22 amino acids spliced out of exon 2.  To 
determine the functional role of both isoforms of TBX3 in the transition to an 
invasive phenotype, the isoforms were transfected separately into 21NT cells.  
Functional assays including colony profile (spherical vs. irregular), lumen 
formation, cell polarization, proportion of single cells, proliferation index, 
apoptosis index, cell invasion and presence of epithelial to mesenchymal 
transition (EMT) markers were then used to analyze the cells. 
 
3.3.3.1.  TBX3 mRNA Expression Levels are Altered in 21MT-1 Compared to 
21NT Cells 
 Since the 21T series model of early breast cancer progression was 
created in a 3D system, prior to generating transfectants, we first wanted to 
determine whether the differential expression of TBX3 between 21NTci and 
21MT-1 cells was specific to 3D culture.  Using qRT-PCR, we determined that 
when 21NTci and 21MT-1 cells are grown in 2D culture, TBX3 is elevated 1.7-
fold in 21MT-1 compared to 21NTci cells (Figure 3.20).  This was less of an 
increase than that seen for 3D culture (2.8-fold; Figure 3.20).  Thus, the stage-
specific gene expression pattern of TBX3 is more pronounced when cells are 
grown in 3D than in 2D.      
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Figure 3.20. mRNA expression levels of TBX3 in 21NTci and 21MT-1 cells
grown in 2D and 3D culture. For ease of comparison, the mRNA expression
level for 21NTci was set to 1 for both 2D and 3D. In 2D culture, TBX3 mRNA
is 1.7-fold higher in 21MT-1 compared to 21NTci cells, while TBX3 mRNA
expression is increased 2.7-fold in 21MT-1 cells compared to 21NTci cells
when grown in 3D culture. For 2D culture, cells were grown in 6-well plates
for 72 hours, while for 3D culture, cells were grown in Matrigel for 9 days.
mRNA expression levels were calculated as a ratio with 18S rRNA, a
housekeeping gene. Bars labeled with letters that are not the same indicate
significant difference between the bars at a p-value of at least <0.05.
Statistics were performed before levels were modified to set 21NTci levels as
1.
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When microarray analysis was completed with the 21T series cells, the 
21NT cells contained an empty neo-selection vector (21NTci).  Since we planned 
to transfect TBX3 into the 21NT cells, we decided to use the parental 21NT cells, 
to eliminate any issues that may arise with two transfected vectors.  To ensure 
that TBX3 mRNA levels were similarly altered in the parental cell lines, qRT-PCR 
was used to determine the increase in TBX3 mRNA expression in 21MT-1 cells 
compared to both the 21NTci and parental 21NT cell lines.  It was found that 
TBX3 mRNA was increased 2.9-fold in 21MT-1 cells compared to 21NT parental 
cells (Figure 3.21).  From these data, it was determined that TBX3 mRNA was 
elevated in 21MT-1 (IMC-like) cells compared to parental 21NT (DCIS-like) cells.       
 
3.3.3.2.  21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 Cells Show mRNA and 
Protein Levels Increased Over 21NT+EV Cells 
 Expression vectors containing TBX3 isoform 1 fused to ZsGreen and 
TBX3 isoform 2 fused to ZsGreen were constructed and transfected into 21NT 
cells (21NT+TBX3 Iso1, 21NT+TBX3 Iso2).  In addition, a control expression 
vector containing only ZsGreen was also transfected into 21NT cells (21NT+EV).  
Quantitative RT-PCR was used to determine the endogenous mRNA levels of the 
two TBX3 isoforms in transfected cells, as well as empty vector control, 21NT 
(parental) and 21MT-1 cells.  In addition, the mRNA level of the TBX3-ZsGreen 
fusion product was determined.  To quantify and distinguish the endogenous 
transcript from the transgene, a forward primer for the endogenous forms 
targeting 5’UTR (untranslated region) was designed, while reverse primers which 
either spanned (TBX3 Iso1) or were within the splice junction (TBX3 Iso2) were 
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Figure 3.21. mRNA expression levels of TBX3 in 21NTci and 21NT cells
compared to 21MT-1 cells. For ease of comparison, the mRNA expression
level for 21NTci was set to 1. TBX3 mRNA was expressed at the same level
in both 21NTci and the parental 21NT cell lines. The mRNA expression is
2.8-fold higher in 21MT-1 cells compared to 21NTci cells and 2.9-fold higher
compared to 21NT parental cells. Cells were all grown in 3D Matrigel for 9
days before RNA was extracted. mRNA expression levels were calculated as
a ratio with 18S rRNA, a housekeeping gene. Bars labeled with letters that
are not the same indicate significant difference between the bars at a p-value
of at least <0.05. Statistics were performed before levels were modified to
set 21NTci levels as 1.
116
designed, to ensure the isoforms were amplified separately (Table 3.1).  For 
quantitation of only the TBX3-ZsGreen transgene, forward primers were designed 
to anneal to a sequence downstream of the splice junction, while the reverse 
primer was designed to anneal to a sequence specific to the TBX3-ZsGreen 
junction (Table 3.1).  Results indicate that 21NT+TBX3 Iso1 and 21NT+TBX3 
Iso2 cells both have increased TBX3-ZsGreen mRNA expression for their 
respective isoform over that of 21NT+EV cells (Figure 3.22A), although the levels 
in 21NT+TBX3 Iso2 transfectants are higher than 21NT+TBX3 Iso1 (6.6-fold over 
21NT+EV, compared to 3.5-fold).  Also, mRNA of endogenous TBX3 isoform 1 is 
increased 2.0-fold in 21NT+TBX3 Iso1 cells and 1.6-fold in 21NT+TBX3 Iso2 
cells (Figure 3.22A).  Similarly, mRNA of endogenous TBX3 isoform 2 is 
increased 1.8-fold in 21NT+TBX3 Iso1 cells and 2.9-fold in 21NT+TBX3 Iso2 
cells (Figure 3.22A).  Endogenous TBX3 isoform 1 mRNA is increased in 21MT-1 
cells 3.7-fold compared to 21NT+EV cells, while isoform 2 mRNA is increased 
2.6-fold in 21MT-1 cells compared to 21NT+EV cells (Figure 3.22A).  Thus, via 
mRNA it appears that both isoforms of TBX3 are increased in transfected cells 
over 21NT cells.          
 Western blots using a monoclonal antibody against TBX3 were also 
performed to determine the protein level of TBX3 in the transfected cell lines, as 
well as 21NT, 21NT+EV and 21MT-1 cells.  A band at 80kDa was resolved, 
which corresponds to endogenous TBX3 (Figure 3.22B).  Since the two isoforms 
are only 22 amino acids different in size, separate bands for each isoforms could 
not be resolved.  TBX3 protein at this size was increased in 21NT+TBX3 Iso1 
and 21NT+TBX3 Iso2 compared to 21NT (and 21NT+EV) cells (Figure 3.22B). 
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Figure 3.22. mRNA and protein levels of endogenous TBX3 and TBX3-ZsGreen after
transfection into 21NT cells. The two isoforms of TBX3 (TBX3 Iso1, TBX3 Iso2) were
separately fused to ZsGreen protein and stably transfected into 21NT cells. mRNA and
protein were extracted from cells grown in Matrigel for 9 days. In cells transfected with only
TBX3 Iso1, (A) endogenous TBX3 Iso1 mRNA is increased as well as the TBX3-ZsGreen
fusion product. Similarly, cells transfected with TBX3 Iso2 alone (A) show increased
endogenous TBX3 Iso2 as well as TBX3-ZsGreen mRNA. Control 21NT+empty vector (EV)
cells had the same mRNA level of both TBX3 isoforms and TBX3-ZsGreen, compared to
21NT cells. mRNA levels were obtained using real-time quantitative PCR. For ease of
comparison, the mRNA expression level for 21NT was set to 1 for endogenous TBX3, while
21NT+EV was set to 1 for the fusion product. Bars labeled with letters that are not the same
indicate significant difference between the bars at a p-value of at least <0.05. Western
blotting (B) shows similar increases in endogenous TBX3 (80kDa) protein for both
transfected cell lines and presence (C) of a TBX3-ZsGreen fusion protein (100 kDa) in
21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 transfected cells. The 21NT+EV cell lines also
show a ZsGreen product. A β-tubulin loading control was used in (B), however different
amounts of protein were loaded in (C) to resolve bands. Thus, (C) is not used to compare
amounts of TBX3-ZsGreen protein but to show expression only. Proteins were detected
with a monoclonal anti-TBX3 antibody (B) or a polyclonal anti-ZsGreen antibody (C).
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C)
~ 100kDa
~ 60kDa
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However, since the transfected TBX3 was fused to ZsGreen, which is 
approximately 20kDa, the fusion protein should have been resolved at 
approximately 100kDa.  No band was resolved at this location (Figure 3.22b) 
when using the TBX3 antibody, even after altering many blot conditions, including 
amount of protein loaded, concentration of primary and secondary antibody, 
incubation time with primary and secondary antibody, transfer time and exposure 
time.  Instead, immunoblotting with a polyclonal antibody against ZsGreen was 
used in order to resolve the protein band corresponding to the TBX3-ZsGreen 
fusion protein.  21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 cells both showed protein 
banding at approximately 100kDa (Figure 3.22C), corresponding to the size 
expected for TBX3 (80 kDa) plus ZsGreen (20 kDa).  The empty vector control 
cells (21NT+EV) showed a protein band resolved at approximately 60kDa (Figure 
3.22C).  Although the predicted protein size of ZsGreen is ~20kDa, this 60kDa 
band could represent a trimeric form of ZsGreen because this blot was performed 
under non-denaturing and non-reducing conditions.            
 Confocal microscopy was also employed to determine the relationship 
between TBX3 and ZsGreen.  Both 21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 cell 
lines showed increased TBX3 and ZsGreen compared to 21NT cells (Figure 
3.23).  Much of the TBX3 and ZsGreen signal also colocalized, indicating that the 
increased TBX3 was a result of the transfected ZsGreen fusion protein.  Thus, 
TBX3 is increased in the transfected cell line compared to 21NT cells.  It is also 
worth noting that a proportion of the ZsGreen signal was confined to the nuclear 
volume (34% of total signal for TBX3 Iso1, 23% of total signal for TBX3 Iso2), 
consistent with TBX3’s action as a transcription factor.     
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Figure 3.23. Relationship between TBX3 and ZsGreen using confocal
microscopy. 21NT (A), 21NT+TBX3 Iso1 (B) and 21NT+TBX3 Iso2 (C) cells
were grown on coverslips for 24 hrs. Cells were fixed and stained with an
anti-TBX3 antibody. In order to incorporate florescence, the secondary was
conjugated to Alexa488 (red). Cells were also stained with Hoechst (blue) for
nuclear detection. The 21NT cell line (A) lacked ZsGreen expression. The
transfected cell lines (B, C) show more TBX3 than the 21NT (A) cells. In the
TBX3-ZsGreen transfected cell lines (B, C), the majority of the TBX3 and
ZsGreen signal colocalized, indicating that most of the increased TBX3 is a
result of the transfected ZsGreen fusion protein. Scale bar represents 10
µm.
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3.3.3.3.  3D In Vitro Cultures of 21NT+TBX3 Cells Display Features of a More 
Advanced Stage of Progression  
 To assess the ability of TBX3 to alter morphologic characteristics of 21NT 
cells, TBX3-transfected cells (both isoforms), as well as control, 21NT and 21MT-
1 cells, were grown in Matrigel matrix for 9 and 15 days.  At day 15, it was 
apparent that both 21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 cells had a reduced 
ability to form extracellular lumena and polarized cells compared to 21NT+EV 
cells (Figure 3.24).  For TBX3 isoform 1 overexpressing cells, ability to form 
extracellular lumena were reduced to the same levels as 21MT-1 cells; however, 
for TBX3 isoform 2 overexpressing cells, the ability to form extracellular lumena 
was reduced past 21MT-1 levels (Figure 3.24).  Overexpression of both isoforms 
resulted in reduced ability to form polarized cells past levels seen for 21MT-1 
cells (Figure 3.24).  These findings suggest that both 21NT+TBX3 Iso1 and 
21NT+TBX3 Iso2 cells were less differentiated than 21NT+EV cells and perhaps 
even less differentiated than 21MT-1 cells. Both TBX3 variant overexpressing 
cells also had a reduced ability to form spherical colonies compared to 21NT+EV 
cells, although not lower than 21MT-1 cells (Figure 3.24).  Similarly to 21MT-1 
cells, 21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 cell Matrigel plugs showed a higher 
proportion of single cells compared to 21NT+EV control cells (Figure 3.24).  
Matrigel plugs of TBX3 overexpressing cells also showed a small percent of very 
large, irregularly shaped, loosely packed aggregates, unlike any seen with 21T 
series cells in 3D culture before (Figure 3.24).  These results are consistent with 
the conclusion that the TBX3 overexpressing cells acquired characteristics of 
invasive behaviour, similar to those seen with 21MT-1 cells.  Similar trends were 
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Figure 3.24. Characteristics of 21T and TBX3 transfected cells after 15 days
growth in 3D Matrigel. 21NT +TBX3 Iso1 and Iso2 cells form fewer lumens
and polarized cells than 21NT+EV cells, indicating that the TBX3 cells are
less organized. In addition, TBX3 transfected cells also formed less spherical
colonies, in line with the invasive 21MT-1 cell line and more single cells, also
similarly to 21MT-1 cells. 21NT+EV cells show no differences from 21NT
cells. For (A), all sections were H&E stained and the scale bar represents 50
µm. In (B) for ‘single cells’, an event is either a single cell or a cell group,
whereas for the ‘lumen formation’ , ‘polarized cells’ and ‘spherical colonies’
comparisons, an ‘event’ was defined as a cell group only. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05. Statistics for each comparison were calculated
separately from the other comparisons.
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seen in day 9 cultures (Appendix C, Figure 5).  Invasive ability of the TBX3 
transfectants was then directly tested as described in section 3.3.3.4.  
 
3.3.3.4.  Altered Proliferation, Apoptosis and Invasive Ability Indicate 
21NT+TBX3 Cells Exhibit Characteristics of a More Invasive Phenotype  
 Proliferation and apoptosis rates were calculated for the TBX3 
overexpressing cells after growth in 3D Matrigel for 9 and 15 days.  
Immunohistochemistry using Ki67 was used to calculate proliferation indices, 
while caspase 3 immunohistochemistry was used to calculate apoptosis indices.  
By day 15, proliferation rates for 21NT+TBX3 Iso1 and 21NT+TBX3 Iso2 were 
greatly increased over 21NT, 21NT+EV or 21MT-1 levels (Figure 3.25A).  In fact 
21NT+TBX3 Iso1 cells had 61.0% proliferating cells, while 21NT+TBX3 Iso2 had 
58.8% proliferating cells, compared to 3.5% seen for 21NT+EV cells and 6% for 
21MT-1 cells.  The apoptosis index showed that at day 15, there was no 
difference in apoptosis rates between 21NT+EV (and 21NT) and 21NT+TBX3 
Iso1 or 21NT+TBX3 Iso2 cells (Figure 3.25B).  However, 21MT-1 cells have a 
lower apoptosis rate at day 15 compared to 21NT+EV and TBX3 overexpressing 
cells.  Ratios of proliferation/apoptosis were then calculated for 21NT, 21NT+EV, 
21NT+TBX3 Iso1, 21NT+TBX3 Iso2 and 21MT-1 cell lines grown in Matrigel, 
using the Ki67 vs. the caspase 3 index.  The ratios indicate that at day 15, both 
TBX3 overexpressing cell lines have proliferation/apoptosis ratios that are greatly 
increased compared to 21NT+EV (p<0.001) and 21MT-1 (p<0.001) cells (Figure 
3.25C).  Similar results were seen at day 9 (Appendix C, Figure 6).  
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Figure 3.25. Proliferative and apoptotic activity of 21T and TBX3 transfected
cell lines after 15 days growth in 3D Matrigel. Proliferation (A) was quantified
by Ki67 immunohistochemical staining of Matrigel plugs, while proliferation
(B) was quantified by caspase 3 immunohistochemistry. 21NT+TBX3 Iso1
and Iso2 cells showed a large increase in proliferation (A) over 21NT+EV
cells, while apoptosis levels (B) remained similar to the 21T cells. When the
ratio of proliferation/apoptosis was calculated (C), TBX3 transfected cells
showed a much higher ratio than the 21NT+EV and even the 21MT-1 cells.
21NT+EV cells showed no differences from the 21NT cells. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05.
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In order to assess the invasive ability of the TBX3 overexpressing cells, 
21NT, 21NT+EV, 21NT+TBX3 Iso1, 21NT+TBX3 Iso2 and 21MT-1 cells were 
grown in Matrigel for 9 days and followed with time lapse microscopy until day 15.  
It was found that 83.7% of TBX3 isoform 1 overexpressing cells were able to 
travel through the Matrigel, while 92.7% of TBX3 isoform 2 overexpressing cells 
were able to invade (Figure 3.26).  This is significantly more than 21NT+EV cells 
(p<0.001) and not significantly different from the 100% of 21MT-1 cells that are 
able to invade through Matrigel.  In addition, 21NT+TBX3 Iso1 cells traveled 154 
μm on average over the seven days, while 21NT+TBX3 Iso2 cells traveled 182 
μm, both of which were significantly (p<0.01) farther than the 15 μm traveled by 
21NT+EV cells, but similar to 21MT-1 cells (212 μm).  These results indicate that 
the TBX3 overexpressing cells (both isoform 1 and 2) are as invasive as 21MT-1 
cells.         
 
3.3.3.5.  21NT+TBX3 Cells Show Vimentin and E-Cadherin Alterations 
Consistent with EMT 
 While maintaining the TBX3 cells (21NT+TBX3 Iso1, 21NT+TBX3 Iso2) in 
2D culture, it was noted that the cells had a more mesenchymal-like or spindled 
appearance than the 21NT or 21NT+EV control cells.  To determine if the cells 
had undergone an EMT conversion, confocal microscopy was used to analyze 
expression of two EMT markers, vimentin and E-cadherin.  Since we had already 
established that TBX3 colocalized with ZsGreen, ZsGreen presence was used to 
determine cells with increased TBX3 expression.  The confocal microscopy 
demonstrated that E-cadherin is greatly reduced in both 21NT+TBX3 Iso1 and 
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Figure 3.26. Cell invasion through Matrigel matrix for 21T and TBX3 transfected
cells. Cells were grown in Matrigel for 9 days and then transferred to the
incubator stage platform of a time lapse microscope until day 15. Z-stack
images were taken every 12 h and all cells were followed for the entire 6-day
incubation. (A) Percentage of total cells that invaded (moved) through the
Matrigel matrix. A higher percentage of 21NT+TBX3 Iso1 and Iso2 cells were
able to invade than 21NT or 21NT+EV cells. In fact, the percentage of TBX3
cells that were able to invade through Matrigel was not significantly different
from the invasive 21MT-1 cells. Similarly, when looking at the distance (µm)
moving cells are able to travel through the matrix (B), TBX3 transfected cells
were able to travel as far as 21MT-1 cells and significantly further than
21NT+EV or parental 21NT cells. Bars labeled with letters that are not the same
indicate significant difference between the bars at a p-value of at least <0.05.
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21NT+TBX3 Iso2 cells compared to 21NT+EV cells (Figure 3.27).  Isoform 1 
overexpressing cells appear to have an even greater E-cadherin reduction than 
the isoform 2 overexpressing cells.  In contrast, vimentin is greatly increased in 
the TBX3 overexpressing cells compared to 21NT+EV controls (Figure 3.28).  
These results indicate that TBX3 may have indeed induced an EMT conversion in 
the overexpressing cells.   
       
3.4.  DISCUSSION 
Gene expression profiling of clinical breast cancer specimens has yielded 
abundant differences between stages of progression (eg. [46-50]).  However, this 
gene profiling has not elucidated which of these differently expressed genes are 
key players in functionally regulating the transitions through stages of breast 
cancer.  Moreover, there are few model systems, in vitro or in vivo, that can be 
used to test the influence of candidate genes on human breast cancer 
progression.  The 21T human breast epithelial cell line 3D model system of early 
breast cancer progression which we have previously described (Chapter 2 and 
[8]) has been used in the present study to functionally characterize gene targets 
identified as stage-specifically altered between ADH, DCIS and IMC.  A major 
advantage of this system lies in the isogenic background of these cells, 
eliminating individual genetic background variability, which can cloud results 
when comparing across cell lines of different patient origin.  A second major 
advantage hinges on the ability of the cells to represent specific stages of 
progression when grown in 3D in vitro culture [8].  Use of a 3D system allows us 
to rapidly (9-15 days) test multiple functional characteristics of candidate genes to 
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21NT+TBX3 Iso1
Hoechst ZsGreen
α-E-cadherin Merge
21NT+TBX3 Iso2
Hoechst ZsGreen
α-E-cadherin Merge
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Figure 3.27. Levels of E-cadherin in TBX3-ZsGreen transfected cells using
confocal microscopy. 21NT+EV (A), 21NT+TBX3 Iso1 (B) and 21NT+TBX3
Iso2 (C) cells were grown on coverslips for 24hrs. Cells were fixed and
stained with an anti-E-cadherin antibody. In order to incorporate florescence,
the secondary was conjugated to Alexa488 (red). Cells were also stained
with Hoechst (blue) for nuclear detection. Both cells transfected with TBX3
Iso1 (B) and TBX3 Iso2 (C) show reduced levels of E-cadherin compared to
empty vector control cells (21NT+EV; A). Scale bar represents (A) 20 µm,
(B) 10 µm and (C) 8 µm.
21NT+EV
Hoechst ZsGreen
α-E-cadherin Merge
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21NT+EV
Hoechst ZsGreen
α-Vimentin Merge
21NT+TBX3 Iso1
Hoechst ZsGreen
α-Vimentin Merge
21NT+TBX3 Iso2
Hoechst ZsGreen
α-Vimentin Merge
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C)B)
Figure 3.28. Levels of vimentin in TBX3-ZsGreen transfected cells using
confocal microscopy. 21NT+EV (A), 21NT+TBX3 Iso1 (B) and 21NT+TBX3
Iso2 (C) cells were grown on coverslips for 24 hrs. Cells were fixed and
stained with an anti-vimentin antibody. In order to incorporate florescence,
the secondary was conjugated to Alexa488 (red). Cells were also stained
with Hoechst (blue) for nuclear detection. Both cells transfected with TBX3
Iso1 (B) and TBX3 Iso2 (C) show increased levels of vimentin compared to
empty vector control cells (21NT+EV; A). Scale bar represents (A) 20 µm
and (B,C) 9 µm.
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determine their role in regulating the transitions through the stages of breast 
cancer.   
 
3.4.1.  VANGL1 Promotes the Transition from ADH to Invasive Malignancy  
 VANGL1 was overexpressed in 21PT (ADH-like) cells to learn if the 
transfected cells would acquire attributes of a malignant (DCIS and or invasive) 
phenotype.  We compared the 21PT+VANGL1 cells to parental 21PT (and control 
21PT+EV) cells, as well 21NT cells, which represent DCIS, to determine the role 
of VANGL1 in this early transition.  When grown in 3D Matrigel, the VANGL1 
overexpressing cells appeared less organized.  This was based on the cells’ 
complete loss of the ability to form extracellular lumena and the decreased ability 
to form polarized cells.  In fact the reduction in ability to form polarized cells was 
decreased beyond even that of the 21MT-1 cells, which are invasive and actually 
represent IMC when grown in 3D culture and in vivo.  The VANGL1 
overexpressing cells also had a greatly reduced ability to form spherical colonies 
compared to the parental 21PT cells (even more reduced than for the 21MT-1 
cells) and showed an increased percentage of single cells.  These features would 
suggest that VANGL1 overexpressing cells did acquire characteristics of 
malignancy, that were at least progressed to the point of a DCIS-like (21NT-like) 
phenotype, and for some features suggestive of an invasive (21MT-1-like) 
phenotype.  This increased invasive ability was substantiated by the invasion 
assay, which showed that the VANGL1 overexpressing cells were indeed more 
invasive than 21NT cells.  Proliferation rate, as visualized by 
immunohistochemical staining with Ki67, demonstrated that VANGL1 
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overexpressing 21PT cells had a greatly increased rate of cell growth compared 
to the 21PT parental line, the 21PT+EV control cells and the 21NT line.  In fact 
this increase in proliferation was past the levels observed for 21MT-1 cells in 
other experiments (see Figure 3.17 and 3.24 for documented rates).  However, 
the apoptosis rate for VANGL1 transfected 21PT cells was also increased, but 
only to levels usual for 21NT cells.  When we calculated a ratio of proliferating 
over apoptosing cells, we saw that the ratio for VANGL1 overexpressing cells 
was much higher than for 21PT, 21PT+EV or 21NT cells, indicating that the 
VANGL1 overexpressing cells have a growth advantage.   
 The characteristics of invasive ability seen with the VANGL1 
overexpressing cells may be a result of the ability of VANGL1 to negatively 
interact with the metastasis suppressing actions of its binding partner, KAI1.  
Previous studies have shown that VANGL1 increases metastatic ability through 
its interaction with KAI1 [10, 11].  Additionally, the role of VANGL1 in the PCP 
(planar cell polarity) pathway may elucidate the reason we see progression past 
DCIS (21NT cells) with VANGL1 overexpressing cells.  The role of the PCP 
pathway in cancer development is controversial.  Previously it has been shown 
that the canonical Wnt/β-catenin pathway is upregulated in tumourigenesis and 
that there is antagonism between canonical Wnt signalling and noncanonical Wnt 
signalling, leading to a belief that PCP signalling should suppress tumourigenesis 
[51].  Moreover, Wnt5a, a noncanonical Wnt, is downregulated in many types of 
cancer [52-56] and a tumour suppressing role for Wnt5a, as an antagonist of 
Wnt/β-catenin signalling has evolved [15].  However, in other studies, especially 
in cancer of advanced stage, Wnt5a is upregulated and associated with invasion, 
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metastasis and angiogenesis [15, 57-59].  From this, a new theory involving a 
biphasic role for the PCP pathway has emerged [15].  It was theorized that at 
early stages activated Wnt/β-catenin signalling is involved in the transformation 
from normal cells to neoplastic ones, while PCP signalling, which is often 
mediated by Wnt5a, inhibits progression by antagonizing Wnt/β-catenin 
signalling.  However, tumours are still able to develop by escaping the inhibition 
of PCP signalling, either by downregulation of PCP signalling or upregulation of 
downstream effectors of canonical Wnt signalling.  As the tumour progresses, the 
role of PCP signalling becomes altered to promote migration and invasion and 
support angiogenesis, which all contribute to metastasis in advanced stage 
cancers [15].  As was mentioned previously, the binding of non-canonical Wnt 
molecules, such as Wnt5a, to the Fzd receptor, activates the PCP pathway [15].  
Interestingly, we previously found that Wnt5a mRNA is moderately high in 21PT, 
low in 21NT and very high in 21MT-1 (see real-time validation in Chapter 2 (Table 
2.3) and [8]).  Hence the theory of a dual role for the PCP pathway fits with the 
21T model system.  At early stages of progression VANGL1 is low even though 
Wnt5a is slightly elevated, potentially resulting in low PCP signalling and reduced 
antagonism of Wnt/β-catenin signalling.  By the stage of DCIS, VANGL1 is 
increased, potentially resulting in increased PCP signalling (which may require 
VANGL1).  Finally, in IMC, Wnt5a levels increase (with further activation of the 
PCP pathway), while VANGL1 remains elevated.  Thus, the effects of a non-
canonical pathway signal (such as that from Wnt5a) may differ depending on 
whether or not the cells are expressing VANGL1 (tumour suppressing in the 
absence of VANGL1, promoting of malignancy in the presence of VANGL1).  
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These results also suggest that the increased expression of VANGL1 promotes 
progression to both in situ and invasive mammary carcinoma.       
 
3.4.2.  S100A2 Inhibits the Transition to an Invasive Phenotype  
 S100A2 was knocked-down in 21NT (DCIS-like) cells to determine if the 
transfected cells would undergo a transition to a more invasive phenotype.  We 
compared the 21NT+shS100A2 cells to 21NT, 21NT+EV and 21MT-1 (IMC-like) 
cells, to evaluate the role of S100A2 in this later transition.  When cultured in 3D 
Matrigel, the S100A2 knockdown cells showed a more disorganized pattern of 
growth than both 21NT (and 21NT+EV) and 21MT-1 cells, with complete loss of 
the ability to form extracellular lumena and a lack of cell polarization.  In terms of 
spherical colonies formed and presence of single cells, the S100A2 knockdown 
21NT cells showed levels altered from that of the parental DCIS-like 21NT (or 
21NT+EV) cells and similar to the levels of IMC-like, 21MT-1 cells.  The 3D 
invasive characteristics of S100A2 knockdown cells were directly assessed by 
invasion assay using time lapse microscopy.  Not only were 100% of S100A2 
knockdown 21NT cells able to invade through Matrigel, but these cells were also 
able to travel as far through Matrigel as 21MT-1 cells.  Immunohistochemical 
staining for Ki67 (proliferation) and caspase 3 (apoptosis), performed on Matrigel 
plugs, showed that the proliferation rate of S100A2 knockdown cells was 
increased over both 21NT (and 21NT+EV) and 21MT-1 cells, while the apoptosis 
rate for the transfected cells did not differ from the 21NT parental cells or 
21NT+EV control cells.  When we calculated a ratio of proliferation to apoptosis 
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we found that the growth profile of the S100A2 knockdown cells matched that of 
21MT-1 cells.   
Previous studies have theorized that the tumour suppressing ability of 
S100A2 is a direct consequence of its ability to block Cox-2 [27].  Since in the 
present study, we are knocking down S100A2, the enhanced cell motility, 
invasiveness, and proliferation effects associated with Cox-2 activity [28, 29] 
should be present and we do see these characteristics in the S100A2 knockdown 
cells.  However, the mRNA expression of Cox-2 is not significantly higher in 
21MT-1 cells compared to 21NT cells [8].  Thus, at least for the 21T model 
system of early breast cancer progression, S100A2 may be enhancing the 
invasiveness characteristics via a Cox-2-independent pathway.   
A possible alternative mechanism of S100A2 effects is via regulation of 
RUNX3.  The 21T microarray analysis (Chapter 2 and [8]) has shown that there is 
decreased RUNX3 in 21MT-1 cells.  RUNX3 signals downstream in the TGFβ 
pathway, which has been shown to play a complex role in breast cancer.  It has 
been demonstrated that during early breast tumour outgrowth, elevated TGFβ is 
tumour suppressive, while at later stages there is a switch towards induction of 
malignancy and progression [60-62].  Since previous literature has indicated that 
S100A2 can induce RUNX3 [23] and as there are reduced levels of S100A2 in 
21MT-1 cells, it is possible that the tumour suppressing abilities of RUNX3 [24], 
and consequently TGFβ signalling are inhibited due to loss of S100A2.    
Similarly, previous literature has shown that S100A2 represses NFkB2 
[23], and we have previously shown that 21MT-1 cells have increased NFkB2 
(Chapter 2 and [8]).  It may be then that low levels of S100A2 in 21MT-1 cells 
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result in a lack of repression and overactivity of NFkB2, perhaps resulting in 
NFkB2 being able to exert its oncogenic control over apoptosis, cell cycle, 
migration and differentiation [26].  The lack of apoptosis alteration in S100A2 
knockdown cells was surprising, considering S100A2 is thought to stimulate p53 
activity [22].  However, the 21T series cells do all have a p53 mutation [63], which 
may have altered the sensitivity of the p53 pathway to S100A2 effects.     
  
3.4.3.  TBX3 Promotes the Transition to an Invasive Phenotype  
 We transfected constitutive expression vectors of both isoforms of TBX3 
into 21NT (DCIS-like) cells to determine if the transfected cells would acquire 
attributes of an invasive phenotype.  We compared the 21NT+TBX3 Iso1 and 
21NT+TBX3 Iso2 cells to both 21NT+EV (and 21NT) cells and invasive 21MT-1 
cells, to determine the role of TBX3 in this stage of progression (from in situ to 
invasive disease).  Western blotting with a combination of a monoclonal mouse 
antibody against TBX3 and a polyclonal rabbit antibody against ZsGreen was 
able to resolve protein banding indicating that 21NT transfectants did indeed 
express the TBX3-ZsGreen fusion protein.  Due to the design of the TBX3 
expression vector, the empty vector control cells (21NT+EV) were able to 
produce ZsGreen.  Western blotting of the control cells with the ZsGreen 
antibody resolved a protein band at 60 kDa, which is three times larger than the 
expected 20 kDa size of ZsGreen.  It is believed that since this Western blot was 
performed under non-denaturing and non-reducing conditions that the 60 kDa 
product was a ZsGreen trimeric complex.  As further evidence that 21NT 
transfectants expressed the TBX3-ZsGreen fusion protein, PCR primers, which 
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distinguished between endogenous TBX3 and the fusion protein were designed 
and the PCR results indicated that transfected cells of both TBX3 variant-
ZsGreen fusion constructs had increased mRNA expression of the fusion TBX3-
ZsGreen protein.  Further analysis using confocal microscopy and the TBX3 
antibody, as well as ZsGreen signal, showed that the transfected cells had 
increased TBX3 and that much of the TBX3 signal colocalized with ZsGreen 
signal.  These three experiments determined that the transfected TBX3 
overexpressing cells did have increased TBX3.  Although TBX3 overexpressing 
cells were transfected with isoform specific TBX3 fused to ZsGreen, an increase 
in endogenous TBX3 observed by qPCR and Western blotting reveals that TBX3 
transgene expression can induce increased endogenous TBX3 expression in 
21NT cells.  We theorize that TBX3 works in a feed forward manner such that 
increased TBX3 leads to induction of TBX3 transcription.  This induction appears 
to not be specific for either isoform, as overexpression of one isoform leads to 
transcriptional induction of both isoforms, with the specific overexpressed isoform 
being induced at a higher level than the alternate isoform.   
  When grown in 3D Matrigel, 21NT cells overexpressing both TBX3 
isoforms appeared more disorganized, based on the cells’ reduced ability to form 
extracellular lumena and polarized groups, compared to either the empty vector 
21NT control cells, or 21MT-1 cells.  In addition, in 21NT cells transfected with 
both TBX3 isoforms, several very large, highly disorganized and irregular shaped 
cell aggregates were seen in 3D Matrigel colonies.  Both TBX3 overexpressing 
cell lines had reduced ability to form spherical colonies, similar to 21MT-1 cells.  
Also similar to 21MT-1 levels, TBX3 Iso1 and TBX3 Iso2 overexpressing cells 
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had a higher percentage of single cells present in the Matrigel plugs than 21NT 
cells.  Since the TBX3 overexpressing cells acquired 3D colony morphologies 
more closely related to 21MT-1 cells than 21NT cells, it appeared that both 
isoforms of TBX3 were able to drive transfected 21NT cells to an invasive 
phenotype.  This was directly confirmed by invasion assay in 3D Matrigel using 
time lapse microscopy.  A large proportion of TBX3 Iso1 and TBX3 Iso2 
overexpressing cells were able to invade through Matrigel.  In addition, these 
invading cells were able to travel as far through Matrigel as 21MT-1 cells.  When 
we examined proliferation and apoptosis rates of the TBX3 overexpressing cells, 
we found that the proliferation rate of both TBX3 isoform transfectants was 
greatly increased over 21NT+EV and 21MT-1 cells.  Interestingly, in the large 
irregular cell aggregates, that were previously mentioned, more than 90% of the 
cells stained positive for Ki67.  The apoptosis rates for the TBX3 overexpressing 
cells were not significantly different from the parental 21NT cells or 21NT+EV 
control cells.  Not surprisingly, when we calculated a ratio of proliferation over 
apoptosis, the ratio for both isoforms of TBX3 overexpressing cells was much 
higher than for 21NT+EV and 21MT-1 cells, indicating that the TBX3 
overexpressing cells have a growth advantage.   
In apparent agreement with the study by Hoogaars and colleagues [43], 
we have found that transfection of both isoforms of TBX3 show similar functional 
effects, inducing an invasive phenotype.  However, in our work, transfection of 
one TBX3 isoform did result in low level increase in expression of the alternate 
isoform, such that functional effects seen could have been the result of some 
combination of the two.  Previous studies have determined that TBX3 achieves 
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senescence bypass through both p53-dependent and independent pathways [35, 
37].  The p53-dependent pathway signals through p14 (ARF), which is repressed 
by TBX3 [35].  Interestingly, regarding the 21T microarray data from Chapter 2, 
that we have previously published [8], we did not see a decrease in p14 (ARF) in 
21MT-1 cells (compared to 21NT cells) represented on our list of genes with 
significantly altered expression (Supplemental Table 2).  However, upon 
examination of the raw microarray data, we have found that p14 (ARF) mRNA 
was reduced 1.4-fold in the 21MT-1 cells, compared to 21NT cells, just missing 
our 1.5-fold changed cut off, such that whether or not TBX3 may be acting 
functionally through repression of p14 (ARF) in these cells requires further 
investigation.  TBX3-induced invasiveness may also be a result of its ability to 
repress E-cadherin, which has been shown in the past [39] and in the present 
study.   
 The present study builds on the limited evidence that there is a potential 
role of TBX3 in EMT [39].  EMT is a process by which epithelial cells alter their 
phenotype and acquire mesenchymal-like properties, through disruption of 
intercellular adhesion, leading to enhancement of cell motility [64].  Mesenchymal 
cells, in contrast to epithelial cells, have the ability to migrate as individual cells, 
thus the aim of this phenotype modulation is to grant the otherwise stationary 
epithelial cells the ability to break away from the primary site, penetrate into 
surrounding tissues and move to distant sites [65, 66].  In vitro functional markers 
for EMT include increased migration, invasion, scattering and elongation of cell 
shape [64], all of which we see for the TBX3 overexpressing cells.  In addition, it 
has been well documented that cells that have undergone EMT have decreased 
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E-cadherin, as well as increased vimentin [64], both of which we also see in the 
TBX3 overexpressing cells (both isoforms).  These findings indicate that TBX3 
may induce EMT.  A more thorough analysis looking at other markers of EMT, 
including increased fibronectin, snail1, snail2 (slug) and accumulation of β-
catenin in the nucleus, would further this theory.      
 
3.4.4.  Genes Identified by the 21T Series Model System are Involved in 
Controlling the Transitions Between Stages of Progression    
The present study has made use of the 21T human breast epithelial cell 
line 3D model system to functional characterize genes previously identified as 
altered between stages of early breast cancer progression [8].  We determined 
that VANGL1 drives cells towards a more malignant and a more invasive 
phenotype and promotes the transition from ADH through DCIS to IMC (Figure 
3.29).  Loss of S100A2, as well as elevated TBX3 promotes invasive 
characteristics and promotes the transition from DCIS to IMC (Figure 3.29).  The 
21T 3D model system is thus a powerful tool that not only is able to identify 
targets with potential significance in breast cancer progression, but also provides 
a rapid and manipulatable system to test the functional characteristics of the 
targets.   
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Figure 3.29. The roles of VANGL1, S100A2 and TBX3 in early breast cancer
progression. VANGL1 drives cells towards a more malignant and a more
invasive phenotype and promotes the transition from ADH through DCIS and
in some respects to IMC. Loss of S100A2 promotes invasive characteristics
and the transition from DCIS to IMC. Similarly, TBX3 (both isoforms)
promotes characteristics of invasiveness and the transition from DCIS to
IMC.
↑ VANGL1
↓ S100A2
↑ TBX3
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(21PT)
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CHAPTER 4.  GENERAL DISCUSSION  
 
4.1.  THESIS SUMMARY 
 The work described in this thesis has addressed the need to identify 
molecular factors that drive cells to transition through the stages of early breast 
cancer progression.  Early breast cancer progression involves advancement 
through specific morphologic stages including atypical ductal hyperplasia (ADH), 
ductal carcinoma in situ (DCIS) and invasive mammary carcinoma (IMC), 
although not necessarily always in a linear fashion [1-5].  Although the pathology 
of these distinct stages is well described, the underlying molecular events 
controlling progression remain unclear.  Model systems are required to study the 
molecular events and determine the molecular changes that are driving 
progression.  This thesis made use of the 21T series human breast epithelial cell 
lines grown in a 3D Matrigel system.  I hypothesized that when grown in 3D 
culture, the 21T series cells could be used to identify genes involved in the 
transition from ADH to DCIS and the transition from DCIS to IMC.  Additionally, it 
was hypothesized that the 3D model system could be further used to determine 
the role of the identified genes in early breast cancer progression.  In order to 
address these hypotheses, three objectives were defined.  First, it was necessary 
to determine the growth characteristics of the 21T series cell lines in 3D in vitro 
culture.  Next, the 3D system was used to identify genes potentially involved in 
the transition from ADH to DCIS and in the transition from DCIS to IMC.  Finally, 
the validated genes were functionally characterized in the 3D system to 
determine their role in induction of tumor progression.    
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 The 21T series cell lines, all originally derived from a single patient with 
metastatic breast cancer, have been previously proposed to represent a 
mammary tumour progression series [6].  In Chapter 2 (and [7]), we reported that 
the 21T cell lines indeed mimicked specific stages of  human breast cancer 
progression when grown in the mammary fat pad of nude mice, albeit after a 
year.  More specifically, the 21PT-derived cells developed lesions with 
morphologic features of ADH, while the 21NT-derived cells formed lesions of 
DCIS and the 21MT-1 cells lesions of IMC.  In order to develop a more rapid, 
readily manipulatable in vitro assay for examining the biologic differences 
between these cell lines, we have used a 3D Matrigel system.  When the three 
cell lines were grown in 3D Matrigel, they showed characteristic morphologies in 
which quantifiable aspects of stage-specific in vivo behaviours (i.e. differences in 
acinar structure formation, cell polarization, colony morphology, cell proliferation, 
cell invasion) were recapitulated in a reproducible fashion.  Additionally, in order 
to determine differential gene expression profiles between the 21T series cell 
lines, in vitro expression arrays were performed on cells grown in 3D culture.  
Genes that were significantly altered (p<0.05) at least 1.5-fold in either the 
transition from ADH to DCIS, or DCIS to IMC, were further considered.  In order 
to assess whether these alterations were clinically relevant, we compared our list 
of differentially expressed genes with a database we generated from established 
literature on gene expression profiling of breast cancer clinical cancer specimens 
[8-19].  Ingenuity Pathways Analysis was then used to choose genes involved in 
the most highly altered canonical pathway and functional categories.  Finally, 
GeneCards (www.genecards.org) was used to further explore the potential role of 
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the genes in breast cancer.  Nineteen genes (Table 2.3) were then chosen for 
real-time qRT-PCR validation, with seventeen genes showing the same 
expression trend as the microarray.  These genes were specifically altered in 
either the transition from pre-malignant (ADH: 21PT cells) to malignant growth 
(DCIS: 21NT cells), or the transition from growth within a duct (DCIS: 21NT cells) 
to invasion at the primary site (IMC: 21MT-1 cells).     
 From the PCR validated list, three genes were chosen for functional 
testing in the 21T series 3D model system.  For the transition from ADH to DCIS, 
VANGL1 was functionally characterized to determine its role in promoting 
conversion to malignancy (in situ and/or invasive disease).  Two genes 
differentially expressed in the DCIS to IMC transition were chosen for functional 
characterization, S100A2 and TBX3, to determine their role in progression to an 
invasive phenotype.  Experimental studies focusing on these three genes were 
the basis for the work in Chapter 3.        
 VANGL1 was found to be elevated in 21NT (DCIS-like) cells compared to 
21PT (ADH-like) cells.  To determine the functional role of VANGL1 in the 
malignant transition, a myc-tagged VANGL1 expression vector was constructed 
and transfected into 21PT cells.  The resulting VANGL1 overexpressing cells 
were functionally characterized according to colony profile (spherical vs. 
irregular), lumen formation, cell polarization, proportion of single cells, 
proliferation index, apoptosis index and cell invasion.  The cells were found to 
have lost characteristics of the parental 21PT cells and gained some of those 
typically seen for 21NT or 21MT-1 cells.  The VANGL1 overexpressing 21PT 
cultures were found to be more disorganized (less polarized cell groups, less 
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extracellular lumen formation) than 21NT or even 21MT-1 cells.  Additionally, 
when a ratio of proliferation over apoptosis was calculated for the VANGL1 
overexpressing cells, these cells had a higher ratio than 21NT cells.  
Furthermore, direct examination of invasiveness using transwell assay showed 
that the VANGL1 transfected 21PT cells had gained a significant level of 
invasiveness.  Thus, the introduction of VANGL1 into 21PT cells induced change 
from a more ADH-like phenotype, beyond the stage of a DCIS, to a clearly 
invasive phenotype, without the need for any further experimental intervention.   
 S100A2 was found to be reduced in 21MT-1 (IMC-like) cells compared to 
21NT (DCIS-like) cells.  To determine the functional role of S100A2 in the 
transition to an invasive phenotype, shRNA against S100A2 was transfected into 
21NT cells and the cells were analyzed using several functional parameters, 
including colony profile (spherical vs. irregular), lumen formation, cell polarization, 
proportion of single cells, proliferation index, apoptosis index and cell invasion by 
time lapse microscopy.  The S100A2 knockdown 21NT cells were found to have 
lost characteristics of parental 21NT cells and gained those of 21MT-1 cells.  The 
cells formed more disorganized groups (less polarized, less extracellular lumen 
formation) than either 21NT or 21MT-1 cells and showed a growth profile (ratio of 
proliferation to apoptosis) similar to 21MT-1 cells.  In addition, knockdown 
S100A2 in 21NT cells resulted in cells that were invasive in 3D Matrigel to a 
degree comparable to 21MT-1 cells.  Thus, loss of S100A2 in these cells 
originally mimicking DCIS, promotes their progression to the invasive phenotype.   
 TBX3 was found to be increased in 21MT-1 (IMC-like) cells compared to 
21NT (DCIS-like) cells.  To determine the functional role of both isoforms of TBX3 
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in the transition to an invasive phenotype, expression vectors of the isoforms 
fused to ZsGreen were transfected separately into 21NT cells.  Functional assays 
including colony profile (spherical vs. irregular), lumen formation, cell polarization, 
proportion of single cells, proliferation index, apoptosis index, cell invasion and 
presence of EMT markers were then used to analyze the cells.  The TBX3 
overexpressing 21NT cells obtained characteristics more similar to 21MT-1 cells 
than to the parental 21NT cells.  Both TBX3 overexpressing isoform variant cells 
formed more disorganized colonies (less polarization, less extracellular lumen 
formation) and had a much higher proliferation vs. apoptosis ratio than any of the 
parental 21T cell lines (including 21MT-1).  In addition, assays in 3D Matrigel 
showed the TBX3 overexpressing cells (both isoforms) to be more invasive than 
the 21MT-1 cells.  Thus, overexpression of either isoform of TBX3 is capable of 
inducing a transition of the DCIS-like 21NT cells to a clearly invasive phenotype.   
 Together, these studies have revealed that the 21T cell series 3D model 
system is a powerful tool that not only is able to identify targets with potential 
significance in breast cancer progression, but also provides a rapid and 
manipulatable system to test the functional characteristics of the targets.   
 
4.2.  DISCUSSION  
Much interest surrounds the need to determine new molecular targets for 
breast cancer therapy.  To this end, information from clinical studies examining 
pre-invasive lesions vs. invasive mammary carcinoma has yielded abundant 
gene expression profile differences between stages of progression (eg. [8-12]).  
The limitation we are facing is appropriate processing and synthesis of this data.  
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Several of these studies looked at specimens from different patients, leading to 
genetic differences that can mask the importance of specific gene targets.  Also 
testing the involvement of individual genes in progression takes time, especially 
when using in vivo culture. 
The 21T series 3D model system is of great advantage in this regard.  As 
was discussed in Chapter 2, the parental cell lines stably represent three distinct 
stages of breast cancer.  This is advantageous over the HMT-3522 and 
MCF10AT breast epithelial cell line systems, since both show mixed phenotypes 
and lack stability after culture [20-24].  Additionally, the 21T series cell lines are 
all derived from one patient, thus having an isogenic background.  As a result, 
targets identified by the system are more likely to be those associated with 
cancer progression, as opposed to variation between individuals.  Finally, the 
ability of the 21T series cell lines to represent the stages of progression in a 3D in 
vitro system allows us to rapidly test multiple functional characteristics of 
candidate genes to determine their role in regulating the transitions through the 
stages of breast cancer.  The three targets examined in this thesis were 
VANGL1, S100A2 and TBX3, all of which have been identified as genes altered 
during progression in expression array profiling of clinical specimens, but for 
which very little functional information in relation to a role in breast cancer 
progression is currently available.   
 VANGL1 is a transmembrane protein that has been implicated in 
promoting malignancy and invasion of gastric, squamous, colon and laryngeal 
cancer [25-30]; however, no functional information is available in relation to 
breast cancer progression.  The tumour enhancing ability of VANGL1 is believed 
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to be a result of both the negative interaction of VANGL1 with KAI1, a metastasis 
suppressor, and through the PCP signalling pathway, which is influenced by 
VANGL1.  The microarray data from Chapter 2 identified VANGL1 as increased 
in 21NT (DCIS-like) compared to 21PT (ADH-like) cells.  Consequently, in 
Chapter 3, we investigated the role of VANGL1 in the transition from ADH to 
DCIS.  The 3D functional assays indicate that cells overexpressing VANGL1 did 
acquire characteristics of malignancy; however, several of the criteria examined 
indicated that the cells had progressed even further and had acquired 
characteristics of invasion.  The present data implicates a role for VANGL1 in 
early breast cancer progression.  This role may be achieved through the 
interaction of VANGL1 with KAI1, which blocks inhibitor effects of KAI1 on 
signalling and/or through the interaction of VANGL1 with the Wnt5a/Fzd/Dvl 
complex to alter signalling via the noncanonical Wnt/PCP pathway.  Future 
studies that focus on these interactions would more fully elucidate the role of 
VANGL1 in early breast cancer (see section 5.3).   
 S100A2 is a member of the S100 calcium binding family and has been 
implicated in tumour suppression [31].  The tumour suppressing abilities have 
been noted in several forms of cancer and are theorized to be partly obtained 
through the interaction of S100A2 with the Cox-2 pathway [32], p53 signalling 
[33], RUNX3, EGFR and NFkB2 signalling [34].  In Chapter 3, we characterized 
the role of S100A2 in the transition from DCIS to IMC.  S100A2 was knocked-
down in 21NT (DCIS-like) cells to mimic the decreased S100A2 mRNA levels in 
21MT-1 compared to 21NT cells that were discovered in Chapter 2.  The 3D 
functional assays indicate that S100A2 knockdown cells did acquire 
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characteristics of invasion.  These results give evidence for the first time that 
S100A2 may indeed be a gatekeeper of the invasive phenotype in breast cancer 
progression, such that downregulation of S100A2 allows the transition from the in 
situ to the invasive phenotype.  The potential mechanisms of this phenomenon 
warrant further study (as described in section 5.3). 
 TBX3 is a member of the T-box family of transcription factors, previously 
linked to tumourigenesis and senescence bypass [35-37]; however, very little is 
known about the function of TBX3 in breast cancer.  There are two isoforms of 
TBX3, which are created by alternative splicing [38].  Although TBX3 Iso1 (TBX3 
splice variant) has been consistently implicated in senescence inhibition, there is 
controversy over whether TBX3 Iso2 (TBX3+2a variant) is also tumour promoting 
in action [39, 40].  Our interest in TBX3 in the transition from DCIS to IMC arose 
as a result of the microarray data in Chapter 2 that demonstrated that TBX3 was 
increased in 21MT-1 (IMC-like) cells compared to 21NT (DCIS-like) cells.  In 
Chapter 3, we overexpressed both isoforms of TBX3 in 21NT (DCIS-like) cells to 
see if the transfected cells would acquire attributes of an invasive phenotype.  
When grown in 3D Matrigel, cells overexpressing both TBX3 isoforms did acquire 
attributes of the invasive phenotype, indicating for the first time that TBX3 (both 
isoforms) may influence the progression of breast cancer from the in situ to 
invasive phenotype.  This data also provides evidence in the controversy over 
function of the two TBX3 isoforms, indicating that both isoforms show function in 
this system (consistent with Hoogaars and colleagues [40]).  Other mechanisms 
of TBX3 effect include repression of p14 (ARF) [36] and induction of EMT through 
repression of E-cadherin [41].  These mechanisms could be explored in future 
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work (as discussed in section 5.3) to determine a more exact mechanism for the 
functional effect seen here.   
 The 21 human epithelial cell line 3D model system is a powerful tool.  The 
system represents distinct stages of early breast cancer progression and has 
been shown to correctly predict molecular targets capable of affecting the 
transitions through these stages.  In addition to identifying the targets, this model 
also provides a rapid and manipulatable system to test the functional 
characteristics of the targets.  In this way, we are identifying genes as potential 
key regulators in the transitions of early breast progression, ideal for development 
as targets for preventative therapies directed at attacking cancer at its roots 
(before the development of invasive disease).  At the same time, further use of 
this system will continue to provide insight into the molecular processes that drive 
early progression.    
 
5.3.  FUTURE DIRECTIONS 
 This thesis demonstrated that the 21T series 3D model system, which 
represents distinct stages in early breast cancer progression, can be used not 
only to identify genes which are involved in controlling the transitions between 
stages of progression, but also provides a means to functionally characterize the 
gene targets.  The results from these studies raise a number of experimental 
questions that may form the basis of interesting continuation projects designed to 
further our understanding of early breast cancer progression. 
 First, choosing potential genes to further study from microarray data is 
challenging.  We originally chose nineteen genes to validate with PCR and 
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determined that seventeen of the genes showed the same expression alteration 
trend by PCR as by microarray (Table 2.3).  Only three of these seventeen genes 
were characterized, leaving fourteen genes ready for functional characterization.  
Also, several rules and guidelines were used in Chapter 2.  These rules were 
used to ensure that genes chosen for further study were clinically relevant and 
involved in highly altered canonical pathways and functional categories; however, 
this does not mean that all genes important in progression were caught.  Thus, 
the array data still holds much potential for further mining to identify genes 
involved in progression.   
 Second, the characterization of VANGL1, S100A2 and TBX3 has provided 
very exciting information about the roles of these genes in early breast cancer 
progression.  However, there are still areas for each gene that need further 
development.  Additionally, now that the functional effects of these candidate 
genes have been carefully characterized in vitro, the more time consuming and 
expensive confirmatory nude mouse assays can be done in a more selective 
fashion.  Since 21T series cells require one year to develop lesions in mammary 
fat pads of nude mice, selective injection of cells that are up- or down-regulated 
for the well characterized gene targets will save much time and money.  Injection 
of VANGL1 overexpressing 21PT cells into nude mice can be compared to 
21PT+EV, 21NT and 21MT-1 cells to determine if VANGL1 results in progression 
to DCIS or even IMC.  S100A2 knockdown 21NT cells can be injected into nude 
mice and compared to 21NT+EV and 21MT-1 cells to determine if loss of S100A2 
drives 21NT cells to an IMC phenotype.  Finally, injection of TBX3 
overexpressing 21NT cells (both isoforms) into nude mice can be compared to 
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21NT+EV and 21MT-1 cells to determine if TBX3 promotes development of IMC.  
It will also be interesting to see if manipulation of any of these genes will result in 
a reduced latency in lesion development in nude mice.        
 Given the interplay between VANGL1 and Wnt5A in the planar cell polarity 
(PCP) pathway, it would be of interest to further explore the relationship between 
these two genes in PCP signalling.  To examine the interplay between VANGL1 
and Wnt5a, Wnt5a could be upregulated in 21NT cells, which have low Wnt5a 
(compared to 21PT cells), but elevated VANGL1 (compared to 21PT cells).  
Functional assays could then be used to analyze the effects on the transitions 
through early breast cancer progression.  This manipulation would also aid in our 
understanding of the biphasic role of the PCP pathway in breast cancer.  
Additionally, it would be interesting to determine whether VANGL1 affects the 
Wnt/Fzd/Dvl interaction and this could be easily viewed by comparing the 
downstream PCP signals after up- and down-regulating VANGL1.  Finally, since 
VANGL1 can potentially complex with and regulate KAI1, further study into the 
levels of KAI1 in the 21T series cells, as well as examination for direct interaction 
of VANGL1 with KAI1 and potential effects on activation of downstream targets of 
KAI1 (growth factor receptors and integrins) may elucidate if the promotion of 
malignancy and invasion observed here is due in part to VANGL1 regulation of 
KAI1. 
 Much of the literature points to the down-regulation of Cox-2 gene 
expression by S100A2 as a means by which S100A2 exerts its tumour 
suppressing ability.  We did not see an alteration in Cox-2 expression with the 
microarray data, with the level of change that we had set for our initial screen.  
158
However given that S100A2 has been shown to repress Cox-2, resulting in 
reduced tumourigenesis, it would be of interest to perform a qRT-PCR 
experiment to more accurately determine if Cox-2 is altered in the 21T series 
cells as well as the S100A2 knockdown cells.  Also, it would be worth examining 
the regulation of S100A2 on both NFkB2 and RUNX3 and their respective 
signalling pathways, given that both the literature and our microarray data have 
elucidated a possible role for S100A2 signalling through these genes.  qRT-PCR 
experiments could be conducted to determine if the levels of NFkB2 and/or 
RUNX3 are altered in the S100A2 knockdown cells compared to the 21NT+EV 
control cells.  Additionally, levels of downstream effectors in the respective 
pathways of each of these genes can be viewed to determine if loss of S100A2 
affects signalling.      
 Since TBX3 is a transcription factor, its effects on cells are numerous.  
Two pathways identified by the literature and partly corroborated by this thesis 
involve a role with p14 (ARF) and in EMT.  Given that levels of p14 (ARF) are 
marginally decreased in 21MT-1 cells compared to 21NT cells, it would be of 
interest to determine if there is an alteration in expression of p14 (ARF) in the 
TBX3 (both isoforms) overexpressing 21NT cells.  This thesis also used 
decreased E-cadherin and increased vimentin as indicators that TBX3 may play a 
role in promoting EMT.  To further analyze this theory, other markers of EMT, 
including increased fibronectin, snail1, snail2 (slug) and accumulation of β-
catenin in the nucleus, could be investigated.   
Collectively these studies indicate that the 21T 3D model system is an 
influential tool that not only is able to identify targets with potential significance in 
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breast cancer progression, but also provides a rapid and manipulatable system to 
test the functional characteristics of the targets.  Continued research in the areas 
described above should elucidate more targets in early breast cancer progression 
and further our understanding of the targets already identified, which will aid in 
the development of novel detection, treatment and preventative strategies for 
progression.  
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A) B)
C) D)
Figure 1. Examples of each type of cell colony examined in the 3D colony
morphology assay. A) represents a cell group/colony, while B) represents a
single cell. C) is representative of a spherical colony, while A) would not be
considered spherical. The cell colony in D) is able to form an extracellular
lumen, while a lumen is not present in the cell colony displayed in C). Finally,
the cells within the colony in D) are polarized, as the nuclei are basally
oriented, while the cells found within the cell colony in C) are not polarized.
Scale bar represents 10 µm.
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Table 1.  Genes that are significantly different among the 21T series cell lines 
(Supplemental Table 1 and 2) and also present on clinically relevant databases 
from the literature (Supplemental Table 3). 
 
A) 21PTci to 21NTci 
Probe Set ID Gene Symbol 21NTci  (ratio to 21PTci) 
216620_s_at ARHGEF10 0.59 
211022_s_at ATRX 1.97 
208478_s_at BAX 0.57 
211813_x_at DCN 0.60 
242605_at DCN 7.52 
220668_s_at DNMT3B 1.39 
217497_at ECGF1 1.60 
208180_s_at HIST1H4H 1.56 
209984_at JMJD2C 1.66 
210662_at KYNU 4.98 
208403_x_at MAX 0.65 
242479_s_at MCM4 0.62 
230848_s_at MGA 3.23 
204475_at MMP1 0.24 
221805_at NEFL 0.31 
209997_x_at PCM1 0.65 
212240_s_at PIK3R1 1.75 
206509_at PIP 3.95 
204051_s_at SFRP4 0.65 
219103_at UPLC1 9.31 
229997_at VANGL1 2.19 
229802_at WISP1 2.18 
213425_at WNT5A 0.53 
 
B) 21NTci to 21MT-1 
 
Probe ID Gene Symbol 21MT-1 (ratio to 21NTci) 
208161_s_at ABCC3 0.05 
202850_at ABCD3 0.61 
206513_at AIM2 7.16 
224655_at AK3L1 0.47 
224151_s_at AK3L1 0.30 
205623_at ALDH3A1 0.01 
223333_s_at ANGPTL4 0.28 
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222608_s_at ANLN 0.38 
1552619_a_at ANLN 0.37 
208702_x_at APLP2 0.58 
204205_at APOBEC3G 3.37 
201288_at ARHGDIB 0.03 
209394_at ASMTL 1.96 
218782_s_at ATAD2 0.43 
222740_at ATAD2 0.40 
213106_at ATP8A1 0.10 
202391_at BASP1 4.23 
204908_s_at BCL3 1.84 
209373_at BENE 0.06 
210538_s_at BIRC3 2.49 
230499_at BIRC3 2.23 
207655_s_at BLNK 0.04 
203571_s_at C10orf116 0.01 
211368_s_at CASP1 3.62 
205476_at CCL20 19.98 
205099_s_at CCR1 7.85 
201131_s_at CDH1 0.02 
207173_x_at CDH11 0.24 
204252_at CDK2 0.26 
213618_at CENTD1 0.07 
209395_at CHI3L1 0.13 
209396_s_at CHI3L1 0.09 
201428_at CLDN4 0.02 
208792_s_at CLU 3.43 
225438_at CML66 0.50 
204740_at CNKSR1 0.29 
222073_at COL4A3 1.64 
212489_at COL5A1 0.15 
203325_s_at COL5A1 0.11 
207442_at CSF3 11.23 
210140_at CST7 18.14 
823_at CX3CL1 2.04 
204470_at CXCL2 0.04 
211919_s_at CXCR4 0.20 
209201_x_at CXCR4 0.07 
217028_at CXCR4 0.04 
202435_s_at CYP1B1 0.18 
202436_s_at CYP1B1 0.15 
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202437_s_at CYP1B1 0.10 
211896_s_at DCN 33.95 
209335_at DCN 21.17 
211813_x_at DCN 20.03 
201893_x_at DCN 15.35 
242605_at DCN 1.77 
210749_x_at DDR1 0.18 
1007_s_at DDR1 0.13 
208779_x_at DDR1 0.06 
207169_x_at DDR1 0.04 
211272_s_at DGKA 0.23 
222621_at DNAJC1 1.93 
201843_s_at EFEMP1 0.07 
201842_s_at EFEMP1 0.04 
201325_s_at EMP1 0.28 
214782_at EMS1 1.85 
201313_at ENO2 10.08 
217061_s_at ETV1 2.05 
211742_s_at EVI2B 3.64 
221565_s_at FAM26B 0.21 
202995_s_at FBLN1 0.46 
202994_s_at FBLN1 0.13 
201540_at FHL1 7.54 
218035_s_at FLJ20273 0.07 
214915_at FLJ25476 0.62 
214211_at FTH1 2.84 
206002_at GPR64 0.30 
219327_s_at GPRC5C 0.08 
212873_at HA-1 2.63 
216693_x_at HDGFRP3 0.40 
213537_at HLA-DPA1 11.27 
212143_s_at IGFBP3 0.02 
210095_s_at IGFBP3 0.01 
206172_at IL13RA2 13.55 
205992_s_at IL15 6.56 
206295_at IL18 0.06 
226218_at IL7R 14.04 
205798_at IL7R 3.87 
208436_s_at IRF7 3.73 
228462_at IRX2 0.25 
204990_s_at ITGB4 0.04 
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1566465_at KCNK1 0.11 
204678_s_at KCNK1 0.02 
204679_at KCNK1 0.02 
212314_at KIAA0746 0.16 
206785_s_at KLRC1 3.77 
212236_x_at KRT17 2.16 
213680_at KRT6B 0.26 
209016_s_at KRT7 0.11 
213711_at KRTHB1 0.09 
241305_at KYNU 2.98 
210663_s_at KYNU 2.32 
204385_at KYNU 2.04 
211651_s_at LAMB1 1.84 
202728_s_at LTBP1 15.51 
205668_at LY75 0.16 
213489_at MAPRE2 0.09 
202350_s_at MATN2 0.19 
211340_s_at MCAM 3.28 
242479_s_at MCM4 1.69 
203417_at MFAP2 0.54 
203434_s_at MME 2.16 
204475_at MMP1 20.75 
201069_at MMP2 0.48 
205828_at MMP3 7.41 
204259_at MMP7 0.24 
219959_at MOCOS 2.35 
37408_at MRC2 0.16 
201521_s_at NCBP2 1.64 
209949_at NCF2 0.16 
206022_at NDP 0.62 
202237_at NNMT 5.23 
202238_s_at NNMT 5.05 
219773_at NOX4 1.91 
205552_s_at OAS1 0.36 
213075_at OLFML2A 0.09 
205041_s_at ORM1 46.41 
210448_s_at P2RX5 2.15 
202465_at PCOLCE 3.31 
214582_at PDE3B 0.27 
222719_s_at PDGFC 0.07 
218718_at PDGFC 0.02 
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205226_at PDGFRL 7.30 
205960_at PDK4 0.04 
225207_at PDK4 0.02 
221816_s_at PHF11 0.08 
225136_at PLEKHA2 0.48 
205479_s_at PLAU 0.59 
236297_at PLXDC2 1.62 
201578_at PODXL 0.10 
210910_s_at POMZP3 0.52 
203407_at PPL 0.05 
201602_s_at PPP1R12A 1.66 
201858_s_at PRG1 5.89 
209606_at PSCDBP 18.29 
202006_at PTPN12 1.67 
203029_s_at PTPRN2 20.15 
210127_at RAB6B 0.48 
218723_s_at RGC32 0.02 
200962_at RPL31 0.50 
204268_at S100A2 0.25 
206027_at S100A3 3.67 
203453_at SCNN1A 0.19 
201286_at SDC1 0.19 
204855_at SERPINB5 0.03 
209044_x_at SF3B4 1.81 
209980_s_at SHMT1 0.04 
213355_at SIAT10 0.44 
206510_at SIX2 0.23 
202800_at SLC1A3 6.78 
1569054_at SLC1A3 5.98 
206097_at SLC22A1LS 2.03 
202498_s_at SLC2A14 3.60 
202499_s_at SLC2A3 4.06 
206628_at SLC5A1 0.56 
209830_s_at SLC9A3R2 0.06 
213139_at SNAI2 2.93 
220987_s_at SNARK 0.67 
227697_at SOCS3 7.01 
212560_at SORL1 0.12 
220922_s_at SPANXB1 18.34 
220217_x_at SPANXC 5.36 
218638_s_at SPON2 0.21 
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233555_s_at SULF2 0.05 
224724_at SULF2 0.02 
202168_at TAF9 2.00 
225973_at TAP2 2.07 
225544_at TBX3 2.84 
203919_at TCEA2 0.65 
214476_at TFF2 9.71 
201506_at TGFBI 3.65 
201147_s_at TIMP3 15.63 
219580_s_at TMC5 0.03 
222450_at TMEPAI 0.02 
202644_s_at TNFAIP3 3.94 
206025_s_at TNFAIP6 1.50 
202688_at TNFSF10 0.06 
210314_x_at TNFSF13 0.46 
209500_x_at TNFSF13 0.44 
221601_s_at TOSO 5.07 
201746_at TP53 1.62 
209863_s_at TP73L 0.36 
209227_at TUSC3 0.50 
201009_s_at TXNIP 0.31 
201010_s_at TXNIP 0.23 
226681_at UBE2H 1.90 
208998_at UCP2 0.51 
225242_s_at URB 0.33 
210513_s_at VEGF 3.09 
212171_x_at VEGF 2.48 
210512_s_at VEGF 2.15 
202664_at WASPIP 8.87 
213425_at WNT5A 9.30 
203585_at ZNF185 0.37 
213196_at ZNF629 0.44 
211796_s_at 30.26 
213193_x_at 2.60 
243020_at 0.63 
244579_at 0.57 
210136_at   0.23 
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Table 1.  S100A2 shRNA sequence.  
 
 
Mature Product 
(22 mer) Sequence 
Hairpin Sequence  
CCAGACCGACCC
TGAAGCA 
TGCTGTTGACAGTGAGCGACCCAGACCGACCCTGAAG
CAGTAGTGAAGCCACAGATGTACTGCTTCAGGGTCGG
TCTGGGCTGCCTACTGCCTCGGA 
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Figure 1. Quantification of characteristics of 21T and VANGL1
overexpressing cells after 9 days growth in 3D Matrigel. 21PT+VANGL1 cells
show no lumen formation and fewer polarized cells than 21PT+empty vector
(EV) cells, indicating that the VANGL1 cells are more disorganized. In
addition, VANGL1 transfected cells also formed far fewer spherical colonies,
with the percentage being lower than even 21MT-1 cells. The percentage of
single cells seen in Matrigel plugs for 21PT+VANGL1 cells was at the same
level as 21NT cells. 21PT+EV cells show no differences from 21PT cells. For
‘single cells’, an event is either a single cell or a cell group, whereas for the
‘lumen formation’ , ‘polarized cells’ and ‘spherical colonies’ comparisons, an
‘event’ was defined as a cell group only. Bars labeled with letters that are not
the same indicate significant difference between the bars at a p-value of at
least <0.05. Statistics for each comparison were calculated separately from
the other comparisons.
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Figure 2. Proliferative and apoptotic activity of 21T and VANGL1
overexpressing cell lines after 9 days growth in 3D Matrigel. Proliferation (A)
was quantified by Ki67 immunohistochemical staining of Matrigel plugs, while
apoptosis (B) was quantified by caspase 3 immunohistochemistry.
21PT+VANGL1 cells showed a large increase in proliferation (A) over
21PT+EV cells, while apoptosis levels (B) were unaltered from 21PT+EV
cells. When the ratio of proliferation/apoptosis was calculated (C), VANGL1
overexpressing cells showed a much higher ratio than the 21PT+EV and
even the 21NT cells. 21PT+EV cells showed no differences from the 21PT
cells. Bars labeled with letters that are not the same indicate significant
difference between the bars at a p-value of at least <0.05.
A) B)
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Figure 3. Quantification of characteristics of 21T and S100A2 knockdown
cells after 9 days growth in 3D Matrigel. 21NT+shS100A2 cells show
complete loss of lumen forming ability and fewer polarized cells than
21NT+EV or 21MT-1 cells, indicating that the S100A2 knockdown cells are
less organized. In addition, S100A2 shRNA cells also formed fewer spherical
colonies than 21NT+EV cells and in line with 21MT-1 cells. The percentage of
single cells seen in Matrigel plugs for 21NT+shS100A2 cells was unaltered
from 21NT+EV (or 21NT) cells. 21NT+EV cells show no differences from
21NT cells. For ‘single cells’, an event is either a single cell or a cell group,
whereas for the ‘lumen formation’ , ‘polarized cells’ and ‘spherical colonies’
comparisons, an ‘event’ was defined as a cell group only. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05. Statistics for each comparison were calculated
separately from the other comparisons.
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Figure 4. Proliferative and apoptotic activity of 21T and S100A2 knockdown cell
lines after 9 days growth in 3D Matrigel. Proliferation (A) was quantified by Ki67
immunohistochemical staining of Matrigel plugs, while apoptosis (B) was
quantified by caspase 3 immunohistochemistry. 21NT+shS100A2 cells showed
an increase in proliferation (A) over 21NT+shEV and 21MT-1 cells, while
apoptosis levels (B) of S100A2 shRNA cells were not different from 21NT cells.
When the ratio of proliferation/apoptosis was calculated (C), S100A2 knockdown
21NT cells showed a higher ratio than 21NT+EV cells. 21NT+shEV cells
showed no differences from the 21NT cells. Bars labeled with letters that are not
the same indicate significant difference between the bars at a p-value of at least
<0.05.
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Figure 5. Quantification of characteristics of 21T and TBX3 transfected cells
after 9 days growth in 3D Matrigel. 21NT +TBX3 Iso1 and Iso2 cells form
fewer lumens and polarized cells than 21NT+EV cells, indicating that the
TBX3 cells are less organized. In addition, TBX3 transfected cells also
formed less spherical colonies than 21NT+EV cells and more single cells,
similarly to 21MT-1 cells. 21NT+EV cells show no differences from 21NT
cells. For ‘single cells’, an event is either a single cell or a cell group, whereas
for the ‘lumen formation’, ‘polarized cells’ and ‘spherical colonies’
comparisons, an ‘event’ was defined as a cell group only. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05. Statistics for each comparison were calculated
separately from the other comparisons.
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Figure 6. Proliferative and apoptotic activity of 21T and TBX3 transfected
cell lines after 9 days growth in 3D Matrigel. Proliferation (A) was quantified
by Ki67 immunohistochemical staining of Matrigel plugs, while proliferation
(B) was quantified by caspase 3 immunohistochemistry. 21NT+TBX3 Iso1
and Iso2 cells showed a large increase in proliferation (A) over 21NT+EV
cells, while apoptosis levels (B) remained similar to the 21T cells. When the
ratio of proliferation/apoptosis was calculated (C), TBX3 transfected cells
showed a much higher ratio than the 21NT+EV and the 21MT-1 cells.
21NT+EV cells showed no differences from the 21NT cells. Bars labeled with
letters that are not the same indicate significant difference between the bars
at a p-value of at least <0.05.
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